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Hepatitis A virus (HAV) exhibits slow non-cytopathic replication in tissue culture. When 
adapted to growth in cell culture a change in phenotype to a more rapid and productive 
infection is observed which is associated with changes in the nucleotide sequence of the 
viral genome. Most of these changes are found in the regions of the genome encoding 
non-structural polypeptides. In order to determine the reason for this slow proliferation of 
HAV it is necessary to characterise the non-structural proteins of the virus. It has been 
postulated that slow growth of HAV in cell culture could be due to slow replication of viral 
RNA by an inefficient RNA polymerase and attempts were made here to characterise 
this enzyme.
Constructs which export the P3 HAV-specific sequences into the bacterial periplasmic 
space as a fusion protein with staphylococcal Protein A, with the aim of improving 
solubility, allowed the partial purification, using GTP-agarose affinity chromatography, of 
a 53kDa protein believed to be the HAV 3Dpo1. Unfortunately, the apparent copurification 
of Protein A with the 53kDa protein highlighted the inadequacies of Protein A as a fusion 
partner in this case. Problems of low yield and reproducibility also prompted 
consideration of other methods.
Individual P3 regions, 3AB, 3C, 3D, 3CD and P3 were amplified by PCR and cloned into 
pMAL™-c2, creating MBP gene fusions, directing expression products to the cytosol 
thereby improving the yield and hopefully solubility. Good yields were obtained for some 
of the fusion proteins expressed, however, the final yield of 'purified' 3D was very poor. 
Apparent autocatalysis of the processing intermediates suggested that the MBP-3C 
protease expressed was active. Expression of the MBP-3AB, both as the individual 
fusion protein, and resulting from cleavage of MBP-P3, was lethal, as indicated by the 
lysis of bacterial cultures upon induction. Only HAV 3C was purified, however the pMAL 
expression system did yield several useful products, free from bacterial contamination, 
which were assessed for poly(U) polymerase activity.
A degree of reproducible poly(U) polymerase 'activity' was observed when assaying both 
purified MBP-fusion protein and factor Xa-cleaved fusion protein expressed by 3D/pMAL, 
however this did not display true enzyme 'activity' with a reduction in incorporation of 3H- 
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Standard abbreviations used in text are as defined in “Instructions to Authors” of the 
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Viral hepatitis was reviewed at a Hepatitis Challenge Workshop held in Vienna in 1996 
by the Viral Hepatitis Prevention Board/International Commission on Occupational 
Health.
Six distinct viruses causing viral hepatitis have been identified, each differing in the 
severity of disease they cause, epidemiological characteristics, modes of transmission 
and recommendations for control. These six viruses are hepatitis A, B, C, D, E, and G 
(Table 1).
Hepatitis A virus (HAV) is characterised by low mortality, no chronic carrier state and 
lifelong immunity following infection. Modes of transmission include faecal-oral, person- 
to-person, and contaminated water and food.
Historically, infection with HAV was common in young children and not considered a 
public health problem. With improved hygiene and socio-economic conditions, however, 
the virus now often strikes at a later age and with more severe consequences.
The outcome of hepatitis B virus (HBV) infection is often severe, with acute HBV 
infection leading to chronic carrier state, cirrhosis, liver cancer and death. Six to 10 
percent of infected adults will become chronic carriers; infection during infancy and 
childhood frequently progresses to the chronic carrier state, with 70-90 percent of 
neonates becoming chronic carriers. Hepatitis B is transmitted through infected blood 
and body fluids, perinatal transmission, horizontal transmisssion, sexual transmission 
and intravenous drug use. Both plasma derived and recombinant vaccines are 
approved for use in most parts of the world; even so, worldwide one million deaths per 
year are directly related to HBV infection. To control the disease, the WHO recommends 
that “the most effective strategy is incorporation of universal hepatitis B vaccination into 
the routine infant or adolescent immunisation schedules”.
Discovered in 1989, the hepatitis C virus (HCV) is a small, single-stranded RNA virus. It 
is estimated that approximately 1 % of the world’s population have HCV. The virus is 
blood-borne, and the majority of those infected with HCV show no symptoms initially. 
Approximately 50% of people infected with HCV become chronic carriers; of these, half 
develop cirrhosis or liver cancer.
2
Chapter 1
The hepatitis Delta 'virus' (HDV) is associated with hepatitis B. Too small to replicate 
itself, the Delta 'virus' lives as a parasite on the HBV, using the S antigen of HBV to 
multiply. The Delta 'virus' is relatively rare and is not present with every case of HBV 
infection. The progression to chronicity is not uncommon. If HBV infection does become 
chronic, however, the Delta 'virus' speeds the progression to chronic liver disease. 
Vaccination against HBV protects against Delta infection as well.
Formally known as enterically transmitted non-A, non-B (NANB) hepatitis, hepatitis E 
virus (HEV) has no chronic carrier state and does not cause chronic liver disease. 
Hepatitis E infection is highly dangerous, however, for pregnant women, causing up to 
20% mortality in women in their third trimester of pregnancy. Largely transmitted 
through faecal-oral transmission, hepatitis E epidemics are usually waterborne 
epidemics. The disease can be controlled through the provision of safe water and food. 
There is no vaccine as yet, though recombinant vaccines are currently under 
investigation, with the focus now on immunogen, adjuvant and immunisation schedules.
“Hepatitis E looks like hepatitis A but it has the propensity for killing pregnant women” 
says Dr Mark Kane of the World Health Organisation (WHO). Even though prevalence 
rates of HEV are less than one percent in Western Europe and North America “it is a 
major pathogen around the world and we’ll be hearing quite a bit about hepatitis E in the 
next few years”.
Hepatitis F virus (HFV) has been described in only a handful of cases (from France) with 
subsequent experimental transmission to primates (Deka et al., 1994). The virology, 
epidemiology, hepatotropicity and clinical importance of HFV are quite uncertain.
The hepatitis G virus (HGV; also called hepatitis GB virus C or HGBV-C), only recently 
identified in 1995 and fully characterised in early 1996 (Linnen et al., 1996), is an RNA 
virus and as a member of the Flaviviridae family of viruses, is closely related to HCV. 
Associated with acute and chronic hepatitis, HGV is spread parenterally; the virus can 
cause persistent infection and is prevalent in volunteer blood donor populations. HGV 
and HCV infection can be simultaneously transmitted and result in persistent coinfection. 
It is presently unknown whether a normal carrier state exists for patients infected with 




Table 1: Families of hepatitis viruses
VIRUS TYPE FAMILY NUCLEIC ACID GENOME
A Picomavirus ssRNA 27nm
B Hepadnavirus dsDNA 42nm
C Flavivirus ssRNA 45nm
D Viroid or satellite virus ssRNA 36nm
E Calicivirus ssRNA 32nm
G Flavivirus ssRNA 40-60nm
1.2 Hepatitis A
1.2.1 History
Reported epidemics of human disease resembling acute hepatitis A extend back into 
antiquity, although the specific etiology of these outbreaks is, of course, unknown (Ross 
et al., 1991; Lemon, 1994; Hollinger & Ticehurst, 1996). Acute infectious hepatitis was 
first recognised as a transmissable entity in the early twentieth century and was clearly 
separated from homologous serum hepatitis in 1947 when the terms hepatitis A and 
hepatitis B were introduced by MacCallum (MacCallum, 1947).
The virus responsible for hepatitis A was identified by immune electron microscopy in 
1973 by Feinstone et al. Until recently, however, the only method available for the study 
of this disease consisted of experimental infection of primates, the marmoset Sanguinus 
mystax being the animal most extensively used (Ross et al., 1991). More recently, the 
virus has been propagated in a permanent line (FRhK6) of foetal Rhesus monkey kidney 
cells (Provost & Hilleman, 1979). This and other cell culture systems (e.g. African green 
monkey kidney and human hepatoma cell lines) have proved useful for virus assay and 
production (Ross et al., 1991). Lemon et al. (1983) described a modified plaque assay 
which has become the method of choice for quantitation of infectious hepatitis A virus 
(HAV) in many laboratories (Ross et al., 1991).
Portions of the RNA genome of HAV were molecularly cloned by Ticehurst et al. in 1983 
making possible the use of blot hybridisation as a diagnostic test, and the first full-length 
nucleotide sequences of HAV were reported by Cohen et al. (1987a). These studies 
revealed that the genomic organisation of HAV was similar to that of other 
picornaviruses, containing a single large open reading frame presumably encoding a
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polyprotein which is co- and post-translationally processed during replication of the virus. 
The first infectious cDNA clone of HAV was reported by Cohen et al. in 1987(b).
In recent years, there has been a dramatic increase in research into the molecular basis 
of HAV replication and the function of the viral proteins and their effect on viral 
replication. The most recent findings are discussed later on in this chapter under the 
relevant headings.
1.2.2 Hepatitis A infection
1.2.2.1 Epidemiology
Hepatitis A is a widespread infectious disease that is endemic in developing countries, 
and that also may account for up to 25% of all cases of hepatitis in the developed world 
(Tedeschi et al., 1993). In fact, nearly half of the documented cases of viral hepatitis in 
the United States are caused by HAV (Lemon & Thomas, 1997). HAV is excreted in the 
faeces of infected persons and spread via personal contact and ingestion of 
contaminated water or food (Ross et al., 1991). Some outbreaks have been associated 
with ingestion of uncooked shellfish, as shellfish are capable of concentrating HAV from 
polluted waters (Le Guyader, 1993). In 1987/88 in Shanghai, some 292,301 individuals 
contracted hepatitis A from eating contaminated clams.
Transmission of the infection is almost always by the faecal-oral route. Virus shed in the 
faeces is largely or exclusively replicated within the liver, and gains access to the 
intestinal contents by passage through the biliary tract (Figure 1). There have been 
reports of extra-hepatic replication, suggested by the presence of HAV RNA found by 
dot-blot hybridisation in tissues such as the intestine, spleen and kidney, however the 
presence of viral antigens and nucleic acid at these sites may merely indicate immune 
complex deposition or contamination by faecal contents (Taylor etal., 1992).
A significant viraemia (perhaps as high as 1 x 105 infectious particles per millilitre of 
serum) may be present for several weeks in individuals experiencing primary infection 
with HAV, and this may occasionally lead to blood-borne transmission of the virus 
(Lemon, 1994). The viraemia often precedes the development of clinical symptoms by 
7-10 days and was thought to be short-lived (Hollinger & Ticehurst, 1996). A study by
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Yotsuyanagi et al. (1993), however demonstrated that viraemia may exist as long as 7 
days after clinical onset and also after ALT reached peak levels. Transmission by 
transfusion, or recently by contaminated factor VIII has been reported, but such blood- 
borne transmissions are rare (Purcell, 1994).
It is also possible that needle-bome transmission contributes to the spread of HAV 
among intra-venous drug abusers, although this is not known for certain. Virus has been 
found in saliva late in the course of infection, but the source of this virus (possibly blood) 
is not known. Sexual activity may also influence transmission of hepatitis A, especially 
among homosexual males (Ross et al., 1991). This is probably due to enhanced faecal- 
oral transmission related to oral/anal contact. Heterosexual activity may similarly 






Figure 1: Pathway of hepatitis A infection
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Although infection of young children is usually asymptomatic, infection of older 
individuals often results in clinical illness. In developing countries, rapid improvement in 
sanitation and hygiene can actually result in increased morbidity because infection with 
HAV is often delayed until adolescence or adulthood when the symptoms of infection are 
more severe (Ross etal., 1991; Tedeschi etal., 1993; Hollinger & Ticehurst, 1996). The 
changing epidemiology of hepatitis A is thought to be the result of better sanitation, 
principally in the form of improved treatment of water and sewage and improved 
personal hygiene. Consequently, the epidemiology of hepatitis A has changed from one 
of diffuse person-to-person spread to one of association with specific high risk groups 
(Figure 4) (Purcell, 1994). In countries of low endemicity, HAV infection usually occurs 
in cyclical outbreaks in the general population, according to studies conducted by the 
United States Centres for Disease Control (CDC). The virus circulates in the population, 
striking when large numbers of people become susceptible.
On the basis of cases of hepatitis A reported in 1992 to the CDC, the most frequently 
reported risk factor was household or sexual contact with a person with hepatitis, 
followed by day-care attendance or employment, recent international travel, and 
association with a suspected food- or water-borne outbreak (Shapiro, 1994) (Figure 2). 
Dr Mark Kane of the WHO reckons that hepatitis A is probably the most important travel- 
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Figure 2: Risk factors associated with acquiring hepatitis A infection
Adapted from Shaw (1997).
1.2.2.2 Pathology
The incubation period of hepatitis A is approximately 4 weeks, averaging 25 days, with a 
range of perhaps 2-6 weeks (Figure 3). During the incubation period, the liver is infected 
with virus and copious amounts of virus may be shed in the faeces despite the absence 
of symptoms. This is particularly true near the end of the incubation period (Lemon, 
1994). Yotsuyanagi and colleagues (1996) found that faecal shedding of HAV continued 
for up to 3 months after onset of illness, and even after the normalisation of the serum 
ALT levels, a marker of liver cell damage, using the two-stage reverse-transcription (RT)- 
PCR method. Such patients could be a source of further spreading of the virus in the 
community.
Disease is typically abrupt in onset and at times is associated with high fever (Hollinger 







malaise, nausea, right upper quadrant tenderness, and eventually scleral icterus and 
jaundice, dark urine (at times the colour of Coca-Cola™ and quite frothy) and light clay- 
coloured stool. Diarrhoea is an uncommon manifestation of viral hepatitis A in adults but 
may be seen in children (Ross et al., 1991; Lemon, 1994; Hollinger & Ticehurst, 1996). 
Confluent hepatic necrosis is potentially a progressive lesion that may lead to fulminant 
hepatitis and death (Hollinger & Ticehurst, 1996). Hepatitis A is generally mild to 
moderate in severity with a mortality rate of 0.2% or less, and never becomes chronic. 
However, inapparent infection with shedding of virus may persist for up to 6 months in 
neonates (Purcell, 1994).
1.2.2.3 Immune response and serological diagnosis
Virus-induced cytopathology may not be responsible for the pathologic changes seen in 
HAV infection and it has been suggested that host-mediated immunologic responses 
may contribute to the pathogenesis of hepatitis A (Hollinger & Ticehurst, 1996). The 
humoral immune response to hepatitis A is well characterized. IgM class antibodies to 
the native virion are present in almost all patients by the onset of symptoms, and persist 
for upto a year following infection. IgA and IgG antibodies to HAV also develop within a 
few days of the onset of symptoms. Both IgG and IgM antibodies have been shown to 
have virus-neutralising activity, and the efficacy of passively administered 
immunoglobulins in prevention of symptomatic hepatitis A suggests that IgG anti-HAV is 
protective against subsequent symptomatic re-infection. IgG antibody generally persists 
for the life of the individual. Current evidence suggests that secretory immunity plays 

























Figure 3: Immunologic and clinically relevant biologic events associated with HAV 
infection in humans
Adapted from Hollinger & Ticehurst (1996) and references therein.
1.2.2.4 Prevention and control
As almost all hepatitis A infections are, as previously mentioned, transmitted by the 
faecal-oral route the most effective means of prevention is an improvement in community 
public health measures. These include the provision of clean water, proper disposal of 
sewage and high standards of personal hygiene (Ross etal., 1991).
Passive immunisation, by administering pooled immune serum globulin (ISG) from 
human beings, has had an efficacy as high as 87% in preventing symptomatic hepatitis 
when administered to household contacts within 2 weeks of exposure (Lemon, 1985).
Since only a single serotype of HAV has been identified and infection results in lifelong
10
Chapter 1
immunity, a vaccine to prevent the disease is feasible. In recent years, several 
inactivated hepatitis A vaccines prepared from cell culture-grown virus have displayed a 
high level of immunogenicity in clinical trials, and one was licensed for human use in 
1991 (Tedeschi et al., 1993). Duff and Duff very recently (1998) reported that two new 
inactivated vaccines are available, Vaqta™ (Merck and Co., West Point, PA) and 
Havrix™ (Smithkline Beecham, Philadelphia, PA). However, inactivated vaccines are 
often more difficult than attenuated vaccines to administer to large populations and 
prove costly, given the relatively low yields of virus obtained in cell culture, and therefore 
development of an efficacious attenuated vaccine would be advantageous (Lemon, 
1985).
Development of such vaccines is based on the host range change accompanying the 
adaptation and passage of HAV in cell cultures, usually monkey kidney cells. These 
variants appear incapable of initiating infection and also have a markedly reduced ability 
to replicate in the liver. These candidate attenuated vaccines, however, have been 
plagued with problems of poor immunogenicity and at times residual hepatovirulence 
(Lemon, 1994). For optimum safety and efficiency of production of an attenuated 
vaccine, it would be useful to understand the genetic basis of attenuation and virulence 
and how these relate to efficient growth of the virus in cell culture (Tedeschi et al., 1993).
Other possible avenues for vaccine development, reviewed in Andre (1995), include the 
use of either conventional or recombinant DNA techniques to obtain subunit vaccines, 
empty capsids, live viral or bacterial vectors, genetic immunization, synthetic peptides 
and anti-idiotypes (Table 2) overleaf.
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Table 2: Current options for development of an hepatitis A virus
LIVE VACCINE NON-REPLICATING VACCINES
Attenuated HAV strain
Conventionally attenuated
(passaging in cell culture) by recombinant 
DNA techniques
Live attenuated vectors
Viruses (e.g. vaccinia, polio, canarypox) 
Bacteria (e.g. S. Typhimurium)
Inactivated virions
Empty capsid
(produced by recombinant DNA 
technology)
Subunit
Viral capsid polypeptides 





As well as the groups featured in Figure 4, the individuals most likely to benefit from 
routine vaccination are children living in communities with a high prevalence of hepatitis 
A; persons with clotting-factor disorders, especially those receiving factor concentrates 
treated with solvent detergents; persons working in laboratories where HAV is handled; 
recipients of liver transplants and those awaiting one; and persons older than 30 years of 
age with chronic liver disease (Duff & Duff, 1998).
• Travellers from industrialised countries to regions of world where HAV is endemic
• Military personnel who regularly travel to endemic areas of the world
• American Indians; native Alaskans
• Preschool children attending day-care centres; staff, parents, and siblings
• Residents and staff of closed communities (institutions)
• Refugees residing in temporary camps following catastrophes
• Homosexually active males
• Parenteral illicit drug users
• Food handlers
• Persons residing in areas where extended community outbreaks exist




1.2.3 Taxonomy and classification
Despite early classification among the enteroviruses, HAV, provisionally classified in the 
early 1980s as enterovirus type 72 because its biophysical characteristics are like those 
of enteroviruses and cardioviruses, and its biochemical features resemble those of 
enteroviruses (Table 3), is now widely recognised to constitute a unique genus, 
hepatovirus, within the family Picornaviridae, a family of pathogens which includes 
poliovirus (PV), human rhinoviruses (HRVs), encephalomyocarditis virus (EMCV) and 
foot-and-mouth disease virus (FMDV) with which HAV shares many structural and 
biological attributes (Palmenberg, 1989; Stanway, 1990).
This classification is based on several unique features (Figure 5) of HAV including, 
amongst others: liver cell tropism, small and possibly absent VP4 protein, striking 
thermostability, relatively slow and usually noncytopathic replication cycle and a strong 
tendency to initiate persistent infections in cell culture (Lemon, 1994). The nucleotide 
sequence of HAV, while relatively well conserved among different isolates, is also widely 
divergent from those of other picomaviral genera.
• HAV nucleotide and amino acid sequences are dissimilar from those of other 
picornaviruses, as are the predicted sizes of several HAV proteins
• HAV is difficult to adapt to growth in cell culture and usually replicates very slowly 
without cytopathic effect
• HAV is resistant to temperatures and drugs that inactivate many picornaviruses
• HAV exhibits an outstanding stability at pH1, remaining infectious for up to 5 hours
• HAV has only one serotype and one neutralisation site is immunodominant
• An enteroviral-specific monoclonal antibody does not react with HAV
Figure 5: Characteristics distinguishing HAV from other picornaviruses
1.2.4 Physical properties
A striking property of the HAV particle which may well contribute to its potential for 
epidemic spread is its resistance to thermal denaturation. The HAV particle is stable 
when incubated at 60°C for 60 minutes and is only partially inactivated after 10-12 hours 
at 60°C. The temperature at which 50% of PV particles disintegrate and release their 
RNA in the absence of cations is 43°C after 10 minutes compared with 61 °C for HAV 
(Siegl et al., 1984). In the presence of 1M MgCI2, this striking thermal stability is 
substantially enhanced, with the T50iio (temperature at which 50% of particles
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disintegrate after 10 minutes of incubation) of PV and HAV shifting to 61 °C and 81 °C 
respectively, generating empty capsids that retain antigenicity (Hollinger & Ticehurst, 
1996). The HAV particle is remarkably resistant to low pH conditions, with the loss of 
infectivity reported at pH 1.0 (Scholz et al., 1989). The virus is also relatively resistant to 
detergent inactivation, easily surviving 37°C for 30 minutes in 1% sodium dodecyl 
sulphate. There is no information concerning the radiation sensitivity of HAV, although it 
has been suggested that infectivity may be reduced by microwaving HAV-contaminated 
food (Lemon, 1994). A summary of the biophysical characteristics of HAV compared 
with those of other members of the picornavirus family can be found in Table 3.
Table 3: Biophysical characteristics of HAV compared with other picornaviruses
HAV ENTERO■ - RHINO CARDIO APHTHO
Serotypes 1 >70 >130 2 7
















Tissue Tropism Narrow Narrow to 
wide
Narrow Wide Wide





Acid (pH3) Stable Stable Labile Stable Labile
Heat (60°C) Stable Labile Labile Labile Labile
Guanidine Resistance Sensitive Sensitive Resistance Resistance




1.32-1.34 1.34 1.39-1.42 1.34 1.43-1.45
Sedimentation
coefficient 156-160 156-160 149 156 142-146
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1.3 Properties and replicative strategies of 
the picornaviruses
1.3.1 Picornavirus family
The Picornaviridae, among the smallest ribonucleic acid-containing viruses known, 
comprise one of the largest and most important families of human and agricultural 
pathogens. PV, human HAV, and FMDV virus are all members of the picornavirus 
family. So too are the HRVs, the single most important etiologic agents of the common 
cold. Because of the economic and medical importance of picornaviruses, it is not 
surprising that they have been prominently involved in the development of modem 
virology. Foot-and-mouth disease, the most important single pathogen of livestock, was 
in fact the first animal virus to be recognised when Loeffler and Frosch, in 1898, 
discovered that the causative agent passes through Berkfeld filters and was therefore 
much smaller than other microorganisms then known to transmit disease. That 
poliomyelitis was also caused by a virus was announced about a decade later by 
Landsteiner and Popper but it did not come to be called poliovirus until around 1955 
(Rueckert, 1996).
Members of the picornavirus family share a number of structural and organisational 
features (discussed below); however, picornaviruses are diverse in terms of their host 
specificity and the symptoms they induce. The picornavirus family is currently divided 
into five genera: the enteroviruses, the cardioviruses, the rhinoviruses, the aphthoviruses 
and most recently hepatovirus.
PV is the prototypic member of the Picornaviridae family and is classified with the 
enteroviruses, named for their ability to infect the alimentary (enteric) tract. A high 
degree of sequence similarity exists between the enteroviruses and rhinoviruses. 
Rhinoviruses are so called because of their adapted growth in the nasopharyngeal 
tissue; infection of this tissue by rhinovirus is the major cause of the common cold 
(Rueckert, 1996; Stewart & Semler, 1997).
Strains of EMCV make up one of the two serotypes of the cardiovirus genera, which are 
generally murine viruses, although their host range also includes humans, pigs, 
elephants, and squirrels. The second serotype of cardioviruses is Theiler's murine 
encephalomyelitis viruses (TMEV), which as their name suggests, infect mice and result 
in neuronal degeneration. The aphthoviridae include the foot-and-mouth disease
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viruses, which produce vesicular lesions in cloven-footed animals, especially in cattle, 
goats, pigs, and sheep. Formerly a member of the enteroviruses, HAV lacks a high 
degree of sequence homology with the enteroviruses and is now the sole member of the 
hepatovirus genus (Rueckert, 1996; Stewart & Semler, 1997).
As a basic pattern, the viruses divide into four main phylogenic branches, designated 
(arbitrarily) Groups I, II, III and IV. Group I viruses include the FMDV strains 
(aphthoviruses), Group II the murine cardioviruses (EMCV, Mengo, TMEV), Group III the 
hepaiitis A isolates, and Group IV the rhino, polio, Coxsackie, and other enteroviruses. 
For convenience (and whimsy) the strains in the latter group are sometimes referred to 
as "renteroviruses" because they include isolates from the more traditional rhino and 













—  Echovirus 23
—  Echovirus 22
-  Hepatitis A virus
Figure 6: Dendrogram constructed by comparing alignments of amino acid 
sequences for 15 picornaviruses
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Thus, for simplicity in the following sections, the 'renteroviruses' will be discussed 
primarily. Similarly the cardio- and aphtho-viruses will be covered together and finally 
the hepatovirus genus will be discussed.
1.3.1.1 General properties of virions
X-ray crystallographic structures have now been determined for at least one member of 
each picornavirus genus except HAV. All share similar features: a protein shell roughly 
5nm thick and 30nm in diameter surrounding a single strand of mRNA. The RNA core, 
including VPg, is largely invisible to X-ray crystallographic analysis because, unlike the 
protein shell, the RNA has no symmetry and can occupy 60 different orientations in the 
crystal lattice. Therefore, its contribution to the crystallographic diffraction pattern is too 
smeared to be solved by current methods (Rueckert, 1996).
The capsids of all picornaviruses are composed of a 60-subunit protein shell (20-30nm 
diameter) having intrinsic 5:3:2 icosahedral symmetry. Each subunit contains four 
nonidentical polypeptide chains (virion proteins: VP1, VP2, VP3, and VP4) the largest 
three of which share, as a common structural motif, a wedge-shaped, eight stranded, 
antiparallel p barrel configuration (Hogle et al., 1987; Luo et al., 1987; Acharya et al., 
1989; Kim et al., 1989). Sixty of these identical four-segmented subunits, now called 
protomers, are organised into pentameric units (dodecahedral model of shell structure). 
Of these subunits, 60-n are identical mature protomers (VP1, 2, 3, 4) and n are immature 
protomers (VPO, 1, 3). VPO represents an uncleaved precursor of chains VP2 and VP4. 
Picomavirions rarely if ever contain fewer than two immature subunits. The protein shell 
encapsidates a single-copy of the positive-sense RNA genome, which is released into 
the cytoplasm of a target cell (Palmenberg, 1990).
The dissociation of the shell can be explained by the presence of just two kinds of 
bonding domains within each of the identical protein subunits. One domain holds 
pentamers together; the other binds monomers into pentamers. Assembly of the 
picornaviral shell can be understood by the operation of these domains in reverse order 
















A dodecahedron laid out flat
The protein shell has a simple architecture, 





VPO -►VP4, 2 
Required for infectivity
Figure 7: Dodecahedral model of picornavirus structure and assembly
Adapted from Rueckert etal., 1969.
Coat proteins serve several key functions: (a) they protect the RNA genome from 
nucleases in the environment; (b) they recognise specific cell-coded receptors in the 
plasma membrane and is therefore one important determinant of host range and tissue 
tropism (disease pathology); (c) they determine antigenicity; (d) they carry directions for 
selecting and packaging the viral genome and provides a proteinase involved in 
maturation of the virion; and (e) they disgorge the RNA genome and deliver it through 
the cell membrane and into the cytosol of susceptible host cells. The atomic structure 
has provided significant insight into many of these functions (Rueckert, 1996).
The surface topography of each type of virus is as varied and characteristic as faces in 
the human race, hence the many serotypes listed in Figure 11, Figure 12, Figure 17, and 
Figure 18. Human rhinoviruses and enteroviruses, for example, feature prominent 
canyons, like ragged moats encircling a plateau at the centre of each pentameric unit in 




Myristic acid, also called /7-tetradecanoic acid, is covalently linked to amino terminal 
glycine residues on VP4 and to its precursors VPO, and P1 of most picornaviruses 
(Chow et al., 1987); HAV appears to be an exception (Tesar et al., 1993). Cellular 
enzymes are known to recognise the signal for acylation myristate -Gly-X-X-X-Ser/Thr (X 
= any amino acid) (Rueckert, 1996). In entero- and rhinoviruses the N-terminal glycine 
requires removal of a methionine residue, whereas in the cardio- and aphtho-viruses 
myristylation of the N-terminal glycine requires proteolytic removal of a leader peptide 
(Rueckert, 1996). Myristylation is required for assembly of pentamers (Ansardi et al., 
1992; Moscufu & Chow, 1992) and may also play a role in early stages of infection e.g. 
reorientation of the pentamer and release of VP4 (Chow etal., 1987).
1.3.1.2 General properties ofpicornaviral genome
The picornaviral genome consists of a single "plus" strand of messenger-active RNA that 
can be extracted out of virions by shaking aqueous suspensions of virus with an equal 
volume of buffer-saturated phenol. When the resulting emulsion is separated, proteins 
partition to the phenol-rich phase while RNA remains in the aqueous phase (Rueckert,
1996).
The specific infectivity of the naked RNA is about one millionth that of virions. That this 
infectivity is indeed due to free RNA and not to traces of surviving virions is shown by its 
extreme sensitivity to ribonuclease (<0.01 ng/ml). With intact virions, by contrast, where 
the RNA resides in a protective protein shell, the infectivity is completely resistant to 
ribonuclease even at millionfold higher concentrations. A single break in the RNA, 
whether free or inside the virus, is sufficient to destroy infectivity (Rueckert, 1996).
The first picornaviral RNA to be completely sequenced and molecularly cloned into DNA 
was that of PV1 (Kitamura et al., 1981; Racaniello & Baltimore, 1981). Since this 
landmark work, sequencing of many other picornaviral RNAs has shown a common 
organisational pattern (Figure 8).
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Figure 8: Structure of picornaviral RNA and genetic organisation of its polyprotein
The RNA is organised 5'-VPg-ntr-polyprotein-ntr-poly(A). ntr refers to nontranslated 
regions flanking the polyprotein. L434 is a mnemonic for recalling the polyprotein 
cleavage pattern; L specifies a leader protein found in cardioviruses, Theiler viruses, and 
aphthoviruses, but not in enteroviruses, HRVs, or human HAV. P1, P2, and P3 refer to 
precursor proteins cleaved by virus-coded proteinases into four, three, and four end 
products, respectively (Adapted from Palmenberg, 1990).
Sequence comparisons show significant variations in the size of picornaviral RNAs, 
which range in length from 7,209 to 8,450 bases. The 3' ends of all picornaviral RNAs 
are polyadenylated, as is characteristic of most eukaryotic mRNAs (Ahlquist & Kaesberg, 
1979). However, the 5' ends are not capped in the usual manner with 5'-5' triphosphate 
linkages. Instead, these viruses have small, viral-coded, genome-linked proteins (virion 
protein, genome; VPg) covalently attached by a tyrosine 0 4-phosphodiester bond to the 
5' uridylyl nucleotide of the RNA (Nomoto et al., 1976; Ambros & Baltimore, 1978; 
Rothberg et al., 1978). VPg sequences are rich in basic, hydrophilic amino acids and 
have only one tyrosine residue (the attachment site) at position 3 from the amino end of 
the peptide (Nomoto et al., 1976; Ambros etal., 1978; Rothberg et al., 1978; Ambros & 
Baltimore, 1980; Palmenberg, 1990).
Once released inside the cell, the single-stranded RNA genome must serve several 
distinct functions:
First, the genome serves as an unusual mRNA that successfully competes with cellular 
mRNAs for the cellular translation machinery. As mentioned, picornaviral genomic RNA 
is not capped but, instead linked to VPg. Interestingly, VPg is cleaved from all viral RNA 
molecules that serve as mRNA (VPg-pUUAAAACAG ...->  pUUAAAACAG ...), leaving a 
simple monophosphorylated pU terminus. The reason for removal of VPg, and the 
cellular enzyme catalysing it, is unknown. Initiation of translation is mediated by the 
IRES element, a peculiarly long (400nt) segment of the genomic RNA that directs
20
Chapter 1
efficient cap-independent translation in all picornaviruses. It has been previously shown 
that the picornaviral IRESes can be classified into three distinct groups on the basis of 
primary sequence and secondary structure conservation and also on the basis of their 
requirements for efficient internal initiation of translation in vitro as discussed later.
Second, the viral genome must carry signals to warrant separation from the components 
of the translational machinery so that it can assume the role of template for RNA 
replication. This switch from translation is important only in the initial stage of replication 
as in later stages the abundantly synthesised plus-strand RNA can choose to become 
mRNA (after VPg cleavage), serve as template for minus-strand synthesis, or be 
encapsidated to form progeny virions. However, the mechanism by which the infecting 
virion RNA switches to transcription is unknown.
Third, the viral RNA must express specific signals for the recognition of the viral 
replication proteins. Finally, progeny RNA that will not engage in translation or RNA 
synthesis will be encapsidated. The packaging process, which may also involve a 
specific packaging signal, is still obscure (Xiang et al., 1997).
1.3.1.3 General properties of picornaviral proteins
To complete a round of infection, a number of complex activities must be performed and 
coordinated. These include replication of the plus-strand RNA via minus-strand 
intermediates, translation, proteolytic processing, inhibition of host cell 
transcription/translation, virion assembly, and cell lysis. These activities must be 
directed by the 26 or more viral polypeptides detected in virus-infected cells, although 
most of these polypeptides are intermediates in the processing of the polyprotein 
precursor with no known function (Porter, 1993). Depending on the genus, about 11 to 
13 fully processed viral polypeptides are produced in infected cells (Figure 9). Of these 
about seven to nine proteins are nonstructural (i.e. noncapsid) proteins and their multiple 
roles both in virus replication and in the associated inhibition of cellular functions are 
discussed, for the different genera, in the relevant sections below.
To simplify homologue identification, in 1983 the European Study Group on the 
Molecular Biology of Picornaviruses adopted a uniform nomenclature system, 
designated L-4-3-4, based upon an idealised map of the picornavirus polyprotein (Figure 
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Figure 9: Picornavirus polyprotein and its processing
Processing map of a picornavirus genome. The striped bar over the 5'-nontranslated 
region indicates the presence of a polycytidylic acid tract found in EMC-like viruses and 
aphthoviruses. Synthesis of the protein is from left (N-terminus) to right (C-terminus). 
Growth functions, i.e., proteins needed for RNA synthesis and proteinases required to 
cleave the polyprotein, are encoded downstream from the capsid protein. gr represents 
the guanidine-resistance marker, a genetic locus affecting the action of a drug thought to 
block initiation of RNA synthesis. The 2B gene, hr, carries a host range determinant 
involved in RNA synthesis. The leader protein L is similarly only found in cardio- and 
aphthoviruses. The polyprotein of FMDV contains three 3B (VPg) segments, while all 
other viruses contain only one. Protein 2A has been identified only as a proteinase in 
the rhino- and enterovirus isolates (Adapted from Palmenberg, 1990).
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Mature viral proteins are derived by progressive posttranslational cleavage of the 
polyprotein and this proteolytic processing is a distinguishing feature of the picornavirus 
life-cycle. Though the RNA genomes are effectively monocistronic, the three-tiered 
cascade of primary, secondary and maturation cleavage efficiently produces the 
spectrum of viral proteins necessary for a productive infection (Palmenberg, 1990).
This proteolytic cascade, common to all picornaviruses, is largely mediated by a virally 
encoded protease, 3Cpro, the central enzyme in the cleavage cascade. An exception is 
the first polyprotein scission, a cotranslational (occurring as soon as the ribosome has 
reached the middle, or P2 region, of the genome), autoproteolytic cleavage referred to 
as the primary cleavage. The primary cleavage can occur in one of two places: between 
1D and 2A in enteroviruses and rhinoviruses, or between 2A and 2B in cardio- and 
aphthoviruses. In entero- and rhinoviruses, the cleavage is mediated by a self-coded 
protease 2Apro, and does not require downstream viral proteins. In cardio- and 
aphthoviruses, the cleavage also occurs cotranslationally but the 2A protein is not a 
protease and the mechanism is less understood. Less still is known about this process 
in HAV.
Most subsequent or secondary cleavages are effected by viral protease 3Cpro. The 
eventual result of the secondary cascade is release of all mature viral proteins necessary 
for establishment and completion of a successful infectious cycle as described in 1.3.1.4. 
The final cleavage within picornaviral polyproteins, maturation processing of the 1AB 
peptide (also called VPO), is, interestingly, not catalysed by any of the other identified 
viral proteases (Palmenberg, 1990).
Genetic and biochemical evidence have implicated all nonstructural PV polypeptides, 
including the proteinases, as being involved in genome replication (Wimmer et al., 1993). 
It is important to realise that, in most cases, the virus utilises processing intermediates 
and processing end products for different functions, a strategy designed to expand the 
menu of useful polypeptides derived from a small genome. The best-studied example is 
the P3 region of the polyprotein that yields 3AB and 3CDpro. 3AB is a multifunctional 
RNA-binding protein, the precursor for 3A and 3B(=VPg), the terminal protein, which is 
an essential component in the initiation of RNA synthesis. 3CDpro is a multifunctional 
proteinase, RNA-binding protein and the precursor of 3Cpro and 3Dpc)l (viral RNA 
polymerase). Equally important was the observation that many of the nonstructural 
proteins interact with each other to form homo- or heterodimers, or even oligomers 
(Lama etal., 1994; Molla et al., 1994; Paul etal., 1994; Pata etal., 1995; Xiang, 1995a).
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The most important interactions that have been suggested to play a crucial role in 
genome replication, particularly in PV, are:
1. 3AB + 3CDpro -> [3AB/3CDpro] + cloverleaf -> [3AB/3CDpro/cloverleaf]
2. 3AB + 3CDpro -> [3AB/3CDpro] -» 3AB + 3Cpro + 3Dpo'
3. 3ABmembrane-bound + 3CDpro -> 3A +VPg + 3CDpro
4. VPg + 3Dpo‘ + poly(A) + UTP -> VPgpU(pU) + 3Dptjl + poly(A)+PPj
5. 3AB + 3Dpo' -> [3AB/3D]super'p0‘
6. homointeractions of 2B, 3AB, and 3Dpo1
The AB/CDpro complex, formed after cleavage between the two polypeptide chains, plays 
a central role in these interactions (Molla et al., 1993, 1994). Depending on the 
environment, this complex can react in three different pathways depicted 1-3. 3AB 
stimulates proteolysis of proteinase 3CDpro thereby yielding polymerase 3Dpo‘ (2), while 
3CDpro cleaves membrane-associated 3AB to 3A and VPg (3). 3Dpo' will uridylylate VPg 
to VPg-pU(pU) (4), the primer for initiation of RNA synthesis. 3AB and 3Dpo1 can also 
form a complex with significantly increased polymerase activity (5) (Paul, 1994; Plotch & 
Palant, 1995) and it is likely that this complex is important for the recognition of the 3' 
end of the plus-strand template. At higher enzyme concentration, 3Dpt)l forms 
homooligomers with RNA binding and increased polymerase activity. Head-to-tail 
interactions between polymerase molecules along an extensive interface region have 
been observed in PV, leading to the suggestion that the enzyme complex funtioning in 
chain elongation may therefore be [3ABn/3Dm]superpo1 (Xiang, 1997 and references within).
Of the proteins mapping to the P2 region of the polyprotein, only 2C has been shown to 
have RNA binding activity (Rodriguez & Carrasco, 1993; Rodriguez & Carrasco, 1995). 
2A, a protease plays a role in host-cell shut-off, as well as effecting the primary cleavage 
in some picornaviruses. Protein 2B or 2BC is thought to participate in two of the major 
biochemical alterations that occur during PV infection: the inhibition of protein secretion 
(Doedens & Kirkegaard, 1995), in particular the disassembly of the Golgi complex 
(Sandoval & Carrasco, 1997) and the permeabilisation of the plasma membrane (Lama 




Table 4: Structural characteristics of HAV compared with other picornaviruses
HAV ENTERO RHINO CARDIO APHTHO
Virion Proteins
(Mr ) kDa
VP1 <33.2 33.5 32.4 31.7 23.3
VP2 24.8 30 28.5 29 24.7
VP3 27.8 26.4 26.2 25.1 24.3
VP4 <2.5 7.4 7.2 7.2 8.5
VPg 2.4 2.3 2.4 2.2 2.6-2.7
Genome
Length (kb) 7.48 7.44 7.21 7.84 8.4
%(G+C) 38 47 40 50 43
Poly(C)' - - - + +






1.3.1.4 General replication stra
Multiplication of picornaviruses occurs entirely in the cytoplasm. The initial event in 
infection is attachment of the virion to specific receptor units embedded in the plasma 
membrane (Figure 10, step 1). The function of receptors is twofold: to position the virion 
to within striking distance of the membrane (step 1), then to trigger a conformational 
change in the virion (step 2), which involves loss of an internally located protein and 
delivery of the viral RNA genome across the membrane and into the cytosol (step 3), 
where translation can begin (step 4) (Rueckert, 1996).
The successful completion of the picornaviral replicative cycle depends largely on the 
ability of the viral RNA species to compete with capped cellular RNAs for the host cell 
translation machinery. For all members of the picornavirus family except the 































Figure 10: Overview of the picornaviral infection cycle
This inhibition of capped mRNA translation, known as host cell shut-off, is due, at least in 
part, to the proteolytic cleavage of the cellular translation initiation factor elF-4y (formerly 
known as p220), which is part of the elF-4 cap-binding complex. The cleavage of elF-4y 
is carried out by the 2A proteinase during a rhinovirus, PV, and CV infection and by the 
leader (L) proteinase during FMDV infection. Cleavage leads to the inactivation of the
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cap-binding complex, so that cellular capped mRNAs can no longer associate with the 
40S ribosomal subunit. Picornavirus RNA translation can continue unabated in such 
conditions, as it is initiated in a cap-independent manner by ribosomes which have 
entered the RNA internally. Initiation of translation is mediated by the internal ribosome 
entry site (IRES) element, a peculiarly long higher order RNA structure of about 400 nt 
present in the picornaviral 5' NTR. The different picornaviral IRESes can be separated 
into three distinct groups on the basis of sequence and structural considerations 
required for their optimal activity: type I entero-and rhinoviral IRESes (PV, HRV, 
ECHOvirus); type II cardio- and aphthoviral IRESes (FMDV, EMCV); type III IRESes, of 
which the HAV element is the only example to date (Borman and Kean, 1997). 
Translation is a crucial step because synthesis of new viral RNA cannot begin until the 
virus has successfully manufactured the virus-coded RNA-synthesising machinery.
By confiscating ribosomes and other protein-synthesising machinery of the host cell, the 
incoming RNA strand directs synthesis of a polyprotein, which is then cleaved into 
segments while still in the process of synthesis. Translation of a viral message is not 
restricted to a single ribosome; indeed, polysomes carrying up to 40 ribosomes have 
been reported in PV-infected cells. In PV, the first fragment released from the nascent 
polyprotein is a coat precursor protein (P1); the next released is a mid-piece precursor 
protein (P2); and the last segment released is P3. Each segment is released from the 
polyprotein by proteinases encoded in the poly protein (Figure 10).
Protein P3 can be further cleaved by two separate mechanisms (Palmenberg & 
Rueckert, 1982). One mechanism is a monomolecular or cis cleavage, i.e. a 
concentration-independent self-cleavage that yields (a) a proteinase, 3C or 3CD; (b) a 
protein, 3AB, which is involved in initiating RNA synthesis; and (c) an RNA polymerase, 
3D, which can elongate a primer RNA bound to a template RNA. The other mechanism 
is trans cleavage, i.e. bimolecular cleavage, involving one P3 molecule and the 3C 
proteinase generated by cleavage of another P3 precursor molecule. Cis cleavage of 
P3 presumably dominates the early stages of infection when the concentration of viral 
proteinases in the cytosol is low. Insights from the crystal structure of PV suggest that 
proteinase 3C cannot be active in the monomeric form (Chernaia et al., 1993; Matthews 
et al., 1994). Cis or intramolecular cleavage might therefore be accomplished by pairing 




The first step in synthesis of new viral RNA is to copy the incoming genomic RNA to form 
complementary minus-strand RNA (Figure 10, step 5), which then serves as a template 
for synthesis of new plus strands (step 6). Synthesis of plus-stranded RNA, which 
occurs on smooth endoplasmic reticulum, is initiated so rapidly (20- to 50-fold that of 
minus strands) that it generates multistranded replicative intermediates (Rl) consisting of 
one minus-stranded template and many plus-stranded copies. During the early steps of 
replication, newly synthesised plus-strand RNA molecules are recycled to form additional 
replication centres (step 7 step 5 step 6) until, with an ever-expanding pool of plus- 
stranded RNA, a greater and greater fraction of the plus-stranded RNA in the RC is 
packaged into virions (Rueckert, 1996).
Virion assembly (steps 8 and 9) is controlled by a number of events. One is that, before 
assembly can begin, coat precursor protein P1 must be cleaved to form immature 
protomers composed of three tightly aggregated proteins (VPO, 3, 1). Early in the 
infection cycle this cleavage is likely very slow because the concentrations of P1 and the 
necessary proteinase (3C or 3CD) are low. Later, with increasing proteinase activity, the 
rising concentration of immature (5S) protomers triggers assembly into pentamers (step 
8), which then package the plus-stranded VPg-RNA to form provirions (step 9). Infected 
cells often contain empty 80S protein shells that are reversibly dissociable into 15S 
subunits. Whether pentamers condense around RNA or RNA is threaded into 80S shells 
is still a subject of debate (Rueckert, 1996).
Provirions are not infectious. Formation of infective 150-160S particles (step 10) 
requires a "maturation cleavage" in which most of the VPO chains are cleaved to form 
the mature four-chain subunits (VP4, 2, 3 ,1)  characteristic of picornavirions. Completed 
virus particles, which often form crystals in infected cells, are ultimately released by 
infection-mediated disintegration of the host cell (step 11) (Rueckert, 1996).
The time required for a complete multiplication cycle from infection to completion of virus 
assembly, generally ranges from 5 to 10 hours. The precise timing depends on 
variables such as pH, temperature, the virus, the host cell, the nutritional vigour of the 
cell, and the number of particles that infect the cell (Baltimore et al., 1966). Some 
viruses such as hepatitis A, set up nonlytic infections that persist indefinitely (Provost & 




The available data on rearrangements (recombinations, deletions, and insertions) of 
picornavirus genomes fit the replicative template switch model postulating that an 
incomplete nascent minus RNA strand leaves the template and resumes its synthesis on 
another template (or another locus of the original template). The nascent strand 
dissociation is believed to be facilitated by the elongation pausing caused by secondary 
structure elements or nucleotide misincorporations. Rearrangements may involve 
(nearly) identical or completely dissimilar pairs of parting and anchoring sites (Agol,
1997). Such rearrangements contribute to both conservation and variation of the 
picornaviral genomes and observations for the individual genera will be discussed under 
the relevant headings.
1.3.2 Enterovirus and rhinovirus genera
The enteroviruses include not only the PVs but also the CVs, the ECHOviruses (Enteric 
Cytopathic Human Orphan), human enteroviruses (68-71) and a number of nonhuman 
enteric viruses.
ENTEROVIRUSES
Human polioviruses 1-3 Human enteroviruses 68-71
Human Coxsackieviruses A1-22, 24 Vilyuisk virus
A23 is ECHOvirus 9 Simian enteroviruses 1-18
Human Coxsackieviruses B1-6 Bovine enteroviruses 1 and 2
Human ECHOviruses 1-7, 9, 11-27, 29-34 Porcine enteroviruses 1-8
ECHO 8 is ECHO 1
ECHO 10 is reovirus, type 1
ECHO 28 is human rhinovirus 1A
Figure 11: Enterovirus serotypes
Infections with the enteroviruses - even the more virulent members of the genus - are 
characterised by a high proportion of subclinical manifestations. The clinical expressions 
of infection, when they do occur, range from severe and permanent paralysis, 
sometimes fatal, to minor undifferentiated febrile illnesses. Although certain 
enteroviruses have been more frequently responsible for epidemics involving a specific 
syndrome, at other times or in other places the same serotypes may be associated with 
sporadic or epidemic infections having different clinical manifestations or producing no 
symptoms. However, different enteroviruses may produce the same syndrome.
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Enteroviruses multiply throughout the alimentary tract and cause a variety of infections. 
Because of their acid stability, enteroviruses that have undergone limited replication in 
the oropharynx survive transit through the stomach and become implanted in the lower 
intestinal tract, where they undergo more extensive multiplication. Rhinoviruses, which 
inhabit the upper respiratory tract, not only differ in that they are acid labile (they begin to 
lose infectivity at pH 6 and are completely unstable at pH 3), and this lability has become 
a defining characteristic of rhinoviruses, but are further distinguished from enteroviruses 
by their low optimal temperature of replication (33°C), reflecting their adaptation to the 
nasopharynx. Inactivation at low pH is associated with appearance of empty capsids 
and a loss of VP4 similar to receptor binding-induced uncoating, but possibly by a 
different mechanism. The buoyant density of enteroviruses in CsCI is 1.34g/ml, whereas 
rhinoviruses have a density of 1.4g/ml. Enteroviruses and some rhinoviruses can be 
stabilised by molar magnesium chloride against thermal inactivation (Melnick, 1996).
Rhinoviruses are the most commonly isolated viruses from persons experiencing mild 
upper respiratory illnesses (common colds). In contrast to the enteroviruses, 
rhinoviruses do not appear to replicate in the intestinal tract. They also differ from 
enteroviruses in their more extreme species specificity and more fastidious growth 
requirements (Rueckert, 1996). There are over 100 different serotypes of HRVs, which 
are divided into two groups based on their cellular receptors. The majority of HRVs 
(belonging to the “major receptor group”) use ICAM-1 as their receptor. The remaining 
rhinoviruses (belonging to the “minor receptor group”), except for HRV87, utilise the low 
density lipoprotein receptor (Zhao etal., 1997 and references therein).
RHINOVIRUSES
Human rhinoviruses 1A-100,1B, "Hanks" Bovine rhinoviruses 1-3
Figure 12: Rhinovirus serotypes
PV is the prototype enterovirus that, in many ways, has spear-headed research not only 
on picornaviruses but on plus-strand RNA viruses in general and, along with rhinoviruses 
and CVs, will be the viruses which feature predominantly in the subsequent section.
1.3.2.1 Properties of virion
The diameter of the HRV is about 300A and the molecular weight of the virus is 
approximately 8.16 x 106 Da, including RNA. The crystal structures of HRV14
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(Rossmann etal., 1985), HRV16 (Oliveira etal., 1993), and HRV3 (Zhao eta!., 1996), all 
major receptor group viruses, have been determined, as well as the structure of HRV1A 
(Kim etal., 1989), a minor receptor group virus.
The PV particle is approximately 28nm (31 oA) in diameter with a molecular mass of 8.43 
x 106 (Hogle et at., 1985). The virion, composed of 60 copies of viral proteins VP1 to 
VP4 as previously described and illustrated in 1.3.1.1, contains an RNA core that when 
unravelled and fully extended for measurement in the electron microscope has a length 
of about 2,500nm. The tightly packed RNA resides in the central cavity of a thin protein 
shell.
Figure 13: Molecular surface of poliovirus type 1 and rhinovirus 14
Molecular surface of PV type 1 Mahoney (left) and rhinovirus 14 (right), radially depth 
cued, as solved by X-ray crystallography by Hogle et al. (1985) and Rossmann et at. 
(1985) respectively. Images courtesy of J. -Y. Sgro on Silicon Graphics taken from 
http://www.bocklabs.wisc.edu/imaQes/polio1.ipg and r14.jpg
With general acceptance of the 60-protomer model of capsid structure, attention focused 
on the structural organisation of the four-segmented protomer. The most prominent 
feature of the protomer, evident in HRV14, was the presence of a prominent cleft or 
“canyon” on its surface. This canyon was later shown to be the acceptor site for the 
receptor used by the virus to infect susceptible host cells. Of the four proteins, VP1 
exhibits the greatest sequence variability and VP4 the least. VP1 is also the dominant
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protein, playing key roles in surface topography and in several viral functions, including 
antigenicity, receptor attachment, and probably also viral uncoating (Rueckert, 1996). In 
PV and HRV the dominant neutralising immunogenic sites reside in the BC loop of VP1. 
Some ECHOviruses and CV As attach to a group of receptors called integrins, which 
have the ability to discriminate between different RGD-containing proteins (Rueckert, 
1996).
In all of the rhinoviruses for which the structure is known, there is some density on the 
fivefold axes that cannot be interpreted as a part of the capsid protein and Zhao and 
colleagues (1997) have proposed that it is a Ca2+ ion. The putative Ca2+ ions in HRVs 
have been proposed to play a role in viral stability. When viruses enter the cell, the 
lower pH of the endosome and the lower Ca2+ concentration in cytoplasm may help to 
release the Ca2+ ion and facilitate virus uncoating.
Empty capsids lacking the viral RNA are generated during infection by most 
picornaviruses. Although such capsids have the same total protein content as do normal 
virions, they are noninfectious and are considered to be a by-product of infection or a 
storage form of capsid proteins. Since empty capsids lack viral RNA, maturation 
cleavage of VPO does not usually occur.
1.3.2.2 Properties of genome
Enteroviruses contain a 7.5 kb single-stranded RNA molecule of positive polarity, which 
has a highly unusual structure that is, nevertheless, representative of many RNA viruses 
which is translated into a large polyprotein. This polyprotein is processed by virally 
encoded proteinases to the P1 region proteins, which form the viral capsid, and the P2 
and P3 region proteins, most of which are required for viral RNA (vRNA) replication as 
previously mentioned.
Human rhinovirus (HRV) is a positive-stranded RNA virus, the genome being about 7.2 
kb in length, with an ORF that encodes for a single polypeptide of about 3000 amino 
acids which is also proteolytically processed; eight of nine cleavages being catalysed by 
the 3C and/or the 3CD proteinases.
VPg is attached to the stem of a stable stem-loop "cloverleaf" structure, the first domain 
of the unusually long 5'NTR. Genetic analyses have shown that the integrity of the stem
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regions in stem loops b and d, but not their sequence, is important for viral viability. On 
the other hand, the sequence of the loops in b and d appears to be very important as 
insertions or nucleotide changes lead to severe RNA replication phenotypes. The 
outstanding length of the 5' NTR of the renteroviruses (610-747nt) and the high degree 
of homology within this region (64%-99%), which exceeds that of any coding region in 
the genome, suggest an important role. Additions to or deletions of part of the NTR of 
PV and HRV genomes resulted in transcripts that were not infectious, while transcripts 
containing completely intact NTRs were infectious. This 5'NTR harbours a second, very 
complex structure, the IRES that consists of domains II to VI. The IRES controls the 
translation of the polyprotein. Rivera et al. (1988) found that of the nine members of 
these genera they studied, conserved features in the 5' NTR included long stretches of 
conserved sequence, pyrimidine-rich regions, and over 20 stem and loop structures. 
Pyrimidine-rich regions have been implicated as serving as recognition sites for 18S 
rRNA which contains a purine-rich region at its 3'-terminal end and may play an 
important role in initiation of translation, initiation of positive-strand replication, and 





Figure 14: Poliovirus 5' NTR with type I IRES
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Following the 5' NTR comes the ORF for the polyprotein that occupies nearly 90% of the 
viral genome. Finally the genome is terminated by the 3' NTR consisting of two stem- 
loop structures and poly(A). The cloverleaf and entire 3' NTR are involved in RNA 
synthesis. Pilipenko et al. (1992) compared the 3' NTR sequences of entero- and 
rhinoviruses and proposed that they have highly organised secondary structures (stem 
loops or domains X, Y, Z) that can be grouped into three categories; (i) a single stem- 
loop structure (Y) in rhinoviruses (e.g. HRV14); (ii) two stem-loop strucutres (Y, X) in 
PVs; and (iii) three stem-loop strucutres (X, Y, Z) in some Coxsackieviruses and 
ECHOviruses (e.g. CV B3). Jacobson et al. (1993) proposed that a pseudoknot, formed 
between sequences in domain Y and upstream sequences may play an important role, 
however some sequences in loops Y and X of PV1 and CV B3 are complementary and 
could interact in a "kissing mode", and this model, which is supported by genetic 
analyses, is currently favoured. Interference with kissing resulted in an RNA replication 
phenotype whereas mutations interfering with the pseudoknot showed little or no effect 
of the growth properties of the corresponding viral variants. The heteropolymeric regions 
of the 3' NTR of different picornavirus species is very diverse, even within a single 
genus. HRV14 has, in addition, evolved a third structural element essential for RNA 
synthesis that maps, surprisingly, to the coding region P1 of the capsid precursor.
1.3.2.3 Properties of viral proteins
Of the viral noncapsid proteins, 2A, 3C, and 3CD are viral proteinases involved in the 
processing specific to PV polyprotein. 2C has ATPase activity, 3B is VPg, 3D is a viral 
RNA-dependent RNA polymerase which has unwinding activity, 2B and 2C are 
considered to play important roles in viral RNA synthesis, and 3A could have an 
important role(s) in uridylylation of VPg in the process of initiating RNA synthesis (Shiroki 
etal., 1995).
In the renteroviruses, the 2A region codes for a cysteine proteinase (2Apro), which shares 
significant sequence homology to the trypsin-like small serine proteases (Sommergruber 
et al., 1989; Lu et al., 1995), cleaves only at tyrosine-glycine bonds in PV, and is 
autocatalytically released from the nascent polyprotein by rapid cotranslational cleavage 
in cis at its own amino terminus at (Y, T, H, F, A, or V)-G dipeptide pairs and studies by 
Wang et al. (1997) suggest that the eight residues upstream of the scissile bond are 
sufficient for the cleavage by HRV2 2A. Cleavage is a prerequisite for further proteolytic 
processing of the capsid precursor region.
34
Chapter 1
The first cleavage of the HRV polyprotein is catalyzed by the 2A protease and has been 
found to be a co-translational event. This cleavage, occurring between the capsid 
protein VP1 and the N-terminus of 2A itself, separates the viral capsid from the 
nonstructural proteins.
A wealth of evidence, both genetic and biochemical, shows that a second function of 
2Apro is to initiate the cleavage of the large subunit elF-4G (also known as p220) of the 
eukaryotic translational initiation factor 4 (elF-4), thereby causing a shut-off of cap- 
dependent translation of cellular mRNAs (Wang et al., 1997). The inactivation of the 
cellular cap-dependent translational machinery facilitates the IRES-driven translation of 
the viral open reading frame. However, recent studies showed that cap-dependent 
translation could still occur in the presence of cleaved p220. It is believed that PV 2Apro 
does not directly cleave p220, rather it activates a quiescent cellular protease which then 
cleaves p220 (Wyckoff et al., 1990). In contrast, rhinovirus or Coxsackievirus 2Apro is 
capable of cleaving p220 directly. No cellular protein has been shown to be directly 
cleaved by PV 2Apro to date (Yalamanchili etal., 1997a).
In addition, recent studies from a number of groups suggest that the 2Apro protein of PV 
is involved in viral RNA replication and in the frans-activation of IRES-driven translation 
(Molla etal., 1993(b); Macadam etal., 1994; Lu etal., 1995). Interestingly, PV genomes 
containing heterologous 2A-encoding sequences displayed different translational 
activities in vitro, while the kinetics of proteolytic processing of their translation products 
were indistinguishable from those of wild-type PV (Lu et al., 1995).
It has been shown that PV-encoded protease 3Cpro directly inhibits host cell transcription 
catalysed by RNA polymerase II (Pol II) and III both in vivo and in vitro. The TATA- 
binding protein (TBP), a component of transcription factor TFIID, is directly cleaved by 
3Cpro, which leads to Pol II transcription shut-off. The cleaved TBP is unable to form a 
complex with the TATA box. Likewise, the largest subunit of the Pol III DNA-binding 
transcription factor is cleaved by 3Cpro, leading to shut-off of Pol III transcription. 
Apparently cleavage of TBP does not contribute to Pol III transcription shut-off, although 
the multicomplex Pol III transcription factor TFIIIB contains the TBP polypeptide. 3Cpro 
also catalyses shut-off of Pol I transcription. However, the precise nature of the Pol I 




Davies et a!. (1991) demonstrated that transient expression of 2Apro in eukaryotic cells 
inhibited both cellular translation and transcription. The inhibition of transcription seen in 
cells expressing 2Apro could be due to a primary effect or a secondary effect caused by 
inhibition of translation. TBP contains a cleavable tyrosine-glycine bond, and it was 
recently determined that 2Apro directly cleaves the single tyrosine-glycine bond (at 
position 34) of TBP. This cleavage is also seen in virus-infected cells. Surprisingly, 
despite TBP cleavage at this bond, Yalamanchili et a i (1997a) found that 2Apro was 
unable to inhibit RNA Pol II transcription in vitro.
Ziegler etal. (1995) have not only shown that the protein and RNA components involved 
in the stimulation of IRES-driven translation are interchangeable between rhino- and 
entero-viruses, but not the distantly related cardioviruses, but also that the HRV2 2A 
proteinase is more efficient at stimulating IRES-driven translation than any other protein 
identified to date and that the stimulation correlates with the enzymatic activity of the 2A 
proteinase, the proteolytic conversion of some cellular component(s) being involved in 
2A proteinase-mediated translational transactivation. More recently, Haghighat et al. 
(1996) demonstrated that HRV2 2Apro cleaves purified recombinant elF4G directly in 
vitro, although relatively poorly. In contrast, a complex of elF4G with elF4E is a 
preferable substrate for HRV2 2Apro. It was therefore proposed that elF4F, and not the 
elF4G subunit alone, is the primary target for cleavage by HRV2 2Apro. Consistent with 
these results, restoration of cap-dependent translation in 2Apro-treated extracts requires 
both the elF4E and elF4G subunits of the elF4F complex.
Recently it was found that the expression of PV protein 2B or 2BC results in two of the 
major biochemical alterations that occur during enterovirus infection: the inhibition of 
protein secretion (Doedens & Kirkegaard, 1995), in particular the disassembly of the 
Golgi complex (Sandoval & Carrasco, 1997) and the permeabilisation of the plasma 
membrane (Lama & Carrasco, 1992). The relevance of these activities to the viral life­
cycle remains to be elucidated (van Kuppeveld etal., 1997). Both biochemical functions 
in CV B3 are dependent upon the integrity of one of two hydrophobic domains found 
within enterovirus 2B proteins, one, the more amino-terminal of which, a predicted 
cationic amphipathic a-helix, involved in both the inhibition of protein secretion and the 
permeabilising activity, whereas mutation of the second hydrophobic domain, near the 
C-terminus of 2B, has a greater effect on the secretion inhibition function (van Kuppeveld 
et al., 1997). A moderate degree of hydrophobicity of this domain is essential for the 
function of 2B. In CV B3, mutations which caused a major increase or decrease in 
hydrophobicity as well as the introduction of negatively charged residues interfered with
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virus growth by an effect on its interaction with the membrane (van Kuppeveld et al., 
1995). By interfering with the 2B/2C cleavage site, the importance of efficient processing 
at this site was identified and subsequently it was determined that a critical level of CV 
B3 protein 2B or 2BC, or both, may be required to alter membrane permeability (2C does 
not alter plasma membrane permeability) and, possibly as a consequence, to shut-off 
host cell translation (van Kuppeveld et al., 1996). Sandoval & Carrasco recently (1997) 
demonstrated that transient expression of the PV protein 2B in COS-7 cells causes the 
disassembly of the Golgi complex by a process preceded by the accumulation of the 
protein in the Golgi area. Inhibition of protein secretion during enterovirus infection is not 
a direct result of increased membrane permeability, but is likely to result from alteration 
or sequestration of membranes or proteins required for secretory transport. This could 
simply be a consequence of RNA RC assembly, or it may play an additional role in viral 
amplification such as blocking host antiviral responses (Doedens & Kirkegaard, 1995).
Proteins 2C and 2BC, in the absence of other PV proteins, associate with membranes 
and induce formation of vesicles and therefore may be the viral protein(s) responsible for 
the generation of the small membrane vesicles on which vRNA replication takes place. 
In addition to inducing proliferation of membranous vesicles PV 2BC also alters cellular 
calcium homeostasis (Aldabe et al., 1997). As well as vesicles, protein 2C induces 
formation of a tubular, myelin-like membrane structure which is not seen in PV-infected 
cells (Cho et al., 1994). Although the 2C protein lacks a defined membrane binding 
domain, Echeverri & Dasgupta (1995) demonstrated that the N-terminal region, 
encompassing amino acids 21-54 and containing a putative amphipathic helix, plays an 
important role in membrane binding both in vivo and in vitro, whereas the C terminus 
half, includes the NTPase motifs (RNA binding is abolished when C terminal 74 amino 
acids are removed (Rodriguez & Carrasco, 1993)) and the other amphipathic helix, 
appears to be unecessary for membrane association. More recently however, Teterina 
etal. (1997b) showed that both the N- and C-terminal regions, but not the central region, 
of 2C interact with intracellular membranes and induce major changes in their 
morphology, leading to the prediction that the protein folds into a structure composed of 
three domains, connected by small conserved loops or disordered regions. Prior to this, 
the observation that 2C copurifies with 3AB, led to a speculation that 2C may be 
associated with membranes by virtue of its affinity to 3AB (Takegami et al., 1983). Paul 
et al. (1994) believe it is likely that 2C associates with the membrane through a 
hydrophobic face formed on an alpha helix and/or p sheets. It has been seen since, 
however, that cells expressing plasmid-encoded PV 2C or 2BC protein, in the absence 
of other viral proteins, displayed extensive rearrangement of intracellular membranes, to
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form vesicles as well as other organised membrane structures by virtue of an interaction 
of 2C and 2BC with intracellular membranes (Cho et al., 1994; Aldabe & Carrasco, 
1995).
Protein 2C is a small NTPase with RNA binding properties (Rodriguez & Carrasco, 1993; 
Mirzayan & Wimmer, 1994) located at the cytoplasmic surface of the virus-induced 
membrane vesicles where it may be involved in attaching the vRNA to the membranous 
RC, and is one of the most highly conserved viral proteins among all picornaviruses.
Identification of putative NTP binding motifs in the highly conserved region of the protein 
suggested that 2C may be involved in binding and/or hydrolysis of NTP and led to a 
speculation that 2C may function as an RNA helicase (Gorbalenya et al., 1990), 
consistent with its proposed role in RNA replication. The NTP binding activity of the 
central domain of 2C is not required for vesicle induction, although, when fused to the N- 
terminal domain, profound changes in the specific membrane architecture, generating 
formation of numerous smooth vesicles, is seen (Teterina et al., 1997b). Recently, PV 
2C and 2BC were expressed in E. coli as MBP-fusion proteins and shown to have 
ATPase and GTPase activities (Rodriguez & Carrasco, 1993). A recombinant 
baculovirus expression system was used to produce PV 2C that also displayed ATPase 
activity (Mirzayan & Wimmer, 1994). However, no helicase activity was reported and it 
remains to be seen whether 2C possesses an RNA helicase activity which may perhaps 
function at the initiation step of RNA synthesis (Cho et al., 1994).
Guanidine has been shown to inhibit viral RNA replication by affecting coupling between 
the NTP binding and/or splitting, on the one hand and the 2C function (related to 
conformational changes), on the other, thereby implying that oligomerisation of 2C is an 
essential step in the replication of viral genome (Tolskaya et al., 1994). The data of 
Vance et al. (1997) support a role for 2C in the assembly of mature virions. Perhaps 2C 
affects the association of capsid precursors with each other or with the RNA to facilitate 
the encapsidation of the RNA.
Mutations in 2B and 2C have been shown to be important with respect to RNA synthesis 
and host range change that occurs during adaptation and passage of virus in cell culture 




3B is usually referred to as VPg, a small peptide of 22 amino acids in PV covalently 
linked via tyrosine to the 5' termini of all full-length and nascent viral plus- and minus- 
strand RNAs. PV VPg is removed by a cellular unlinking enzyme (leaving 5' pU) from 
those viral RNAs destined to become mRNAs. An attractive hypothesis is that 5'-linked 
VPg serves as an encapsidation signal, leaving the mRNAs free for translation without 
obstruction from the replication machinery (Porter, 1993).
The PV-encoded, membrane-associated VPg-precursor, 3AB, a 12kDa polypeptide 
abundantly found in PV-infected cells, has been implicated in the initiation of viral RNA 
synthesis and may be used for the delivery of VPg to the membrane-associated PV RC. 
RNA RCs form on membranous vesicles that contain viral proteins, newly synthesised 
viral RNA, and host proteins. Both RNA synthesis and RNA packaging occur in 
association with the membrane-associated RC (Hope et a/., 1997). It has been 
postulated that a uridylylated form of VPg (VPg-pU) or a precursor thereof (3AB-pU) may 
serve as primer for 3Dpo1, a mechanism by which the viral protein would be linked to the 
nascent strand. A second hypothesis proposes that hairpins, formed at the 3' termini of 
the viral RNA, serve as primers. VPg supposedly functions subsequently as a highly 
specific nuclease that cleaves the hairpin structure thereby linking itself to newly 
generated 5' termini of viral RNA (Tobin et al., 1989). Available evidence favours the 
first of these models (Lama et al., 1994).
Expression of PV 3AB and 3A is extremely toxic to bacteria and this toxicity correlates 
with the ability of these proteins to make E. coli cells permeable to different compounds. 
This suggests that the two PV polypeptides may act as pore-forming proteins when 
expressed in E. coli (Lama et al., 1992; Lama & Carrasco, 1996). The C-terminal 22 
amino acids of 3A constitute a hydrophobic domain through which 3AB is believed to be 
anchored onto cytoplasmic smooth membranes where active RNA replication occurs. 
Further evidence making 3AB, which associates with intracellular membranes in isolation 
(Datta & Dasgupta, 1994) and binds directly to polymerase 3D, a likely candidate for the 
membrane tether for 3D polymerase comes from Hope and colleagues (1997) who 
discovered that detergent-solubilised and purified 3AB can be co-immunoprecipitated 
with either 3D polymerase or 3CD protease, which contains all 3D sequences but does 
not exhibit polymerase activity. Detergent-solubilised 3AB has been shown to stimulate 
both the polymerase activity of purified 3D polymerase and the proteolytic activity of 3CD 
in cell extracts. However, detergent-solubilised 3AB is not a substrate for 3CD cleavage, 
whereas membrane-associated 3AB is.
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PV protein 3AB has been shown to form a complex with and stimulate the activity of the 
viral RNA polymerase, 3Dpo1 (Plotch & Palant, 1995) which will be discussed later. More 
recently Hope et al. (1997) described the use of the yeast two-hybrid system to isolate 
and characterise mutations in the 3D polymerase that cause it to interact less efficiently 
with 3AB and concluded that interaction between 3AB and 3D or 3D-containing 
polypeptides plays a role in RNA synthesis during PV infection. Lama et al. (1994) have 
investigated the properties of purified recombinant PV 3AB and have suggested that it 
acts as substrate for viral proteinases and as cofactor for RNA 3Dp0‘. Molla et al. (1994) 
have shown that addition of VPg or 3AB stimulated the appearance of the cleavage 
products of 3CDpro by an effect on the 3C protease of PV.
The 3C regions of all picomaviruses code for a protease (3Cpro) with a critical function as 
the enzyme responsible for the majority of maturation cleavages in the precursor 
polyprotein (Figure 9). PV 3C proteinase proteolytically cleaves the translated 
polyprotein at 9 of 12 specific processing sites and is largely responsible for the 
liberation of the individual gene products. Proteolysis by 3Cpro occurs in a complex and 
incompletely understood cascade of cis and trans cleavages at mainly Q-G, Q-S, Q-A, 
and Q-N pairs (except in FMDV strains for which cleavage sites are more diverse, e.g., 
E-G, V-G, C-N, L-N, and Q-G). PV 3C also participates in the formation of the viral 
replicative initiation complex where it specifically recognises and binds the stem-loop 
structure in the 5' NTR of its own genome (Andino et al., 1990, 1993; Harris et al., 1994). 
The recognition site of 3C is located on the opposite side of the molecule in relation to its 
proteolytic active site and is centred about the conserved KFRDIR sequence of the 
domain linker (Gorbalenya et al., 1989; Hammerle et al., 1992; Mossimann et al., 1997). 
Mosimann et al. have recently (1997) published the refined X-ray crystallographic 
structure of the PV 3C gene product.
PV 3C is comprised of two six-stranded antiparallel p-barrel domains and is structurally 
similar to the chymotrypsin-like serine proteinases. The shallow active site cleft is 
located at the junction of the two p-barrel domains and contains a His40, Glu71, and a 
Cys147, equivalent to Cys146 in HRVs, as the active site nucleophile in the catalytic 
triad (Lawson & Semler, 1991; Leong et al., 1993; Mosimann et al., 1997). The 
polypeptide loop preceding Cys147 is flexible and likely undergoes a conformational 
change upon substrate binding (Mosimann et al., 1997). Certain substitution mutations 
in the putative catalytic triad of PV 3Cpro had differential effects on cleavage at different 
3Cpro-sensitive sites, which complicated the task of identifying the members of the
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catalytic triad (Hammerle etal., 1991; Kean etal., 1991).
Severe inhibition of host cell RNA transcription by all three classes of host cell RNA 
polymerase (Pol I, Pol II, and Pol III) is observed in PV-infected cells, and known as host 
cell transcription shut-off, however, the RNA polymerases themselves are not affected 
by PV infection. There is persuasive evidence that PV 3Cpro specifically and directly 
cleaves the TATA-binding protein (TBP) subunit of transcription factor IID both in vivo 
and in vitro, leading to a loss of formation of of the TBP-TATA box complex in vitro, 
resulting in the inactivation of Pol II transcription (Yalamanchili et al., 1996). More 
recently the cyclic AMP-responsive element binding protein (CREB) mediated activated 
Pol II transcription was shown to be inhibited by proteolytic cleavage of the 
phosphorylated, transcriptionally active form of the CREB protein by 3Cpro (Yalamanchili 
et al., 1997b) and that cleavage mediated by 3Cpro both in vivo and in vitro of another 
transcription activator, Oct-1 occurs (Yalamanchili et al., 1997c). Similarly, a RNA Pol III 
DNA-binding transcription factor, NIC, the a subunit of which actually contacts the Pol III 
promoter and is the target of cleavage, is cleaved and inactivated by 3Cpro (Shen et al., 
1996) In addition, PV 3Cpro completes the proteolysis of an active form of transcription 
factor NIC to an inactive form by about 5h post-infection, suggesting that this is an 
important mechanism for the shut-off of host transcription by Pol III. PV 3Cpro is further 
implicated in the destruction of a transcription factor complex essential for Pol I 
transcription. Thus, 3Cpro may be centrally involved in inhibiting transcription by the 
three major classes of RNA polymerase (Porter, 1993). In 1993 Leong and co-workers 
provided evidence that HRV14 3Cpro, which binds specifically to the 5' NTR of the viral 
RNA, has different domains for this binding and its proteolytic activities. Joachims et al. 
(1995) have also described the cleavage of a cytoskeletal protein, microtubule- 
associated protein 4 (MAP-4) by 3Cpro and 3CDpro in PV and HRV14 which correlated 
with a marked “collapse” of microtubules during late infection.
3Cpro of the renteroviruses is unable to perform, however, the VP0-VP3 cleavage, which 
is carried out by 3CD (Ypma-Wong & Semler, 1987; Takahara etal., 1989) and which in 
the case of purified PV 3CDpro can accumulate due to the cleavage efficiency of 3C at its 
carboxy terminus being rather low (Gauss-Muller et al., 1991). The 3CD precursor of the 
renteroviruses is, in fact, the catalytic unit vested with the cleavage of most capsid 
precursor locations. (Ypma-Wong et al., 1988). Unlike 3Cpro cleavages, the 3CD 
cleavage at VP0-VP3 site in PV requires myristylation of the amino terminus of the 
polyprotein, and an unknown cellular cofactor facilitates efficient 3CD cleavage at the PV
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VP0-VP3 site and, to a lesser extent, at the VP3-VP1 site. It should be kept in mind that 
3CD may also play a role (with or without 3Cpro) in the modification of transcription factor 
complexes associated with the inhibition of cellular Pol I, Pol II, and Pol III transcription 
by PV (Porter, 1993). Genetic evidence has revealed that, surprisingly, 3CDpro has the 
propensity to bind the 5'-terminal cloverleaf of PV RNA, but this occurs only in the 
presence of a 36kDa host factor, one of two proteins (p50 and p36) that interact with this 
cloverleaf structure. Host protein p50 is the eukaryotic elongation factor EF-1a, and p36 
an N-terminal fragment thereof (Harris et al., 1994). Mutations in stem-loop structures 
within the first ~100 nt of the PV 5' NTR and mutations in the 3C domain of protein 3CD 
affect in vitro binding of 3CD to viral RNA and plus-stranded RNA synthesis in infected or 
transfected cells (Andino et al., 1990, 1993). The 3AB-3CDpro complex, however, 
interacts with cloverleaf RNA and binds to 3' RNA fragments of the PV genome in the 
absence of host factor (Harris et al., 1994). Very recently, Roehl et al. (1997) 
demonstrated that the activity of the 3CD/3C proteinase results in the modification of a 
cellular precursor protein, yielding a 38kDa protein which binds to PV negative-strand 
RNA and is thought to be used for assembling a ribonucleoprotein complex at the 3' end 
of PV negative-strand RNA. Hope et al. (1992) concluded from their work that 3CDproM 
(M designates the cleavage site mutant 3CDpro T181K) can process both structural and 
nonstructural precursors of the PV polyprotein and moreover, that cleavage of 3CD, 
inactive as a RNA polymerase (Harris et al., 1992), to 3Dpo1 is needed to activate the 3D 
RNA polymerase (Gauss-Muller et al., 1991). Blair et al. (1996) described mutations in 
the 3C residues (Thr-142 and Ala-172) of 3CD which may exert their effects on RNA 
binding through formation of an RNA binding domain rather than via direct interaction 
with RNA, as might be expected of properly positioned basic amino acid residues. Davis 
et al. (1997) have shown that the 3D domain of 3CD proteinase had some influence on 
substrate recognition, but did not have dramatic impact on its interaction with inhibitors, 
and thus suggest that the active site of 3CD has a similar conformation to that of the 3C 
proteinase.
The 3D regions of all picomaviruses code for a polymerase (3Dp0‘) which exhibits a RNA 
chain elongation activity that is dependent upon an RNA template and a DNA or RNA 
primer. The enzyme has been extensively purified from PV-infected cells, and its cDNA 
has been cloned and expressed in bacterial and insect cells (Richards et al., 1987; 
Plotch et al., 1989; Neufeld et al., 1991). Neufeld et al. demonstrated in 1991 that PV 
RNA polymerase from native and recombinant sources, when purified exhibit identical 
properties validating the use of these recombinant proteins for further studies.
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Several amino acid sequences are conserved among all RNA-templated polymerases, 
most likely reflecting their shared catalytic functions and serving as a signature to identify 
RNA-dependent polymerase function. In PV 3Dpo1, a 52kDa protein, these conserved 
residues include a YGDD sequence (residues 326 to 329), D-233, and G-289. Three- 
dimensional structural analysis of several polynucleotide polymerases reveal striking 
core structures, which are designated fingers, palm, and thumb domains, referring to the 
resemblance of the core structure to a right hand. The conserved residues in PV 3Dpo1 
appear to reside in the palm domain and are thought to contribute to the catalytic pocket 
of the polymerase. D-328 and D-329 are residues which are probably involved in metal 
ion coordination. The roles of the other conserved residues are unknown. These 
enzymes, however, all share properties of template and nucleotide binding, as well as 
catalysis of phosphodiester bond formation. The PV 3Dpo1 contains two peptide 
segments previously shown to cross-link to nucleotide substrates via lysine residues 
(Richards et al., 1995) and in fact, a lysine residue at position 61 of 3Dpo‘ has been 
shown to be essential for polymerase catalytic function and that a basic (lysine or 
arginine) residue at position 276 is required for some other function of 3D important for 
virus growth but not for RNA chain elongation or polyprotein processing (Richards et al., 
1996). Data produced by Richards et al. in 1992 suggested that nucleotide binding 
causes conformational alteration of the polymerase enzyme’s structure.
Together with 2C and the cellular protein actin, 3CD, 3C, and 3D are present in highly 
purified preparations of FMDV and PV. They remain bound in variable amounts to the 
RNAs when they are extracted with phenol. As described before RNA prepared by 
these methods is rapidly degraded, but hydrolysis can be prevented by antibody against 
E. coli-expressed 3D, indicating that it is the RNA polymerase that has nuclease activity 
(Newman & Brown, 1997).
In the studies by Richards etal. in 1987, it was shown that PV polymerase was produced 
(a) by intermolecular cleavage of a fusion protein by another protein with protease 3C 
activity and (b) by cleavage of a fusion protein containing 3C and 3D sequences in the 
same polyprotein. Cho and colleagues (1993) reported that highly purified recombinant 
PV 3Dpo1 can in vitro unwind a long stretch of RNA duplex so as to displace strands for 
continued polymerisation of nascent chains and that the unwinding reaction proceeds in 
an elongation-dependent, ATP-independent manner requiring no additional proteins. It 
was determined also that PV 3Dpo1 was able to add multiple adenylate (A) residues to the 
3' terminus of RNA in a nontemplated manner which was classified by Neufeld et al. in 
1994 as a terminal adenylyl transferase (TATase) activity and proposed to effect the
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initiation of plus-strand synthesis. PV 3Dp0‘ is, in fact, the only protein required for 
elongation of RNA chains in vitro, however current models propose that in vivo 3Dpo‘ 
must function in concert with other viral and/or cellular proteins (Cho et al., 1993) as 
discussed later.
1.3.2.4 Replication
The replication of rhinoviruses is similar to that of enteroviruses except that time to 
completion is more variable and tends to be longer. In one-cycle growth experiments, 
new virus is frequently detectable in 5 to 7 hours, and a cycle is complete in 10 to 12 
hours, whereas first appearance may be as late as 9 hours and completion as late as 15 
to 17 hours. Yields vary from 10 to 200 plaque-forming units (PFU) per cell.
Molecules belonging to the immunoglobulin (Ig) superfamily serve as receptors for the 
major-group HRVs (intercellular cell adhesion molecule 1) and for PV (unknown cellular 
function) (Bibb et al., 1994). Interestingly, Zhang & Racaniello (1997) have shown that 
expression of the PV receptor is not sufficient to permit replication in the mouse gut 
indicating that other factors are involved in determining the ability of PV to replicate in 
this tissue. ECHOviruses 1 and 8 attach to integrin VLA-2 and avp3 integrin is reported 
to be the receptor for CV A9 and ECHOvirus 22. Minor-group HRVs, except HRV87 
(Uncapher et al., 1991), bind to cells via members of the low-density lipoprotein receptor 
family (Zhao et al., 1997). Decay-accelerating factor (DAF, CD55) is recognised as the 
cellular receptor for at least six ECHOvirus serotypes and as a receptor for CVs B1, B3, 
and B5, and is the HeLa cell receptor for enterovirus 70 (Kamauchow et al., 1996). 
Interaction of group B CVs with permissive cells may also involve a nucleolin-like 
membrane protein.
PV enters susceptible cells via the PVR as mentioned above, however the mechanism of 
uptake and uncoating are still unknown (Xiang et al., 1997). PV and HRVs have been 
shown to attach to their receptor molecules on the cell membrane and enter the host cell 
or deliver its RNA by a poorly understood process involving the loss of VP4 and the 
formation of 135S “A” (“Altered”) particles. After the “A” particles, found to be infectious 
in the case of PV (Curry et al., 1996), have released their RNA, they form empty 80S 
particles. In PV, the N-terminus of VP1 is externalised and is available for proteolytic 
cleavage (De Sena and Mandel, 1977) and is thought to be deployed optimally for entry 
of the RNA genome (Curry et al., 1996). While uncoating of major-group viruses results
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in lysis of the endosomal membrane or release of subviral 135S and 80S particles into 
the cytoplasm, as described above, it appears that minor-group rhinoviruses transfer 
their genomic RNA to the cytoplasm through a pore in the endosomal membrane 
(Schober et al., 1998).
Some picomaviruses inhibit cellular protein synthesis soon after infection. In the case of 
PV-infected HeLa cells, shut-off occurs quickly within the half hour or so required for 
attachment, penetration, and uncoating of the RNA genome. Host-cell shut-off and the 
proteins involved have been discussed previously.
Upon entry into the cell, the infecting RNA genome serves as messenger to direct the 
synthesis of virus-specific proteins which are required for RNA replication. The viral 
proteins are synthesised by translating a single large coding region on the genome, and 
the protein products are then produced by cleavage of the nascent polyprotein by the 
mechanisms discussed in 1.3.1.3. The time required for a ribosome to translate the 
RNA genome of PV from one end to the other is about 10 to 15 minutes. Because 
replication cannot begin until the polymerase gene has been completed, this probably 
represents the minimum time between the time of uncoating and the moment when 
synthesis of viral RNA can begin. Elongation of the RNA molecule is performed by 3Dpt)l, 
some of which is found in the cytoplasm of infected cells tightly associated with its RNA 
template and with cellular membranes. Most 3Dpo‘ is found in soluble form. It is not 
likely engaged in RNA synthesis but may simply result from the excess produced by the 
polyprotein strategy of expression.
Because ribosomes are known to bind and initiate translation internally on the PV 
genome, it is perhaps not surprising that elF-2a is found in complexes that map to 
regions (nt 97-182 and nt 510-629) within the 5' NTR. del Angel et al. (1989) speculate 
that the interactions between the complexes and elF-2a may represent an early step in 
virus replication that precedes ribosome binding to PV mRNA.
It is unclear which translation features are required for IRES-driven translation initiation; 
however, it has only recently been shown that cellular proteins other than the generally 
recognised translation initiation factors are necessary. A 50kDa protein has been shown 
to interact with the RNA stem-loop structure located between nt 186 and 221 in PV type 
1 RNA (Najita & Samow, 1990). Another protein present in abundance in HeLa cells 
compared with RRLs, called p52, found to be identical to the previously identified La
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autoantigen, involved in host cells in the termination and reinitiation of RNA polymerase 
III transcription, has been shown to interact with PV RNA consisting of the 
polypyrimidine-rich region and stem loop VI and without which translation of PV in RRLs 
produced aberrantly initiated polypeptides. Das et al. (1994) discovered a small yeast 
RNA called l-RNA which competes with virus RNA structures within the 5' NTR which 
bind the cellular p52 protein. It is reported elsewhere that the addition of at least two 
HeLa cell proteins to RRLs is required for efficient initiation of translation from the PV or 
HRV IRES. One of these, a 57kDa factor has been shown to interact with HRV and PV 
IRESs, as well as EMCV, HAV and FMDV. The physical, biochemical, and antigenic 
properties of p57 were found to be identical to the previously identified polypyrimidine 
tract-binding protein, PTB, which binds to pyrimidine-rich sequences in mammalian 
introns and is involved in pre-mRNA splicing. The second protein, of 97kDa, which 
apparently acts in concert with PTB, remains to be identified. Hellen et al. (1993) 
showed that immunodepletion of HeLa extracts using PTB antibodies nearly abolished 
both PV and EMCV translation; however, addition of purified PTB to these extracts did 
not restore translation, indicating that additional required factors may interact with PTB. 
Blyn and co-workers in 1996 isolated specific host cell proteins that bind to stem-loop IV 
of the PV 5' NTR and identified one of these as poly (rC)-binding protein 2 (PCBP2) and 
in 1997 Blyn et al. demonstrated that PCBP2 is an essential factor required for efficient 
translation of PV RNA in HeLa cells.
In addition to the requirement for noncanonical cellular translation initiation factors, 
IRES-driven translation can be stimulated by viral components. Ziegler et al. (1995) 
demonstrated that the HRV2 2A proteinase is more efficient at stimulating IRES-driven 
translation than any other protein identified to date and that the stimulation correlates 
with the enzymatic activity of the 2A proteinase, the proteolytic conversion of some 
cellular component(s) being involved in 2A proteinase-mediated translational 
transactivation. Hence, 2A is important not only as a downregulator of cellular 
translation, but also as an enhancer of IRES-driven virus-specific translation (Macadam 
etal., 1994).
Efficient functioning of the IRES itself involves two smaller elements in PV: UUUCC, 
considered to be an analogue of the Shine-Dalgarno sequence because of its 
complementarity to a segment at the 3' end of the 18S rRNA, whose position, about 
100nt upstream from the initiating AUG, in the PV system must be strictly fixed, relative 
to upstream c/s-acting elements, and an AUG, which may not necessarily serve as an
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initiation codon (Pilipenko etal., 1992).
One of the major determinants for picomaviral species and tissue tropism is the 
presence or absence of the viral receptor on the cell surface. However, several results 
suggest that the IRES may also represent a determinant of viral tropism. In vitro studies 
have identified different cell factors that bind to the different IRESes and that may be 
required for translation initiation (del Angel et al., 1989). Shiroki et al. suggested in 1997 
that host factor(s) affecting IRES-dependent translation of PV differ between human and 
mouse and that the mutant IRES constructs they created detect species differences in 
such host factor(s), and the interaction between IRES and host factors is an important 
determinant of host specificity of PV replication.
Similarly, RNA sequences in the 5' NTR of CV B1 and CV B3 are involved in virulence, 
however the sequences involved in the cardiovirulent phenotype are not within the 
boundaries of the predicted IRES. Thus, the interactions between IRESs and cellular 
cofactors involved in translation may only be involved in the cell-type tropism of some 
picornaviruses (Borman et al., 1997; Stewart & Semler, 1997). Johnson and Semler 
(1988) suggest that sequences involved in “replicative fitness” are located in the 5' NTRs 
of picornavirus genomic RNAs.
Further to their investigations into the poor translation efficiency of genome-length HRV 
RNA in vitro using HeLa cell-extract supplemented RRL compared with PV, Todd et al. 
(1997a) suggested that the rate-limiting step for rhinovirus assembly during an infection 
occurs at a step other than translation and the primary impediment for rhinovirus 
production is likely in packaging or capsid assembly discussed later.
One would envisage that the polymerase released from the polyprotein might first bind to 
a specific site near the 3' end and then translocate to the end of the poly(A) tract to 
initiate negative strand RNA synthesis (Oberste & Flanegan, 1988). Flanegan and 
Baltimore (1977) isolated a template-dependent RNA polymerase from PV-infected cells, 
capable of copying poly(A) complexed to an oligo(U) primer, which may be important in 
initiating minus-strand synthesis by making poly(U), and which, by being unable to copy 
poly(A)-deficient RNA, supports the observation that poly(A) is required for infectivity.
The genomic RNA 3' NTR is believed to be a major cis-acting molecular genetic 
determinant for regulating picornavirus negative-strand RNA synthesis by promoting RC
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recognition, however it has been shown that while intact RNA 3' NTRs may be required 
for efficient viral replication, they are not essential and they may have evolved to 
promote or regulate negative-strand synthesis, but the basic mechanism of replication 
initiation is not strictly template specific and may rely primarily upon the proximity of 
newly translated viral replication proteins to the 3' terminus of template RNAs within tight 
membranous RCs (Todd etal., 1997b).
Higher-order RNA structures in the 3' NTR, however, are thought to play a pivotal role in 
the initiation of negative-strand RNA synthesis. The secondary structures predicted for 
the enterovirus 3' NTR all seem to point to a conformation consisting of two (X and Y) to 
three (X, Y, and Z) hairpin structures, in which the poly(A) tract is partly included. It has 
been suggested that interactions occur either between the two predominant loops (X and 
Y) within the 3' NTR or between one hairpin loop (Y) and the flanking coding sequences 
of the 3D RNA polymerase (Jacobson et al., 1993), forming two higher-order tertiary 
RNA structures. The higher-order RNA structure of the 3' NTR appears to be 
maintained by an intramolecular kissing interaction between the loops of the two 
predominant hairpin structures (X and Y) within the 3' NTR, and this kissing interaction 
has been shown by Melchers et al. (1997) to be the essential structural feature of the 
origin of replication required for its functional competence in virus negative-strand RNA 
synthesis.
The presence of such a tertiary structure in the 3' NTRs of both the CV B- and PV-like 
viruses allows the exchange of the 3' NTR between these viruses without affecting 
subsequent replication since the binding sites are identical (Rohll et al., 1995). On the 
other hand, the rhinovirus genus 3' NTR, consisting of a single stem-loop structure 
cannot form a kissing interaction, and a PV chimera containing the HRV14 3' NTR is, 
interestingly, still capable of initiating PV negative-strand synthesis (Rohll et al., 1995). 
One explanation might be that this occurs because ribonucleoprotein (RNP) complex 
formation occurs differently in the rhinovirus 3' NTR, although formation of the complex 
as such is sufficient to initiate replication.
As in the case of other complex higher-order RNA structures like pseudoknots, it is 
reasonable to assume that the kissing interaction in the 3' NTR acts as a specific binding 
site for viral and/or cellular proteins involved in the initiation of negative-strand synthesis. 
Indeed, Harris et al. (1994) have described the formation of a 3'-terminal RNP complex 
composed of a 3AB-3CD interaction with the 3' NTR. The subsequent proteolysis of
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3CDpr° releases the 3D polymerase. Protein 3AB then forms a complex with protein 3D 
to stimulate the activity of the virus polymerase (Harris et al., 1994; Lama et al., 1995; 
Plotch & Palant, 1995) which may use the uridylated VPg to initiate negative-strand RNA 
synthesis. A similar protein 3D interaction with tertiary (pseudoknot) structure in the 3' 
NTR of EMCV has been proposed. Although Harris et al. (1994) did not consider other 
proteins to contribute to the complex formation, Todd et al. recently (1995) provided 
evidence for an interaction of the 3' NTR with certain unidentified cellular proteins as well 
and more recently, (1997b) Todd et al. suggested that, while specific 3'-terminal RNA 
sequences and/or secondary structures may have evolved to promote or regulate 
negative-strand synthesis, the basic mechanism of replication initiation is not strictly 
template specific and may rely primarily upon the proximity of newly translated viral 
replication proteins to the 3' terminus of template RNAs within tight membranous RCs.
The importance of RNA structures in RNA-protein interactions is generally known, and 
the tertiary RNA structure can be essential for stabilising the structure for the subsequent 
interaction with proteins (Frankel etal., 1991).
Studies on cell-free synthesis of minus strands from the plus template indicate that at 
least three proteins are required: virus protein 30^', a VPg donor, and one or more host 
factor proteins [a terminal uridylyl transferase (TUT), and perhaps a protein kinase]. Two 
models have been proposed to explain the initiation of viral RNA synthesis on the 
poly(A) tail by 3D1”1: .
In one model, oligo(U) is added enzymatically to the 3' terminus of the poly(A) by the 
host factor, TUTase, and the oligo(U) hybridises to the poly(A) to initiate RNA chains. 
Subsequently , the genome-linked peptide, VPg, cleaves the hairpin and is linked to the 
5'-end of the oligo(U). In the second model, a uridylylated derivative of VPg is the 
primer, although the evidence suggests that it is mainly plus-strands that are synthesised 
by this mechanism (Takegami et al., 1983). The cellular kinase and uridylylate 
transferase are however no longer under consideration and it has very recently come to 
light that synthetic VPg can be uridylylated with 3Dpt)l in a reaction requiring only poly(A) 
template UTP and magnesium. If uridylylation, however depends on a poly(A) template, 
how does 3Dpt)l select the 3' end of PV RNA over the sea of polyadenylated mRNAs? 
Currently, available evidence suggests that the heteropolymeric 3' NTR preceding the 
poly(A) serves as a recognition signal for RNA selection (Xiang etal., 1997).
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Synthesis of the negative-strand RNA yields a double-stranded intermediate, the RF 
which separates. The role of the RF in replication is not clear, but some of the RF in 
infected cells is in fact hair-pinned, i.e., contains a covalented attached plus and minus 
strand (Wimmer et al., 1993). The involvement of RF as intermediate has not been 
generally accepted but is almost a necessity in view of the role of the cloverleaf. Xiang 
et al. (1997) speculate that the left end of RF may serve as a (double stranded) 
recognition signal for plus-strand RNA synthesis. The negative-strand therefore acts as 
a template for amplification of positive-sense genome. The RNA duplex unwinding 
activity of 3Dpo1 demonstrated by Cho et al. (1993) may be responsible for the separation 
of the two RNA strands of the RF at the replication fork.
Initiation of plus strands in a defined in vitro system by PV 3DpDl either does not occur or 
is extremely inefficient. One reason is likely to be that PV plus-strand initiation depends 
on the formation of a RNP complex on the plus strand, comprising 3CD, 3Cpro, 3Dpo‘ (?), 
and a ribosome-associated cellular protein (p36) bound to the proximal 88 nucleotides of 
the 5' end folded into a cloverleaf-like structure. This structure is dispensable for the 
initiation of PV minus strands, suggesting that the complex is essential only for plus- 
strand initiation (Plotch et al., 1989; Andino et al., 1990, 1993). Indeed Borman et al. 
(1994) have shown that essential viral RNA replication signals are located in the 3' 
region of the PV IRES, some 500 nt downstream from the 5' end of the RNA and that a 
second element is located within the IRES whose disruption only minimally affects 
translation efficiency while greatly impairing RNA synthesis.
Shiroki and co-workers (1995) revealed that a host cellular factor(s) interacts with a RNA 
segment around nt 133 of the plus-strand RNA or the corresponding region of the minus- 
strand, contributing to efficiency of plus-strand RNA synthesis.
It is unclear whether PV 3CD, 3Cpro, and 3Dpot all participate in complex formation, 
although it has been demonstrated that purified, recombinant HRV14 3Cpro binds in vitro 
specifically to the 5' terminal 126 nt of the 5' NTR of the viral RNA in the absence of 
3CD and 3Dpo1. Overall, the results support an intriguing speculative model of 
membrane-bound plus-strand initiation in trans involving the following steps (i) 3Dpo1 (and 
an associated protein(s))?, having just completed the synthesis of a minus strand, 
provides the signal for assembly of the RNP complex on the 5' end of the neighbouring 
plus strand, (ii) The complex catalyses the formation of VPg-pU(-pU) via 3AB. The 
presence of a template RNA molecule in the complex triggers the uridylylation reaction
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(Takeda etal., 1987) (iii) The complex then catalyses the initiation of a new plus strand 
in trans, using the RNA template and the newly formed VPg-pU(-pU) as primer for the 
3Dpo‘ (Takeda et al., 1987), at the 3' end of the neighbouring minus strand newly 
exposed by the formation of the complex (Takegami et al., 1983). The source of 3Dpt)l 
for plus-strand synthesis could be either 3Dpt)l or 3CD already present in the RNP 
complex (Porter, 1993). McBride et al. (1996) have identified cDNAs for several host 
proteins that interact with 3D polymerase, most notabiy a 68kDa protein that associates 
with Src during mitosis, Sam 68. Sam 68 coimmunoprecipitates with 3D polymerase 
from infected cells, is found on PV-induced membranes, and relocalises drammatically 
during PV infection which makes it a strong candidate for a host protein with a functional 
role in PV replication. Banerjee et al. (1997) have demonstrated that 2C specifically 
binds to the 3' cloverleaf structure of the negative-strand RNA but not to the 5'-end 
cloverleaf of the positive-strand and as we have seen already, is important in initiation of 
positive-strand RNA synthesis (see Figure 15).
Replication takes place via a replicative intermediate (Rl) which consists of a full-length 
template strand with some six to eight nascent daughter strands. (Figure 10, step 6). 
The time required for synthesis of each RNA molecule has been estimated at about 45 
seconds. The Rl-dependent plus-strand RNA synthesis proceeds in a viral complex, 
proposed by Plotch and Palant in 1995 to contain PV protein 3AB, which forms a 
complex with and stimulates the activity of the viral RNA polymerase and 3AB, 3Dp0‘ (or 
its precursor 3CD) and viral RNA are brought together in host cell vesicles in which all 
viral RNA synthesis occurs.
Schlegel etal. (1996) revealed that the intracellular rearrangements that accompany PV 
infection result in the formation of double-membrane structures, containing replication 
protein 2C, that contain markers from the ER, the trans Golgi stacks and TGN, and 
lysosomes. The double-membrane structure implies that the membranes do not form by 
a simple budding mechanism from a discrete compartment in the cell but instead must 
form either by a double-budding mechanism or, more likely, by wrapping of cytosol by 
membranous compartments.
Likely candidates for the protein or activity that causes accumulation of these double­
membrane structures and rearrangement of the intracellular secretory apparatus include 
PV 2A, 2C, 2BC, which have been found to induce, in various expression systems, the 
formation of large electron-dense cytoplasmic structures, vesicle formation, and 
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Figure 15: Models of PV minus and plus-strand RNA synthesis
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Direct transfection of plasmids encoding 2B or 3A cause the inhibition of protein traffic 
between the ER and the Golgi apparatus and the expression alone of 3A, found to 
localise to intracellular membranes (Datta & Dasgupta, 1994), causes a normally 
secreted protein to colocalise with an ER luminal protein and which were subsequently 
found redistributed throughout the cytoplasm (Doedens & Kirkegaard, 1995).
Upon isolation from infected cells, the virus-induced vesicles were found to form rosettes 
which surround the RC, can be isolated in a functional state, and continue to initiate, 
elongate and release progeny plus-strand RNA in an in vitro transcription system 
(Takeda et al., 1986). It was later found (Egger et al., 1996) that these rosettes could 
reversibly dissociate into virus-induced vesicles and reassociate into rosettes. These 
vesicles carry a set of viral structural and nonstructural proteins as well as Rl RNA and 
Egger etal. (1996) showed that the initiation and elongation of plus strands on individual 
vesicles are comparable to those in rosettes and also, by use of detergent treatment, 
that initiation, but not elongation, is dependent on vesicular membranes.
To form a rosette could be advantageous for virus replication because it could greatly 
increase the effectiveness and speed of plus-strand RNA synthesis. There are two main 
reasons for this: first, macromolecular crowding, exerted by the mass of vesicles, leading 
to an enhanced concentration of factors necessary for RNA synthesis; and second, the 
providing of more membrane-bound initiation sites (Harris et al., 1994) for the Rl. This 
allows the Rl, or rather its minus-strand template RNA, to easily move on within the 
rosette and to combine with its 3' end with the next initiation site on the same or the next 
vesicle. This would make the rosette, as such, a higher-order structure with functional 
subunits (vesicles), although in the infected cell the rosette could well be a short-lived, 
transient structure, changing its framework of individual vesicles continuously as the 3' 
end of the minus strand moves on (Egger etal., 1996).
A terminal adenylyl transferase (TATase) activity has been identified in preparations of 
purified PV 3Dpo1, which is able to add nontemplated A residues by virtue of this activity. 
The implication of the results of Neufeld et al. (1994) is that in vitro, 3Dpo‘ can synthesise 
minus-strand RNA in a primer- and template-dependent manner and that once that has 
occurred, the minus-strand RNA can fold back to prime elongation of a plus-strand of 








Figure 16: A possible role for TATase activity during poliovirus plus-strand RNA 
initiation and synthesis
(1) Poliovirus 3Dp0‘ completes synthesis of minus-strand RNA in a template-dependent 
manner. (2) Following addition of the last templated nucleotide, 3D90' adds three to six 
extra A residues by virtue of its TATase activity. (3) The 3'-terminal A residues fold back 
and pair with the U residues in the minus-strand RNA, priming synthesis of plus-strand 
RNA by 3Dpo1. (4) Uridylylated VPg is transferred to the plus-strand RNA between the 
extra A residues on the template and the base-paired product strand. (5) Following 
transesterification, the protein VPg is linked to the nascent plus-strand RNA (Modified 
from Neufeld etal., 1994).
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Once initiated, PV RNA synthesis proceeds exponentially, producing new templates and 
thus continually increasing the rate of synthesis. During this early stage of synthesis the 
rate doubles every 15 minutes until about 10% of the final yield has been produced. At 
this point the rate of synthesis becomes constant, accumulating linearly for an additional 
hour until the number of RNA molecules reaches about 4x105 per cell. Some 2-5% of 
the total viral RNA in infected cells consists of minus strands. The mechanism 
controlling this differential synthesis is not clear. A substantial fraction of the RNA 
synthesised during the exponential phase of synthesis is destined to become mRNA, 
whereas about 50% of that made during the linear phase is packaged into virions. The 
switch from exponential to linear synthetic rate may reflect siphoning of the RNA pool 
into virions. Troxler et al. (1992) found that PV plus-strand RNA was found accumulated 
in the close surroundings of the membrane-bound complex and that riboprobes from two 
different regions of the viral genome hybridised with the same frequency, suggesting that 
the accumulation of hybridisation signal in the vicinity of the RC represents completed 
rather than RI-RNA. They proposed that newly made viral plus-strand RNA is set free 
from the core RC but remains associated with it, thereby forming a steady-state pool. 
This pool might be the site where the viral progeny RNA proceeds to encapsidation, thus 
linking RNA synthesis and virion formation. Specific interactions between the 2A- 
encoding sequence and the capsid proteins exist and a modification of these interactions 
by point mutations destabilises the virus, thereby contributing to the mouse 
neurovirulence of PV1 (LS-a). If this is the case, it is possible that sequences mapping 
to the coding region of 2Apro function as an encapsidation signal (Lu et al., 1994).
The type of subviral particle that associates with progeny RNA and proceeds to RNA 
encapsidation has not yet been identified, although some investigators have proposed 
that 14S pentamers, rather than empty capsids, may be involved in encapsidation of 
progeny plus-strand RNA and in fact Pfister et al. (1995) have shown that encapsidation 
of PV RNA starts in the RC and is initiated by 14S pentamers. RNase digestion 
experiments with isolated RNA-synthesising RC have shown, that upon completion, 
virtually all 36S RNA (in contrast to Rl RNA) becomes RNase accessible, presumably 
after changing its location in the RC. The altered RNase accessibility seems to be 
coupled to or closely following the release of 36S RNA from the Rl, since no RNase- 
protected 36S RNA can be found in an actively RNA-synthesising RC. Concomitantly or 
following the completion of 36S RNA, its association with 14S pentamers occurs.
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1.3.2.4.1 Adaptation to cell culture and attenua tion of virulence
Among the enteroviruses that are cytopathogenic - which include PVs, ECHOviruses, 
many of the CVs, and the enterovirus type 68-71 - growth can usually be obtained 
readily in primary cultures of human and monkey kidney cells and in some cell lines 
[such as HeLa, Vero, buffalo green monkey (BGM), or, for some serotypes, WI-38]. Until 
recently, primates were the only animal host susceptible to all three PV types (Wood & 
Macadam, 1997). The host restriction is due to the absence of a cellular receptor found 
on human and primate cells, the genes of which have been identified and isolated which 
has allowed the establishment of transgenic mouse lines that express the human 
receptor (TgPVR mice). A significant finding concerning PV host range is that variants of 
PV1 that carry the VP1 B-C loop (exposed loop formed by amino acids 95-105), which 
contributes substantially to neutralisation antigenic site I, of PV2 are neurovirulent in 
mice (Murray et al., 1988). Furthermore, Moss and Racaniello (1991) identified second 
site suppressors, which restore virulence to viruses attenuated by changes in the B-C 
loop and suppressor mutations were located in the N-terminal extension of VP1 on the 
interior surface of the virus particle. The B-C loop and the internal suppressors are 
therefore host range determinants. Because the internal host range determinants are in 
a structure known to be important in conformational transitions of the virion, the host 
range of PV may be determined by the ability of virions to undergo transitions catalysed 
by cell receptors.
In contrast, most rhinoviruses of humans, grow efficiently only in human and some 
primate tissues; the presence of receptors on cell surfaces again influences this tissue 
specificity. Initial isolations were accomplished with rhesus monkey kidney tissue 
cultures, but a clear superiority of human tissues for isolation and growth was shown 
later. The increased frequency of isolations with human tissue cultures led to the 
commonly used designation of M- and H-strain rhinoviruses. The M strains grew in both 
monkey and human tissues, whereas the H strains grew only in human tissues; this 
separation is no longer used because it was shown that many H strains could be 
adapted to grow in monkey tissues. Persistent infection of HeLa M cells with type 2 has 
been described, but the basis for persistence was not identified (Couch, 1996).
Continued passage of viruses in vitro leads to incorporation of mutations into its genome 
as the virus adapts to growth in cell culture. The Sabin vaccine strains of the three 
serotypes of PV have played a large part in the effective control of poliomyelitis in 
developed countries and the molecular basis of attenuation of these live viral vaccines
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has been extensively studied. A striking feature has been the discovery of attenuating 
determinants in the 5' NTR of all three vaccine strains. Point mutations in the 5' NTRs of 
PVs, known to be involved in attenuation of neurovirulence (Skinner et a/., 1989), have 
been shown to affect the ability of viruses to grow at elevated temperatures (Macadam et 
al., 1991,1992). This temperature sensitivity is almost certainly a measure of the ability 
of part of the 5' NTR to form a specific secondary structure capable of interacting with 
cellular and/or viral factors and the ultimate effect of secondary structure perturbation by 
attenuating nucleotides may be on translation, mediated by factor-binding deficiencies. 
PVs containining a mutation at amino acid 424 of the 3Dpo1 displayed a temperature 
sensitive phenotype (Burns et al., 1992). The genetic basis of the attenuated phenotype 
of the type 3 vaccine strain (Sabin 3) has been shown to be almost entirely explicable by 
just two point mutations (Westrop et al., 1989). One of these, at nt 472 in the 5' NTR, 
reverts rapidly when the virus replicates in the human gut and other changes including 
intertypic recombination occur frequently in vaccinees and recent evidence suggests 
that, although apparently not encountering factors that favour rapid reversion toward 
high neurovirulence (Georgescu et al., 1997), this attenuation determinant might disrupt 
the interaction of the PV 5' NTR with PTB in the CNS, reducing viral translation, 
replication and neurovirulence (Gutierrez et al., 1997). The other attenuating mutation, 
which involves a substitution at amino acid 91 of the capsid protein VP3, renders the 
virus temperature-sensitive (ts). Similarly a mutation in the puff region of VP2 attenuates 
the myocarditic phenotype of an infectious cDNA of the Woodruff variant of CV B3 
(Knowlton et al., 1996). Determinants of attenuation in the Sabin type 1 strain of PV are 
located in the 5' NTR, the capsid coding region and the viral 3Dpo‘ coding region. These 
mutations also contribute to a temperature sensitive phenotype of replication. The 
contribution of Sabin 3Dpo1 sequences to the inability of the virus to grow at elevated 
temperatures must, Baker et al. (1995) have shown, lie in a function or activity of the 
enzyme other than RNA polymerisation, most likely the initiation step of RNA synthesis.
A live-attenuated strain of rhinovirus type 15 was developed, and differing plaquing 
properties of the wild parent and the attenuated progeny were described. Use of 
attenuated viruses for immunisation would require use of multivalent live preparations; 
dual infection with two serotypes was induced experimentally and has been identified 
naturally. Despite some promise, the live virus vaccine approach has not been pursued. 
Problems for all rhinovirus immunisation approaches are the multiplicity of serotypes and 
the suggestion that most have epidemiological significance (Couch, 1996).
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Recombination is a valuable strategy by which a virus strain can enhance its virulence 
and promote its growth and may be a more efficient means for evolution of a viral 
genome than mutation alone. In the case of two strains of CV B1, one, CV B1N, being 
less virulent than the other myotropic strain (CV B1T), sequencing of the 5' NTR of CV 
B1T demonstrated areas with a greater similarity to particular ECHOviruses than to CV 
B1N (the less virulent strain), suggesting that recombination events might have occurred, 
perhaps influencing the virulence phenotype (Rinehart et al., 1997). Amazingly, there is 
a report detailing the discovery of a nonhomologous recombination event which occurred 
in tissue culture between an engineered PV genomic RNA containing a lethal lesion and 
the human host cell RNA (Charini et al., 1994).
1.3.3 Cardiovirus and aphthovirus genera
The cardioviruses all belong to a single serotype and are here all considered to be 
strains of EMCV. They are generally regarded as murine viruses although their host 
range includes humans, pigs, elephants, and squirrels among others.
CARDIOVIRUSES
Encephalomyocarditis virus Columbia SK
Mengovirus Maus Elberfeld (ME) virus
Theileris murine encephalomyelitis virus (TO, GDVII) MM Virus
Figure 17: Cardiovirus serotypes
Aphthoviruses (foot-and-mouth disease viruses) infect cloven-footed animals, especially 
cattle, goats, pigs, sheep, and, rarely, even humans. Seven immunotypes have been 
identified: these include types A, C, O, Asia-1, and the South African Territory types, 
SAT-1, SAT-2, and SAT-3. Within these seven types, at least 53 subtypes have been 
designated by complement-fixation tests. The serological characteristics of the subtypes 
are sufficiently different to cause difficulty in classification and immunization. The 
aphthoviruses are highly labile, being rapidly inactivated at pH less than 7.
APHTHOVIRUSES
Foot-and-mouth disease virus 1-7 (serotypes A, C, O, SAT-1, 2, 3, Asia-1) 
Figure 18: Aphthovirus serotypes
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FMDV infection results in a severe disease that develops rapidly, with symptoms that are 
often apparent within 24 hours following exposure to the virus. Thus effective vaccines 
need to stimulate a strong immune response prior to infection since postexposure 
boosting of vaccine-induced responses cannot compete with the rapid onset of disease.
Foot-and-mouth disease, an economically important viral disease of livestock, is a 
problem in many developing countries and poses a continuous threat to FMD-free 
nations of North America and Europe as its remarkable antigenic variability complicates 
the development of new effective vaccines.
1.3.3. 1 Properties of virion
Aphthoviruses, cardioviruses and TMEV are all plus-strand viruses with a molecular 
weight of between 2.70 x 106 and 2.93 x 106. Again, the virus capsid of the aphtho- and 
cardioviruses is made up from 60 copies each of four virus-encoded proteins, VP1 to 
VP4; VP1 to VP3 form most of the capsid shell, with VP4 lining the interior surface.
Figure 19: Molecular surface of foot-and-mouth-disease virus and mengo virus
Molecular surface of FMDV (left) and mengo virus (right), radially depth cued, as solved 
by X-ray crystallography determined by Logan et al. (1993) and Luo et al. (1987) 




The three major capsid proteins of all picornaviruses, VP1, VP2 and VP3, are structurally 
similar to each other and consist of an eight-stranded p-barrel with a jelly-roll topology. 
The surface exposed loops joining the strands of the jelly rolls differ radically between 
the genera, and to a lesser extent between serotypes. These exposed loops define 
much of the antigenic character of each virus. FMDV differs from the other 
picornaviruses in having a relatively smooth surface with one exceptionally long exposed 
loop, the GH-loop of VP1 (residues 134-160), which not only constitutes most of a major 
antigenic site but also contains a conserved RGD (Arg-Gly-Asp) sequence which has 
been demonstrated to be essential for attachment of the virus to cells. This loop is 
highly disordered in the native virus structure of all serotypes examined to date and 
Hewat et al. (1997) have published information on the structure of this receptor-binding 
loop in relation to the rest of the virus capsid and further reinforces the picture of the GH- 
loop acting as a mobile structural module.
Analysis of the structural tendencies of a synthetic peptide corresponding to the GH loop 
from the serotype 01 FMDV was undertaken by de Prat-Gay (1997). The observation 
that a synthetic peptide, corresponding to the GH loop, is largely disordered in aqueous 
solution has implications on the ability of GH loop peptides to elicit humoral protection in 
animals and therefore, on its effectiveness as a vaccine. The loop must be continuously 
subjected to a conflict between sequence conservation to function as receptor 
recognition signal and variation to escape from antibody neutralisation (Mateu, 1995). 
Recently the structure of a complex between the Fab fragment of a neutralising 
monoclonal elicited against FMDV and its 15 amino acid peptide antigen was reported 
(Verdaguer et al., 1996). This type of structural information may eventually allow 
modelling of antibody-entire complex formation, an important event in neutralisation of 
viral infectivity.
There are two subgroups of Theiler's virus, a murine cardiovirus, which are closely 
related, serologically and at the genome level, but which differ in their phenotypes. 
Following intracranial inoculation either an acute encephailitis (strain GDVII) or a chronic 
demyelinating disease (strain DA) ensues. Studies indicate that the viral capsid contains 
determinants for persistence and demyelination (Fu et al., 1990). Jarousse et al. (1996) 
have found that amino acid VP2-141, as well as rendering chimeric virus persistent, can 
modulate the tropism of Theiler's virus and their data indicates that the mechanism by 
which this region affects persistence may involve tropism.
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The acid-labile aphthoviruses inhabit the nasal and oropharyngeal regions with no 
apparent need for acid stability. Indeed it may be that the structure conferring acid 
stability to the virion conveys some still inapparent counteradvantage because the highly 
labile aphthoviruses are among the most contagious viruses known (Rueckert et al.,
1996).
Empty capsids of FMDV, purified by Curry et a/. (1997), were unusual among 
picornaviruses in that most of the capsid precursor VPO had been cleaved into VP2 and 
VP4. Both the N terminus of VP1 and the C terminus of VP4, which pack together close 
to the icosahedral threefold symmetry axis where three pentamers associate, are more 
disordered than they are in the RNA-containing virus. The ordering of these termini in 
the presence of RNA strengthens interactions within a single protomer or between 
protomers belonging to different pentamers. The disorder in the FMDV empty capsid 
forms a subset of that seen in the PV empty capsid, which has VPO intact. Thus, VPO 
cleavage confers stability on the picomavirus capsid over and above that attributable to 
RNA encapsidation.
By contrast to other picornaviruses, the truncation of VP1 in FMDV exposes the five- 
stranded p annulus formed by the N termini of VP3 packing around the icosahedral five­
fold axes. This forms a tube with an average diameter of 11 A. Although VP4 lies below 
this tube, no well-ordered residues obtrude close to the symmetry axis (in PV the N- 
terminal residues and myristic acid form an additional inner layer of structure, resulting in 
a hydrophobic hole (Acharya et al., 1989).
1.3.3.2 Properties of genome
Aphthoviruses possess an RNA genome of approximately 8,400 nucleotides and 
cardioviruses possess an RNA genome of between 7,840 nt (EMCV) and 8,098 nt 
(TMEV).
Again, the protein coding region is flanked on each end by NTRs whose sequences tend 
to be highly conserved and carry signals initiating translation near the 5' end and for 
initiation of RNA synthesis at the 3' ends of the plus and minus strands, respectively.
The 5' NTRs of aphtho- and cardioviruses (with the exception of TMEV) are unique in 
that they contain long homopolymeric polycytidylate (polyC) tracts, between VPg and the
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beginning of the protein coding region, whose length (50-200 bases) and exact location 
relative to the 5' end of the genome (150-330 bases) vary with different isolates of virus. 
Shortening of the long polyC regions markedly reduced the virulence of mengovirus 
(Duke et al., 1990) but not of aphthovirus.
Statistical analyses of RNA folding in 5' NTRs of EMCV, TMEV and FMDV indicate that 
two highly significant folding regions occur in the 5' and 3' portions of the 5' NTR. The 
theoretical, common structural elements predicted in the 3' parts of the 5' NTR occur in a 
c/s-acting element that is critical for internal ribosome binding. Nucleotides in the 
conserved single-stranded polypyrimidine tract for these RNAs are involved in a 
distinctly tertiary interaction that is located about 15nt prior to the initiator AUG. 
Intriguingly, the proposed common tertiary structure in this study shares a similar 
structural feature to that evident in the human enteroviruses and HRVs (Le et al., 1993).
In contrast to the first class of picomavirus IRES elements, representative of the entero- 
/rhinovirus genera which function rather poorly in RRL translation system unless 
supplemented with additional cellular proteins, the second class, found in the cardio- and 
aphthoviruses, also displaying a complex secondary structure though quite distinct, from 
the first class IRES, functions very efficiently in the RRL system. Although often 
regarded as a c/s-acting element, evidence exists that internal initiation of translation by 
severely defective IRES elements can be greatly enhanced by the coexpression (in 
trans) of the parental wt IRES within cells. Moreover, Roberts & Belsham (1997) have 
provided evidence that severely truncated EMCV IRES elements, insufficient to direct 
internal initiation themselves, can complement defective IRES elements.
The AC-folds of aphthoviruses and cardioviruses resemble that of EMCV as shown in 
Figure 20. Interestingly, the IRES of EMCV is now widely used in high-level protein 
expression systems because it is one of the most active translational initiation sites 







Figure 20: Encephalomyocarditis virus 51 NTR with type 2 IRES
The FMDV encodes three VPg genes in tandem, each with 23 or 24 amino acids, 
whereas the other picornaviruses encode one. The length of the poly(A) tract varies in 
size, being shortest in cardioviruses and longest in aphthoviruses.
Initiation of protein synthesis, normally proceeds from a unique start site on each RNA, 
however, in FMDV, two in-phase AUG codons (separated by 84 bases) initiate synthesis 
with equal frequency. Interestingly, molecules complementary to the translational start 
sites, and both sense and antisense molecules covering the 3' end of the FMDV RNA, 
confer resistance to FMDV infection and it is thought that hybridisation of short 
sequences of both sense and antisense transcripts from the 3' end induces distortion of 
predicted highly ordered structural motifs, which could be required for the synthesis of 




Bae et al. (1989) performed a genomic comparison between the diabetogenic EMCV-D 
and nondiabetogenic EMCV-B and have shown that EMCV-D differs from EMCV-B by 
only 14 nucleotides, consisting of two deletions, one insertion, and eight point mutations.
1.3.3.3 Properties of viral proteins
In the aphtho- and cardioviruses, the leader or L region maps in front of the capsid 
precursor region, 1A to 1D (L is absent in renteroviruses). The L protein of FMDV 
occurs in two distinct forms, termed Lab (23kDa) and Lb (16kDa), which are the result of 
ribosomes initiating translation at the two AUG codons 84 bases apart. Both Lab and Lb 
of FMDV are (thiol?) proteases with multiple activities; they cleave themselves (in cis or 
in trans) from the amino terminus of the capsid protein precursor P1 (Strebel & Beck, 
1986) between a K-G dipeptide, thereby initiating the maturation of the adjacent capsid 
proteins. The two forms of L also initiate the cleavage of the p220 subunit of the 
ribosomal initiation factor elF-4F protein complex, which appears to be partly responsible 
for the inhibition of cellular 5' cap-dependent translation without affecting translation of 
the uncapped viral mRNA. The leader proteins of cardioviruses show no similarity to 
that of FMDV. They contain a zinc-binding motif, however their role in replication and 
pathogenesis is unknown and in fact, deletion of the leader region in the genome of 
TMEV had no effect on the replication and spread of the mutant virus in BHK-21 cells 
(Michiels et al., 1997). In cardiovirus-infected cells p220 is not cleaved and shut-off is 
accomplished by an exceptionally active IRES, which enables the viral RNA to out- 
compete host messages (Rueckert, 1996).
Curiously, the 2Apro region of FMDV is only 16 amino acids in length, and is totally 
conserved amongst all aphthovirus genomic RNAs sequenced to date, yet primary 
scission still occurs at the carboxy terminus at the 2A-2B junction (Ryan et al., 1991). 
No host or viral protease has been implicated in this scission, and the balance of 
evidence favours the astonishing possibility that the sequence at the 2A-2B junction 
(consensus Asn-Pro-Gly-Pro - NPGP) is inherently unstable and literally breaks itself 
without being enzymatically cleaved. Synthetic tetrapeptides containing this sequence 
were spontaneously cleaved to Asn-Pro and Gly-Pro when incubated only in buffer 
(Palmenberg, 1990; Ryan & Drew, 1994). Interestingly, FMDV 2A is able also to 
generate cleavage in attenuated Sabin 3 PV vectors engineered for delivery of foreign 
antigens (Mattion etal., 1996). In the cardioviruses, primary cleavage similarly occurs at 
the 2A-2B junction, and microsequencing revealed that scission occurs, as was
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measured for FMDV A12, at the Gly-Pro pair within the NPGP sequence (Porter, 1993). 
The conserved sequence is extremely rare within current databases - the only examples 
are from cardio-, aphtho- and group C porcine rotaviruses - and is always associated 
with a proteolytic cleavage activity.
The 2A protein of cardioviruses, about 140 amino acids long and lacking sequence 
homology with the 2A of renteroviruses, has a C terminus similar to the 16-amino-acid 
2A protein of aphthoviruses and is also involved in the primary cleavage event. The 
larger part of protein 2A, does not resemble any identified protein sequence, and has 
been shown to be dispensable for RNA replication of the viral genome, although spread 
efficiency was restricted in viruses with large deletions in the 2A region (Michiels et al.,
1997).
Lack of data on proteins 2B, 2C, and their precursor 2BC, for these genera leads me to 
surmise they perform functions similar to those of their counterparts in the 
renteroviruses, generally involving membrane proliferation and an involvement in the 
RC.
In FMDV, all cleavages, other than the autocatalytic cleavage of L from P1 and the 
primary 2A cleavage between 2A and 2B, are catalysed by 3C or a 3C containing 
precursor, except for the maturation cleavage of VPO in the provirion to generate the 
capsid proteins VP4 and VP2 (Grubman etal., 1995).
FMDV 3C residues His-46 and Cys-163 (equivalent to PV 3C His-40 and Cys-147), 
respectively) are implicated as part of the catalytic triad and His-181 (equivalent to PV 
His-161) as part of the binding pocket. The data of Grubman et al. (1995) support the 
prediction of Gorbalenya et al. (1989) in that the third member of the triad is Asp-84 and 
not Asp-98. It is interesting to note, however, that while the scissile bond cleaved by 
other picornavirus 3C enzymes is relatively conserved that for FMDV is highly variable.
In FMDV, 3Cpro also induces the specific cleavage of histone H3, in vivo. Because the 
deleted part of histone H3 is in the amino-terminal region corresponding to the presumed 
regulatory domain of transcriptionally active chromatin, it seems likely that this specific 
cleavage is related to the severe inhibition of host cell RNA transcription observed in 




For EMCV, the capsid region cleavages, except 1A-1B, are generally carried out by 
released 3C, although 3ABC, 3CD, and 3ABCD precursors also have demonstrable 
trans activity with these same substrates and it is assumed that these precursors play 
additional catalytic roles in the replication cycle, as they do for the enteroviruses and 
rhinoviruses. Engineered mutations preventing 3C-dependent cleavage at the 2C/3A, 
3A/3B, 3B/3C, and 3C/3D processing sites were created and tested in vitro for their 
consequent blocks in the processing cascade and effects on polymerase activity. The 
mutations were also characterized in vivo within the context of full-length genomic 
sequences for defects in RNA synthesis, genetic stability, and subsequent infectivity. 
The data confirm the essential indispensability and preferred order of the natural 
processing cascade and point to a fine balance between 3C protein precursors and 
polyprotein products in establishment of an infectious cycle (Hall & Palmenberg, 1996).
Hahn & Palmenberg (1996) suggest that primary cleavage itself, though necessary, is 
not sufficient to ensure 3Cpro mediated P1 reactivity and that other functional 
requirements highly sensitive to changes, exist within the DIETNPGP sequence of 
EMCV 2A that they studied. Perhaps primary cleavage, occurring where and when it 
does, may ensure proper folding of the L-P1-2A precursor, making it a suitable substrate 
for 3Cpro-mediated processing, or perhaps the order of cleavage events is critical in L- 
P1-2A processing. The preferred cleavage progression being 2A/2B, then L/1A, 1D/2A, 
1C/1D, and 1AB/1C. A failed or sequence-defective primary reaction may, through steric 
hindrance or improper product release, prevent sequential exposure of the other four 
internal sites in their usual turns.
Evidence that FMDV particles contains replicase protein 3D was provided by Newman et 
ai. in 1994, who showed that, in the presence of ammonium ions, the expressed 
polymerase degrades the RNA of the virus indicating that it can act as a hydrolytic as 
well as polymerising enzyme. Sankar & Porter (1991) expressed and purified the 
polymerase of EMCV and found it to exhibit poly(A)-dependent poly(U) polymerase 
activity and RNA polymerase activity, which are both oligo(U) dependent. Interestingly, 
further work on this enzyme revealed that point mutations which drastically affected the 
polymerisation activity corresponded to the active site of E. coli DNA polymerase I, 
suggesting that a basic structural and functional framework is conserved in the most 
distantly related classes of nucleic acid polymerases which supports the validity of 
modelling the active sites of RNA-dependent RNA polymerases on the known structure 
of a DNA polymerase (Sankar & Porter, 1992).
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Cui et al. (1993) demonstrated binding of EMCV 3Dpt)l to the 3' NTR(A) but not to globin 
mRNA, yeast tRNA or the 3' NTR lacking the poly(A) tail. In contrast PV 3Dpot bound to 
PV RNA and virtually all RNAs tested including poly(U), poly(C), and poly(G), although a 
different assay, using partially purified 3Dpo1 was employed (Oberste & Flanegan, 1988). 
This suggests, as before, that the 3' NTR and poly(A) together play an important role in 
viral template selection by 3Dpo1, and may explain why cDNA clones of EMCV lacking 3' 
poly(A) are noninfectious.
1.3.3.4 Replication and adaptation to ceil culture
FMDV enters the cells via a mechanism of receptor-mediated endocytosis in which the 
low pH of the endosomal compartment triggers uncoating of the viral genome. For 
FMDV A12 the receptor has been identified as the Arg-Gly-Asp (RGD)-binding integrin. 
The RGD to which the integrin binds is located on the G-H loop of VP1 and is highly 
conserved among all seven serotypes. Such conservation in a region that otherwise 
varies considerably in length and sequence suggests that all FMDV serotypes use RGD- 
binding integrins, including avp3, as receptors for virus internalisation (Jackson et al.,
1996). They have also shown that type O FMDV has a specific affinity for heparan 
sulphate, an extracellular matrix component, and that this binding most likely is the initial 
event in cellular entry and is required to establish an efficient infection in cells grown in 
culture. It appears therefore, that FMDV attaches to the cell surface via interactions with 
a nonintegrin component of the plasma membrane or extracellular matrix before integrin- 
dependent internalisation.
Jin et al. (1994) recently indicated that EMCV attachment to permissive human cells is 
mediated by a cell surface sialoglycoprotein(S) with a molecular mass of 70kDa, but not 
by glycophorin A, which is the attachment molecule for EMCV on human erythrocytes 
with sialic acid being the residue involved in the virus binding. Human erythrocytes, 
however, do not support EMCV growth, in contrast to a number of nucleated cells in 
which the virus readily replicates.
As before, these viruses must also translate their genome into proteins required for 
replication and again this is achieved through the use of an IRES. Strong experimental 
evidence exists for the requirement of widely conserved motifs in IRES activity in FMDV 
and other picornaviruses and de Quinto & Martinez-Salas (1997) have shown that the
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aphthovirus IRES loops located at the most distal part of domain 3, which carries GNRA
and RAAA motifs, are essential for IRES function.
The p52 protein, a nuclear protein that binds to the 3' terminus of nascent RNA
polymerase III transcripts, La, mentioned previously binds to the IRES of EMCV as well
as PV. Studies with EMCV and FMDV RNA established that a p57 protein also cross- 
linked to their IRES elements. As with studies on the renterovirus IRES, the p57 species 
has been identified as the PTB. Two binding sites were identified on the FMDV IRES, 
one close to the 5' end (stem loop H [Figure 20]) and a second around the 
polypyrimidine tract at the 5' terminus of the IRES. The major site of association 
between p57 and the EMCV IRES is in stem-loop H, although evidence for a second site 
in a region further upstream in the 5' NTR was also obtained (Belsham & Sonenberg,
1996). Two additional proteins, p70 and p100 (p97), observed to cross-link fragments of 
various IRES elements, have been shown to bind specifically to multiple fragments of the 
EMCV IRES. It is suggested that each of these proteins recognises primarily, like those 
mentioned in the renterovirus section, a structural feature of the RNA rather than a 
specific sequence (Witherell & Wimmer, 1994).
Recently reported was the observation that the translational activities of the renterovirus 
IRES elements (but not the EMCV or FMDV IRES elements) appear to have been 
stimulated by the FMDV L protease. (Ziegler etal., 1995).
EMCV RNA template specificity has been shown to depend only upon 3Dpo‘, the 3' NTR 
and the poly(A) tail, suggesting the poly(A) tail plays an essential role in viral RNA 
template selection by the polymerase. The fact that EMCV cDNA clones lacking the 15- 
20 3' terminal A residues are non-infectious may be explained by the failure of 3Dpt)l to 
bind to the 3'-terminus of the viral RNA template and initiate negative-strand synthesis 
(Cui etal., 1993).
Newman & Brown (1997) have shown consistently that nonstructural proteins 2C, 3C, 
3CD, and 3D, components of the RC, and the cell protein actin are present in highly 
purified preparations of both FMDV and PV (Newman et al., 1994; Newman & Brown,
1997) and it is thought FMDV replicates in a similar manner to that described previously 
for PV. If 2C has a role in virus structure, it may function by facilitating assembly around 
newly synthesised RNA, moreover the RC proteins, with an affinity for the 5' end of the 
newly synthesised sense RNA and membranes, may be necessary for assembly (Andino
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etal., 1993). In addition, a small protruberance, found on some FMDV complexed with 
antibody against 3D, could be the site from which the RNA is released particularly since 
the 3D is attached to the RNA (Newman & Brown, 1997).
To produce a new generation of safer FMDV vaccines, genetic engineering has been 
used to develop attenuated virions. In one case, attenuation has been achieved by 
removing the coding region for the viral leader proteinase, responsible for inhibition of 
translation of host-cell mRNAs during infection. In another case, the virus has been 
attenuated by deletion of the RGD sequences, that comprise the cell binding site. Ward 
et al. (1997) have most recently shown that a DNA vaccine based on a genome-length 
FMDV nucleic acid that undergoes genomic amplification in inoculated animals can 
immunise swine against foot-and-mouth disease.
1.3.4 Hepatovirus genus
1.3.4.1 Properties of the virion
The HAV particle is approximately 27nm in diameter and appears roughly spherical by 
electron microscopy (Feinstone et al, 1973) (Figure 21). HAV possesses a non­
enveloped capsid structure (Lemon et al., 1992). Based on the structure of 
picornaviruses generally, the HAV capsid is thought to have icosahedral symmetry and 
to contain 60 copies of each of three major polypeptides, VP1, VP2 and VP3 (Wheeler et 
al., 1986b; Lemon & Robertson, 1993). It is not known whether HAV contains a fourth, 
smaller capsid protein (VP4) which is present in other picornaviruses. The genome of 
HAV potentially encodes a VP4 protein of 21-23 residues (Baroudy et al., 1985; Cohen 
et al., 1987a; Hollinger & Ticehurst, 1996). This putative VP4 sequence contains an 
internal consensus myristylation site (Gly-X-X-X-Ser/Thr, where X is any amino acid) 
starting at residue 5 from the preferred AUG codon (Palmenberg, 1989; Tesar et al.,
1993), which suggests that if VP4 is actually present in the virion and myristylated like 
the VP4 of other picornaviruses, it may be only 17 amino acids in length (2.5kDa) (Chow 
et al., 1987; Palmenberg, 1989; Ross et al., 1991). Myristylation occurs after the 
removal of an initial methionine residue or a leader peptide, resulting in the exposure of 
an N-terminal eight amino acid myristylation signal. Analysis of culture-adapted HAV 
and engineered mutants demonstrated that myristate was not incorporated, nor was a 5- 
residue leader peptide cleaved from 1A or VPO. Thus, VP4 has not been conclusively 
demonstrated in HAV particles; and if it exists, it is much smaller than other picomaviral 
VP4 molecules and not myristylated. Furthermore, data from Tesar et al. (1993)
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indicates that HAV does not require leader cleavage and myristylation of VP4 for growth 
in cultured cells. Ross & Anderson (1991) estimated VP4 to have a relative molecular 
mass of less than 1kDa, which is substantially lower than the 2.5kDa predicted from the 
nucleotide sequence.
Preparations of HAV made from infected cell cultures typically contain large quantities of 
empty capsids. These capsids are composed of three polypeptides VPO (VP2+VP4), 
VP3 and VP1. Mature capsids contain approximately 2 molecules of VPO (Bishop & 
Anderson, 1993). Studies have shown that VPO of the empty capsid is larger than the 
VP2 present in the complete virion, indicating that maturation cleavage of VPO occurs in 
HAV, as in other picornaviruses (Updike et al., 1991). Bishop & Anderson (1993) 
presented results which clearly show that the provirion is a true intermediate in the 
morphogenesis of HAV, with VPO cleavage being dependent on the presence of 
encapasidated viral RNA. What remains unknown, however, is whether the N-terminal 
cleavage product of VPO (that is, the VP4 moiety) is actually incorporated into the virion.
Recent evidence suggests that HAV may differ from other picornaviruses in that a large 
carboxy-terminal extension of VP1 is present in some virions. The function of this 
protein (termed ‘pX’) is unknown (Anderson & Ross, 1990) but is thought to represent a 
VP1-2A precursor that is cleaved by 3Cpro at a Glu-Ser linkage at amino acid position 
273/274 (Probst et al., 1997), 27 amino acids upstream of the predicted C-terminus of 
VP1, resulting in 1-273/VP1 as opposed to the 1-300/VP1 proposed. This cleavage site 
could represent the authentic carboxy terminus of VP1 generated by 3Cpro from the 
40kDa (42kDa) protein (pX) and accounts for the difference between the 37kDa protein, 
which results from the translation of the proposed ORF for VP1, and the 33kDa protein, 
which is the mature VP1 observed in HAV-infected cells and HAV virions. The release 
of VP1 from its 40kDa precursor through cleavage between the Glu-Ser proposed 
(amino acids 764 and 765 of HAV polyprotein), may imply that 3Cpro alone is sufficient to 
perform release of VP1 and that the low specificity of protease 3C for this junction 
sequence is responsible for the relative stability of the VP1 precursor, as in the case of 
3A/3B, which is separated by the amino acid pair Glu-Gly (Dotzauer etal., 1995).
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Figure 21: Electronmicrograph of a hepatitis A virus particle fixed and stained in 
phosphotungstic acid (x400,000)
The conformationally defined immunodominant antigenic site of HAV includes Asp-70 of 
VP3, but amino acid residues in VP1 also contribute to this site, as well as to at least one 
other functionally independent antigenic site (Stapleton & Lemon, 1987; Ping et al., 
1988; Gauss-Muller et al., 1990; Nainan et al., 1992). Interestingly, Emini et al. (1985) 
demonstrated that an anti-HAV antibody response could be primed by PV-specific 
synthetic peptides, suggesting the existence of a degree of higher-order homology 
between the poliovirion and the hepatitis A virion. HAV, however, shows the greatest 
overall homology to EMCV (Diamond et al., 1986). Synthetic peptides derived from the 
capsid proteins of HAV used to search for B-epitopes, revealed that of the three regions 
used (VP1 (amino acids 115-139), VP2 (amino acids 69-99) and VP3 (amino acids 137- 
150)), only free peptide 69-99 from the VP2 protein caused formation of HAV binding 
antibodies. The dominant antigenic site of HAV is highly conserved among all human 
strains, and reversion of neutralisation escape mutants to the wild-type antigenic 
phenotype has been noted when escape mutants have been tested for virulence in owl 
monkeys (Lemon, 1994). Presumably, neutralisation-resistant HAV mutants arise during 
natural infections but do not replicate to significant levels in vivo. It is intriguing to 
consider therefore, that the immunodominant neutralisation epitopes of HAV may have a 
vital functional role in the replication of the virus in vivo and if this is true, then
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neutralisation escape mutants may have lost a function necessary for in vivo replication 
and may be partially or completely attenuated (Stapleton & Lemon, 1987). Extensive 
digestion with high concentrations of trypsin and chymotrypsin result in cleavage 
primarily of VP2, but do not alter the antigenic characteristics, infectivity or exceptional 
thermostability of the virion (Lemon, 1994; Hollinger & Ticehurst, 1996). Domingo and 
colleagues (1993) suggest that there might be a natural restriction of substitutions at 
some antigenic sites due to their possible involvement in virus attachment and entry.
1.3.4.2 Properties of the genome
The genome of HAV is a single-stranded, positive-sense RNA (Coulepis et al., 1981), 
approximately 7500 bases long. A short genome-linked protein (VPg) of 23 amino acids 
is present at the 5'-end (Weitz et al., 1986) followed by a nontranslated region (NTR) of 
approximately 735 bases. This region contains extensive secondary structure, including 
a 5'-terminal hairpin, and as many as 10 AUG codons, scattered about in all three 
reading frames preceding the AUG which initiates the large open reading frame (ORF) 
encoding the polyprotein of HAV (Najarian etal., 1985; Cohen etal., 1987(a); Paul etal., 
1987). Recent data suggest that the 5' NTR contains a cis-acting element which has 
been variably termed an IRES or ‘ribosomal landing pad’ (nt 154-735) (Brown et al., 
1991; Glass etal., 1993; Whetter et al., 1994), and that its structure and organisation are 
remarkably similar to that of the 5' NTR of EMCV of mice (Glass et al., 1993; Le et al.,
1993). The 5' NTR is capable of forming two or more pseudoknots in the noncoding 
region upstream from the IRES. Also present in this region is a pyrimidine tract (pY1 
domain (Id)) between nt 99 to 138 downstream of the putative 5' pseudoknots, unique to 
HAV but which may be structurally analogous to the poly(C) tract of cardio- and 
aphthoviruses (Figure 23), which is not required for growth in cell culture as long as the 
sequence between nt 140 and nt 144 is present (Shaffer et al., 1994). There are other 
pyrimidine-rich tracts within the 5' NTR of HAV, but the pY1 domain is the lengthiest and 
most prominent of these regions. Large deletion mutations involving the first pyrimidine- 
rich tract of the 5' NTR of human HAV define two adjacent domains associated with 
distinct replication phenotypes. The HAV IRES has only a very low level of functional 
activity in infected cells, which may contribute to the slow replication cycle of the virus 
(Whetter et al., 1994). The 5' NTR is extensively conserved among HAV strains 
(generally >92% nucleotide identity) and is very important for replication (Tesar et al., 
1992; Borman et al., 1994). Harmon and co-workers (1991) observed that deletion of 
HAV nt 1 and 2 (both U residues) or nt 2 and 3 (a C residue), which are thought to form
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part of a stem-and-loop, abolishes the infectivity of the RNA. PV lacking the first terminal 
uridylate residues is, on the contrary, infectious. The IRES itself contains sequences 







Figure 22: Hepatitis A virus 5' NTR with type III IRES
Mutations within the 5' NTR have been shown to be involved in cell culture adaptation as 
discussed later (Brown et al., 1991; Emerson et al., 1993). Considerably greater 
sequence variation is evident within the large ORF, and several distinct genotypes of 
HAV have been described based upon the existence of >15% nonidentity within the 
VP1/2A (or pX) coding region (Lemon, 1994). The 3' end of the genome includes a 
shorter NTR which may also display secondary structure similar to the PV ORF 
(Jacobson etal., 1993) and a polyadenylated tail (Coulepis etal., 1981). A 22S, double­
stranded RNA form, closely resembling the Rl of other picornaviruses, also has been 
detected. The general organisation of the genome is shown in Figure 23.
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Figure 23: Organisation of the positive-stranded genome of hepatitis A virus
There is a small protein (VPg) attached at the 5'-terminus, followed by a nontranslated 
region of approximately 735 bases. A large open reading frame encodes a polyprotein 
of approximately 2235 amino acids which may be divided into three major domains: P1 
(capsid proteins), P2 and P3 (non-structural proteins). The existence of VP4 (1A) 
remains uncertain, as does the possibility of a short leader protein (L, not shown) which 
would precede it within the polyprotein. pX extends into the 2A region shown in this 
figure, making 2A significantly smaller than depicted. The other capsid proteins VP2, 
VP3 and VP1 are also known as 1B, 1C and 1D. The large open reading frame is 
followed by a short 3'-NTR of approximately 64 bases, followed by a 3'-terminal poly(A) 
track.
1.3.4.3 Properties of the viral
In accordance with other picornaviruses, it is presumed that the genetic information of 
HAV is expressed as a single polyprotein which is co- and post-translationally cleaved 
into proteins, named according to the L434 nomenclature of Rueckert and Wimmer 
(1984), involved in genome replication and virion formation (Jurgensen et al., 1993) as 
shown in Figure 24.
HAV protein processing has been difficult to study due to the slow asynchronous, and 
low yielding replication of the virus and its failure to inhibit host-cell protein synthesis, 
although predictions can be made on the basis of sequence homology with other 
members of the Picornaviridae. Relatively little is also known about the specific function 
of the nonstructural proteins of HAV because they do not accumulate in infected cells to 
levels comparable to the capsid proteins (Updike et al., 1991). Anderson & Ross (1990), 
as already mentioned, detected a 42kDa protein, designated ‘pX’, associated with some 
virion preparations which has been suggested to represent VP1 fused to a large 
(approximately 8kD) carboxy-terminal extension i.e. VP1-2A. Jia and co-workers (1993) 
identified a primary cleavage reaction which would generate a capsid protein precursor 
with a C-terminal extension of about one-third of what had been proposed to be the 2A 
sequence. This cleavage was mediated by the 3C protease in trans. If these 
observations are correct, the processing of the HAV polyprotein may differ significantly
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from other picornaviruses (Jia etal., 1993; Jurgensen etal., 1993; Porter, 1993; Lu etal.,
1994).
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Figure 24: Proposed proteolytic cascade for hepatitis A virus
Top, HAV genomic RNA, with its 5' VPg linked protein. 5' nontranslated region, long 
single open reading frame, 3' nontranslated region, and polyadenylated 3' end. Open 
reading frame is cleaved into structural proteins (1AB, 1C and 1D [VPO, VP3, and VP1]) 
and nonstructural proteins. Nonstructural proteins with identified functions are below 
(protease, polymerase, VPg) (Adapted from Palmenberg, 1990).
The 2A protein of HAV, a polypeptide thought to be approximately 10KDa, does not 
contain a consensus protease active site, such as found in the 2A protein of PV, and has 
been found to be liberated by proteinase 3C from its precursors P1-2A and VP1-2A (pX) 
(ScultheiB et al., 1994). The truncated viral protein 2A, as implied above may not be 
functional in HAV or may have acquired a different and as yet unidentified role (ScultheiB
75
Chapter 1
etal., 1994), but 2A is nonetheless relatively large and well conserved (Jurgensen et al., 
1993). The protein pX could contain a 2A fragment produced by cleavage within the 
predicted 2A or it could contain an authentic 2A the size of which had been predicted on 
false positioning of the 2A-2B junction. With this in mind studies have very recently 
shown that the originally predicted Gln-Gly dipeptide cleavage site at position 980-981 of 
the HAV polyprotein (Najairian et al., 1985; Cohen et al., 1987a) has to be relocated to 
position 836-837 and that 2B is significantly larger than previously assumed (27.5kDa) 
(Martin et al., 1995; Gosert et al., 1996). These results not only redefined peptide 2B but 
also showed that 2A of HAV is much smaller than the 10kDa predicted by SchultheiU et 
al. (1994) and would be expected to have a molecular mass of 5.3kDa. 2A of HAV has 
features distinct from that of PV 2A and rhino- and enteroviruses - lack of protease 
activity and lack of p220 inactivation by HAV and thus failure of host-cell shut-off - which 
implies that it is unlikely that 2A of HAV functions in the same manner as the 2A of other 
picornaviruses, and its function remains unknown (Gosert etal., 1996).
Proteins 2B and 2C are also of unknown function, although 2C contains an RNA 
helicase consensus sequence (Porter, 1993; Harris etal., 1994) and in PV is needed 
continually for viral RNA synthesis in the formation and maintenance of RC-associated 
membranous structures as well as in anchoring RCs to these structures.(Cho et al.,
1993) and its function can be provided in trans. HAV 2C protein, like its PV counterpart, 
is thought to be an NTPase and may be involved with sensitivity to guanidine, and which 
in PV has been shown to inhibit viral RNA replication by affecting coupling between the 
NTP binding and/or splitting, on the one hand and the 2C function (related to 
conformational changes), on the other, thereby implying that oligomerisation of 2C is an 
essential step in the replication of viral genome (Tolskaya et al., 1994; Hollinger & 
Ticehurst, 1996). The HAV 2C and 2BC proteins demonstrate efficient membrane 
association properties and causes major rearrangement of the ER and probably Golgi 
and perhaps other intracellular membrane compartments. Its slow growth phenotype is 
therefore not likely due to the inability of 2C to induce membrane changes perse, but the 
absence of such detectable membrane alterations and structural rearrangements into 
viral RCs in HAV-infected cells could be due to production of very low amounts of these 
and other viral proteins in the infected cells (Teterina etal., 1997a).
2B or 2BC is another viral protein of PV required for RNA replication (Datta & Dasgupta,
1994). Mutations in 2B and 2C of HAV have been shown to be important with respect to 
RNA synthesis and host range change that occurs during adaptation and passage of 
virus in cell culture and leads to attenuation of the virus (Emerson et al., 1993; Graff et
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al., 1994; Gosert et al., 1996). The analysis by Teterina et al. (1997a) of the effect of 2C 
(2BC) sequences from either a wild-type strain or a faster replicating cytopathic strain 
demonstrated that mutations acquired in wild-type virus during adaptation to cell culture 
do not change dramatically either the ability of these proteins to associate with 
membranes and induce membrane alterations or the specific architecture of the induced 
membrane structures. Protein 2C, but not 2BC, from the cytopathic strain of HAV 
induced different membrane structures.
Protein 3B has been shown to be the 5' genome-linked viral protein (VPg) of HAV (Weitz 
et al., 1986), initially present in its precursor form 3AB. VPg is required for viral RNA 
replication, and it is believed that the membrane-associated VPg-precursor protein, 3AB, 
may be used for the delivery of VPg into the 5' ends of plus- and minus-strand RNAs 
during replication, as 3AB and 3A are capable of localizing in the endoplasmic reticulum 
and golgi apparatus in transfected HeLa cells in the absence of any other PV protein 
(Datta & Dasgupta, 1994). PV protein 3AB has been shown to form a complex with and 
stimulate the activity of the viral RNA polymerase, 3Dp0‘ (Plotch & Palant, 1995) as 
discussed earlier. Amino acid sequence alignments suggest that membrane binding 
might be due to a hydrophobic stretch near the C-terminus of 3A found in all 
picornaviruses whereas the ability to induce permeability of E. coli membranes is 
determined by an amphipathic helix formed at the N-terminus of 3A of a cytopathogenic 
HAV strain (Pisani etal., 1995). Beneduce and co-workers (1995), expressed protein 3A 
in E. coll and showed that an N-terminal deletion rendered this protein toxic to bacteria. 
Furthermore, Beneduce et al. (1997) have demonstrated that changes in the primary 
sequence involving charged amino acids at the N- and C- termini critically influenced the 
ability of the protein 3A of a cytopathic strain of HAV to change bacterial membrane 
permeability, demonstrating the strict correlation between the structure and pore-forming 
potential of HAV protein 3A. Hypothetical pore-formation into the nuclear membrane 
induced by the protein 3A of a cytopathic strain could account for the accelerated growth 
by promoting a more efficient relocalisation of nuclear proteins to the cytoplasm with 
respect to other strains, thereby possibly leading to a depletion of nuclear proteins 
needed for host cell replication and to cell death (cytopathic effect) (Beneduce et al.,
1997).
All picornaviruses process their polyproteins via a series of cis and trans cleavages, 
catalyzed primarily by the 3C gene product (Harmon et al., 1992). In general, 
picornaviral 3C proteinases adopt a chymotrypsin-like fold and display an active site
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configuration like those of the serine proteinases (Malcolm etal., 1995).
The recently obtained crystal structure for HAV proteinase 3C reveals it is a cysteine- 
containing chymotrypsin-like serine proteinase (Allaire et al., 1994) which seems to be 
the only virus-encoded proteinase which can catalyse cleavage at all sites in the HAV 
polyprotein including the primary cleavage, which separates the precursor of the 
structural from that of the nonstructural proteins (Jia et al., 1991a; Harmon et a!., 1992; 
ScultheiS etal., 1994).
Harris and coworkers (1992) have shown that HAV 3C mediates cleavage at its own N- 
and C-termini and at the proposed junction between 2C and 3A (Jia et al., 1991a), 
however cleavage at its C-terminus is less efficient than at its N-terminus (Harmon etal.,
1992). Comparisons of the HAV 3Cpro with those of other picornaviruses suggested that 
the catalytic triad may be composed of residues His-44, Asp-98 and Cys-172, however 
crystallographic have been interpreted as suggesting that the catalytic site consists only 
of a dyad, including Cys-172 as nucleophile and His-44 as general base, with His-191 
defining the 3C cleavage specificity for glutamine residues (Allaire et al., 1994; Gosert et 
al., 1997; Hollinger & Ticehurst, 1996). Moreover Gosert et al. recently (1997) 
suggested that His-44 and Cys-172 are essential for polyprotein processing, whereas 
Asp-98 is not. Kusov & Gauss-Muller (1997) have shown that HAV 3Cpro is an RNA- 
binding protein with specificity for the most 5'-terminal RNA structures of the HAV 
genome, and further suggest that the RNA-binding region is located in an area distinct 
from the catalytic triad and that HAV 3C might serve multiple, yet unknown, functions 
during the life cycle. Purified PV 3CDpro, a proteinase thought to be essential for 
processing of the P1 capsid precursor, expresses no RNA polymerase activity (Harris et 
al., 1992) and can accumulate due to the cleavage efficiency of 3C at its carboxy 
terminus being rather low (reference within Gauss-Muller et al., 1991). 3CDpro has the 
propensity to bind the 5'-terminal cloverleaf of PV RNA but this occurs only in the 
presence of a 36kDa host factor of uninfected HeLa cells, however the 3AB-3CDpro 
complex interacts with cloverleaf RNA and binds to 3' RNA fragments of the PV genome 
in the absence of host factor (Harris et al., 1994). In contrast to PV, Kusov & Gauss- 
Muller (1997) found that binding of HAV RNA of the 5' NTR was not improved when 
similar concentrations of 3CD were used instead of 3C, suggesting that the 3D moiety 
does not affect the RNA binding specificity of HAV 3C. Furthermore, Jurgensen et al. 
(1993) revealed that for cleavages at 2C/3A and 3C/3D, the complete 3D moiety was not 
required. Kusov & Gauss-Muller (1997) found that HAV 3CD, unlike PV 3CD, was not
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detected as a predominant product of polyprotein processing. Instead, HAV 3ABC, 
whose specific role is unknown, was found to be a relatively stable intermediate when 
the HAV polyprotein was translated in vitro or expressed in bacteria and mammalian 
cells (Harmon et al., 1992; SchultheiR et al., 1994). Kusov et al. (1997) showed that 
recombinant HAV 3ABC specifically interacts in vitro with secondary structures formed at 
both the 5' and 3' terminus of the viral genome. Similar to protein 3AB, HAV 3ABC 
bound to the 3' terminal RNA structure which did not interact with the mature proteinase 
3C. In contrast to 3AB, 3ABC interacted with RNA stem-loop lb and combinations of 
individual secondary structure elements of the 5' NTR. RNA binding of this precursor 
3ABC was 50 times stronger than that of 3AB and 3C, implicating a specific role of this 
stable processing intermediate in viral genome replication. Cleavage of 3CDpro to 3Dp0‘ 
is needed to activate the 3D RNA polymerase (Gauss-Muller et al., 1991). It has been 
shown that 3D is formed by cleavage at the Glu-Arg pair at position 1738 and 1739 of 
the HAV polyprotein (Tesar et al., 1994). The HAV 3D protein produced by autocatalytic 
cleavage of P3 precursor proteins in BS-C-1 cells, however, was found to be virtually 
completely insoluble, unlike its PV counterpart which displayed an extent of solubility.
By analogy with other picornaviruses, HAV 3D is a RNA-dependent RNA polymerase. 
The amino acid homology of HAV 3D with other picornavirus polymerases is low (27- 
33%), but it shares several amino acid motifs with all sequenced RNA-dependent 
polymerases. Updike et al. (1991) have shown that HAV 3D does not accumulate in 
infected BS-C-1 cells. Moreover, 3D was not immunoprecipitated despite labelling 
periods as short as 10 minutes and immediate harvest, suggesting that 3D may have a 
short half-life in infected BS-C-1 cells. It is proposed that the active site of this enzyme 
consists of Tyr343-Gly344-Asp345-Asp346 (Hollinger & Ticehurst, 1996 and references 
therein)
In order for an RNA strand to serve as template for multiple rounds of product RNA 
synthesis, the RNA replicative machinery should either prevent formation of extensive 
base pairing between the template RNA and the complementary strand or contain a 
helicase activity which is able to unwind RNA duplex subsequent to its formation (Cho et 
al., 1993). In addition to RNA-dependent RNA polymerase activity, 3Dpo1 protein 
sequences contribute to 3CD protease activity. Other suggested activities of 3Dpo1 
include RNA unwinding, uridylylation of VPg, interaction with cellular proteins and PV 
RNA near the 5' terminus of the positive strand, and association with membrane 
structures. It was recently determined that 3Dpo1 was able to add multiple adenylate (A)
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residues to the 3' terminus of PV RNA in a nontemplated manner and effect the initiation 
of plus-strand synthesis (Neufeld et al., 1994).
1.3.4.4 Replication and adaptation to cell culture
Relatively few studies have addressed the replication of HAV in cell culture. Although 
HAV demonstrates some unique features, such as a very protracted replication cycle, it 
has generally been considered to replicate by a scheme similar to that of other 
picornaviruses (Figure 10).
Ashida and colleagues (1989) investigated propagation of HAV in hybrid cell lines in 
order to facilitate in vitro propagation. Virus grown in vitro is associated with host-cell 
derived material and has been shown to interact with the serum protein fibronectin. 
Dotzauer et al. (1994) recently investigated the replication of HAV in nonprimate cells 
and found that the cell surface receptor(s) and other host factor(s) required for HAV 
replication are present in nonprimate as well as primate cells. Purified HAV will attach to 
a wide range of cultured cells and attachment is affected by the cell type, the presence 
of calcium, temperature and the presence of serum. Results of investigations by Bishop 
and Anderson (1997) suggest that the major effect of calcium in promoting HAV-receptor 
interactions is through a direct effect on the conformation of the viral capsid. The 
enhancing effects of calcium ions and low pH on HAV, they observed, attachment are 
not additive. It is possible that virion-bound host components play a role in virus 
attachment and dissemination (Zajac et al. 1991). Investigation of HAV antigenic variant 
strains (neutralisation escape mutants) demonstrated identical attachment properties 
with neutralisation-susceptible strains, suggesting that the immunodominant antigenic 
site of HAV is not directly involved in cell attachment. Unlike FMDV, RGD peptides were 
also shown to be unable to interfere with HAV attachment, suggesting that the HAV 
binding region does not involve an RGD sequence or the immunodominant neutralisation 
site (Stapleton et al., 1991). The HAV cellular receptor 1 (HAVcr-1) cDNA codes for a 
novel mucin-like class I integral membrane glycoprotein of unknown natural function 
(Cowan & Anderson, 1997; Locarnini, 1997), contains four putative N-glycosylation sites 
and two distinctive regions: an N-terminal Cys-rich region that displays homology to 
sequences of members of the immunoglobulin superfamily, and a mucin-like C-terminal 
region containing 27 repeats of the consensus PTTTTL (Thompson et al., 1998), and 
serves as an African green monkey kidney (AGMK) cell receptor for HAV (Kaplan et al., 
1996). Further investigation revealed that the Cys-rich region of HAVcr-1 and its first
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glycosylation site are required for binding of protective monoclonal antibody 190/4 and 
HAV receptor function (Thompson etal., 1998).
Following uncoating in the cytoplasm releasing the RNA genome, which alone may take 
up to 12 hours in HAV (Updike et a/., 1991), and translation of genomic RNA the viral 
RNA polymerase 3Dpo' is released, in PV, from the C-terminus of the large polyprotein 
precursor by protease-catalyzed autocatalytic cleavage that generates the mature viral 
proteins (Plotch et al., 1989), and presumably replication in HAV is carried out by its viral 
RNA-dependent RNA polymerase, 3DP°I. This enzyme has been well characterised in 
PV but HAV 3Dpo1 is proving to be more elusive.
The replication of HAV is not associated with shutdown of host-cell macromolecular 
synthetic processes, and usually does not lead to demonstrable cytopathic effects. 
However, rapidly replicating, cytopathic (RR/CPE+) strains of HAV, recovered from cells 
which had been persistently infected with virus for a period of many months, do induce a 
cytopathic effect characterised by vacuolation and cellular degeneration, but not 
associated with specific host cell metabolic shutdown (Lemon, 1994). Cytopathic 
variants of HAV have been shown to arise by a combination of genetic recombination 
and point mutations in both the 5' and 3' NTRs and the capsid region VP2, as well as in 
the nonstructural proteins 2A, 2B, 2C, 3A, VPg and SD*50' (Jansen etal., 1988; Lemon et 
al., 1991; Zhang et al., 1995). The results of Zhang et al. (1995) suggest novel 
interactions between the 5' NTR and P2 proteins during HAV replication. Very recently a 
RR/CPE+ strain was isolated from, persistently infected BS-C-1 cells by serial passages, 
sequencing of the the NTRs and coding regions for 2ABC and 3AB of which, revealed 
that mutations are distributed all over these regions and that certain mutated sites 
correspond to those in other cytopathogenic HAV variants, and on investigating the 
mechanisms causing the CPE in cells infected with this variant, Brack et al. (1998) found 
that an apoptotic reaction takes place. Beneduce etal. (1995) suggested that a deletion 
in 3A might be involved in the induction of a CPE, expression of which induces 
modifications of cell membrane permeability which lead to cell death.
Viral translation appears to proceed following internal entry of the 40S ribosomal subunit 
particle within the 3' half of the 5' NTR, just upstream of the AUG initiating the large ORF 
(Le et al., 1993). Recent studies by Tesar et al. (1992) have shown that HAV RNA has 
two potential translation initiation sites, located at 735-737nt and 741-743nt, and that the 
preferred translational start site, however, is the second AUG within the ORF and not the
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first AUG triplet. In vitro translation of HAV in RRLs is thought to be quite inefficient, and 
apparently plagued by both inappropriate termination and aberrant initiation (Glass et al.,
1993). Aberrant initiation is particularly prominent in the P3 region of the genome 
(Lemon, 1994). In addition, internal initiation of HAV translation appears to proceed only 
at a very low level of efficiency even within permissive cells (Whetter et al., 1994). Jia et 
al. (1991b) demonstrated that translation of HAV RNA in RRLs initiates predominantly at 
a large number of internal AUG codons, especially those in the P3 coding region, 
however, replacement of the HAV 5' NTR with EMCV 5' end sequences increased 
initiation at the correct polyprotein start site and both reduced and altered the products 
generated by internal initiation. Since the EMCV RNA 5' end functions quite well in 
RRLs to direct ribosomes to the appropriate AUG, it is likely that successive loading of 
ribosomes at the 5' end, followed by ribosome translocation due to polypeptide chain 
elongation, makes internal RNA regions unavailable for aberrant initiation events. If 
ribosome entry at HAV 5' end RNA sequences requires factors not adequately present in 
RRLs (as appears to be the case for PV RNA), then the failure to load ribosomes at the 
5' end would leave internal sites exposed and available for aberrant initiation. Chimeric 
RNAs containing the EMCV IRES and various lengths of the 5'-terminal HAV sequence 
were analysed and revealed that more than 151 nt from the 5' terminus of HAV were 
found to be required to support virus replication, indicating either, that the signals 
governing RNA replication are localised to the 5'-terminal portion of the HAV 5' NTR or 
that any replication signals that extend within the HAV IRES can be functionally provided 
by the EMCV IRES sequence-structure indicating that the inherent translation efficiency 
of the HAV IRES may not be the major limiting determinant of the slow-growth 
phenotype of HAV (Jia et al., 1996). Similar experiments using constructs retaining the 
HAV 5' NTR extending into various lengths of HAV coding sequences, using PV coding 
sequences as reporter, demonstrates that sequences downstream of the translation 
initiation AUG codon of the HAV IRES provided a four-fold increase of HAV IRES-driven 
translation in vitro over a construct without HAV downstream capsid coding sequences. 
More than 66nt of the HAV capsid coding sequence are necessary to support this 
stimulation (Graff & Ehrenfeld, 1998). Using dicistronic mRNAs translated in vitro, 
Borman & Kean (1997) have shown that the HAV IRES is inhibited by FMDV Lb 
proteinase, as well as by HRV 2A proteinase and, furthermore, have determined that 
HAV IRES requires intact elF4G for activity which is unique among the picomavirus 
IRESes studied to date and may help explain why HAV does not inhibit host cell 
translation during viral infection (Borman & Kean, 1997). It is likely that cell-specific 
translation initiation factors also play a prominent role in this process, although there is a
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need for further work in this area (Whetter et al., 1994). Internal ribosome binding likely 
requires the interaction of trans-acting factors that recognise both the mRNA and the 
ribosomal complex (Witherell & Wimmer, 1994). Glass & Summers (1993) have 
identified a trans-acting activity from liver that stimulates HAV translation in vitro and 
from their data surmised that the absence of factors necessary for HAV translation could 
play a role in the nonlytic slow growth properties exhibited by HAV in tissue culture 
systems. This idea is supported by reports that have suggested the need for 
accumulation of a cellular component(s) for the HAV life cycle to progress in BS-C-1 
cells (Cho & Ehrenfeld, 1991). This could also suggest that the hepatotrophism of HAV 
may be based in part on intracellular tissue-specific factors required for HAV translation 
and not solely rely on cellular receptors for HAV, therefore lack of factors could result in 
an aborted replication of HAV in tissues other than the liver.
Processing of the polyprotein is probably mediated largely or entirely by the 3C protein, 
as described earlier. Borovec & Anderson (1993) suggest that cleavage of the HAV 
polyprotein to produce pentamers is protracted (though not rate limiting) early in 
infection, while the assembly of pentamers into higher structures is a rapid process once 
sufficient viral RNA is produced for encapsidation.
Initially, a negative RNA strand, present in very small quantities in infected cells, is 
synthesised from the plus-strand template. It is reasonable to suppose that the initiation 
of minus-strand synthesis depends on 3Dp0‘ first recognizing and binding to certain viral 
RNA sequences, including the 3' terminus region and it has been observed in purified 
recombinant PV and ECMV that 3Dp0‘ absolutely requires the 3' poly(A) tail of the viral 
RNA in order to bind the 3' NTR and initiate replication (Cui et al., 1993). More recently 
it has been discovered that the 3' NTR is a binding site for 3AB and 3CD of PV and for 
3Dpo‘ of ECMV (Rohll et al., 1995). A pseudoknot structure has been proposed within 
the 3' NTR of PV RNA which may participate in secondary interactions. As yet there is 
no information regarding the relevance of these 3' interactions to HAV, although Nuesch 
and colleagues reported in 1993 that a signal sequence is present in the 3' NTR of the 
HAV genome which is thought to be involved in regulation of viral RNA replication. 
Involvement of various host-cell proteins in the replication of picornaviruses has been 
reported and is discussed in the previous sections. A higher-order structure formed at 
the junction of the 3Dpol-coding sequence and the 3' NTR of the HAV genome (putative 
RNA pseudoknot) significantly improves binding of host proteins and thus suggests that 
this structure might be essential for the formation of the RC initiating minus-strand
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synthesis (Kusov et al., 1996). Like the other picornaviruses, synthesis of the negative 
RNA strand yields a double-stranded intermediate which separates, the negative strand 
acting subsequently as a template for amplification of positive-sense genome. The 
results of Anderson et al. (1988) indicate that while the very small amount of negative- 
strand HAV RNA is used efficiently as a template for RNA synthesis, HAV positive- 
strand RNA is preferentially encapsidated and only poorly utilised as a template for RNA 
synthesis. The means by which HAV exits the ceil is not known, although HAV has been 
found within cytoplasmic vesicles in infected cells in the liver (Hollinger & Ticehurst, 
1996).
Following infection of permissive cell cultures with cell culture-adapted virus, replication 
of the viral RNA has been shown to proceed in an increasing fashion for several days, 
but then becomes reduced in magnitude as persistent infection becomes established. 
The factors responsible for this down regulation in viral RNA replication remain unknown, 
although it has been shown that, at the critical time during virus replication, proteins 
accumulate which interact specifically with a distinct nucleotide sequence within the 3' 
non-coding region of the HAV genome and/or within the 5' terminal region of the HAV 
antigenome (Nuesch et al., 1993) and may have a regulatory action on viral RNA 
synthesis. De Chastonay & Siegl (1987) have also observed a down-regulation of viral 
RNA synthesis following the initial period of replicative activity, perhaps related to the 
generation of defective interfering particles containing RNA with large deletions 
putatively extending from the P1 (capsid-encoding domain) into the nonstructural region 
of the genome. Viral antigen may continue to accumulate after maximal infectivity has 
been reached in infections carried out at low multiplicity of infection. The reasons for this 
are not clear, although empty capsids at times represent the dominant form of antigenic 
material harvested from infected cells (Lemon, 1994).
Although the apparent synchronisation of HAV replication in BS-C-1 cells following 
removal of guanidine inhibition shortens the infection cycle about three- to five-fold (from 
14 days to 4 days), this replication cycle is still 10-fold longer than that of most 
picornaviruses whose cycles are complete within 6-8 hr (Cho & Ehrenfeld, 1991). 
Hypotheses advanced to explain the slow growth of HAV in cultured cells include a delay 
in uncoating of the virus upon entry, asynchronous uncoating, rapid encapsidation of 
plus-strand RNA (Anderson et al., 1988), production of defective genomes, an inefficient 




The selective forces influencing the spread of HAV within human populations have 
forced the virus to evolve toward such a poor replicative posture. Infection of the liver 
with a virus having the replication properties displayed by PV or EMCV in cell cultures 
would probably result in rapid, overwhelming hepatic failure and death. However, HAV 
depends upon its secretion into bile by a relatively normal functioning liver in order to be 
shed in faeces and transmitted to other individuals. The inefficient translational activity 
of the HAV IRES, and possibly other HAV replicative functions, detailed above, may 
reflect the adaptation of this RNA virus to a relatively unique epidemiologic niche (Lemon 
etal., 1992).
Continued passage of HAV through cells in vitro leads to incorporation of mutations into 
its genome as the virus adapts to growth in cell culture. These mutants have a shorter 
life-cycle and some display an attenuation in their infectivity which could increase their 
potential in vaccine production (Lemon, 1994). Previous studies have shown that 
mutations which occur during adaptation of HAV to cell culture have been found over the 
entire genome (Graff et al., 1994). Mutations present in the 2B/2C genome region, 
however, are common in different HAV strains and are shown to be essential for an 
enhanced viral growth (Emerson et al., 1993; Tedeschi et al., 1993). Prior to this, 
Robertson et al. (1987) found that, of the capsid regions of attenuated HAV isolates 
studies, only limited amino acid changes were observed in VP4, VP2, and VP3, whereas 
amino acid variability was found within VP1 when they were compared with each other. 
It was recently reported that enhanced viral growth required mutations in both 2B and 2C 
proteins, suggesting that these proteins remain closely associated during HAV 
replication. Mutations in the 5' NTR or P3 proteins had no independent effect, but acted 
cooperatively with mutations in P2 proteins to enhance replication and render the virus 
capable of conventional plaque formation (Zhang et al., 1995). Mutations within the 5' 
NTR have a dramatic effect in effect in enhancing growth in certain cell lines and may be 
of relevance to viral attenuation because the change in host range that accompanies 
adaptation of HAV to growth in monkey kidney cells has been associated with reduced 
hepatovirulence in susceptible primates (Brown et al., 1991). Mutations which alter the 
secondary structure of the 5' NTR may lead to a more effective binding pattern for the 
ribosome in the internal segment and possibly enhance the process of viral translation in 
cell culture (Graff et al., 1994). In addition, mutations in the 5' NTR of a cell-culture 
adapted HAV have been shown to enhance viral replication by facilitating cap- 
independent translation in a cell-type-specific fashion, supporting the concept that 
picornaviral host range is determined in part by differences in cellular translation initiation
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factors (Schultz et al., 1996). Mutations, however, in the 5'-most pyrimidine rich tract of 
HAV have been found to reduce its ability to direct internal initiation of translation 
(Carneiro etal., 1995).
The slow growth of HAV in cell culture has hampered the production of sufficient 
quantities of an attenuated vaccine, however recent research into cell culture adaptation 
and attenuation of virulence looks promising in the search for a more practically and 
economically viable vaccine against hepatitis A. Recently Funkhouser et al. (1996) have 
reported progress towards the development of a genetically engineered HAV vaccine.
1.4 Study of the hepatitis A virus 3D1301
In order to determine the reason for slow proliferation of HAV it is necessary to 
characterise the non-structural proteins of the virus. It has been postulated that slow 
growth of HAV in cell culture may be due to inefficient replication of viral RNA but this 
could also be explained by an inefficient RNA polymerase and attempts have been made 
to characterise this enzyme by cloning the P3 region of the genome and expressing in E. 
coli.
Recently a plasmid (pRITPOL) was designed to export HAV-specific P3 sequences into 
the periplasmic space of E. coli as a fusion protein with staphylococcal Protein A. It was 
hoped that this procedure would increase the solubility of the 3Dpo1 protein which had 
previously accumulated in E. coli as an insoluble, inactive product. In E. coli transformed 
with pRITPOL a weak poly(U) polymerase activity was detected which demonstrated 
Mg2+ dependence, inhibition by Mn2+ and a temperature optimum of approximately 32°C, 
but no protein of the predicted size of 53kDa was detected with human convalescent 
























Figure 25: Plasmid construction pRITPOL and its parent vector pRIT5
An attempt was therefore made to improve expression levels and enzymic activity by 
making two new constructs based on the plasmid pMEX8, a strong, inducible expression 
vector (Figure 26). The first construct, HAV P3/pMEX8 contains most of the P3 regions 
with the exception of what was thought to be the first 11 amino acids of 3A under the 
control of a tac promoter. The corresponding proteins should be expressed in high 
levels in the cytoplasm. The second construct, Protein A/HAV P3/pMEX8, contains the 
P3 region as above, fused to selected staphylococcal Protein A sequences which direct 
the expression products to the periplasmic space. All three constructs including 
pRITPOL were transformed into E. coli strain JRR-600, a strain deficient in RNase I 




Purification of a protein believed to be the HAV RNA-dependent RNA polymerase from 
the periplasmic space of E. coli transformed with Protein A/HAV P3/pMEX8 has been 
achieved using affinity chromatography (Palmer, 1994).
A synthetic peptide corresponding to the N-terminus of the 3D region has been used to 
raise antisera in rabbit and this has been used to detect the HAV 3Dpo1 in cells 
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Figure 26: Plasmid constructions HAV P3/pMEX8 and Protein A/HAV P3/pMEX8 




To summarise, HAV shares many structural and biological attributes with other 
picornaviruses such as PV or EMCV. These include at least a superficially similar, non­
enveloped capsid structure, and a positive-sense RNA genome of approximately 7.5kb 
which contains a single large ORF encoding a polyprotein which is post-translationally 
processed by virally encoded proteases into both structural and nonstructural proteins 
required for viral replication. Although the host range of PV is more restricted than 
EMCV, both of these viruses replicate rapidly in cultured cells. Following attachment, 
penetration, and uncoating there is a rapid shut-down of host-cell macromolecular 
synthesis and initiation of viral replication. Maximum titres of replicated virus are 
generally present within 6 hours or less. In contrast, one-step growth studies with HAV 
show that uncoating alone may take up to 12 hours, and that replication even of virus 
which has been substantially adapted to growth in cell cultures takes many hours more. 
Unlike PV and EMCV which generally cause rapid cytolytic infection, infection of cell 
cultures with HAV typically results in viral persistence, with little or no apparent impact on 
cellular growth.
What accounts for this marked difference in these picornaviruses? The virus appears to 
do poorly almost everything it must do to replicate and increase in number. One of 
several hypotheses advanced to explain this slow growth is the possibility that the 
polymerase enzyme is inefficient or rapidly degraded. The purpose of this investigation 
is to characterise the RNA polymerase activity encoded by the HAV. This is a key 
enzyme in viral replication, but the inefficiency of this process has made it impossible to 
study in vivo. The HAV RNA polymerase has previously been expressed in Escherichia 
coli systems and other vector/expression systems and I now propose to study the 
biochemical properties of the bacterially-expressed enzyme.
The polypeptides previously produced by Wolstenholme and colleagues (1993), however 
showed little or no polymerising activity. In this project, I hoped to improve the current 
expression system to maximise the enzyme yield and investigate the effects of viral and 
cellular cofactors on the in vitro activity of HAV RNA polymerase. This involved the 
cloning, expression and purification of other viral polypeptides e.g. 3AB, and the addition 
of the purified polypeptide to standard in vitro RNA polymerase assays. In this way the 
contribution of the RNA polymerase to the distinctive biological properties of HAV - slow, 




Essentially though, at commencement, this investigation had several specific aims.
1. Purification of the poly (U) polymerase, identification of the polypeptide responsible 
for this activity and determination of the N-terminal sequence which was incidently 
discovered in 1994 by Tesar and colleagues.
2. Biochemical characterisation of the poly (U) and RNA polymerase activities of the 
HAV 3Dpo‘ expressed in E. coli.
3. Expression and purification of other viral polypeptides and their effects upon addition 
to standard in vitro RNA polymerase activity assays.
4. Development of a more efficient expression system for the HAV 3Dpo‘. Expression 
levels obtained with the protein A fusion system described in Wolstenholme et al. 
(1993) were rather low, and higher levels of expression was expected to make the 
work described considerably easier.
The cost of an outbreak to society (individual patient, NHS and third parties combined) of 
hepatitis A, in Puglia, Italy, was recently calculated to be L37.406 billion ($US24.45 
million) (Lucioni et al., 1998). The overall aim of this project is the biochemical 
characterisation and reconstitution in vitro of the virus enzyme and it is hoped that in the 
long term, knowledge concerning the replication of viral RNA may permit the 
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XL2-Blue RecA1 endA1 gyrA96 thi-1 hsdR17 (rK'mK+) 







TB1 F  ara A(lac-proAB) rpsL (Stf)[08OdlacA 
(lacZ)M15\thi hsdR (rK"mK+)
New England Biolabs, 
Hitchin, U.K.
TG1 F  traD36 laqf* A(laqZ)M15 proA+B+/supE  
(hsdM-mcrB)5(rK'rr\K'McrB') thi A(lac-proAB)
Amersham International 
Pic, Little Chalfont, U.K.
JRR-600 Produced by conjugation of MRE-600 cells 
with XL1-Blue cells
Courtesy of Janet Rider, 
University of Bath, U.K.
2.1.2 Escherichia
PLASMID GENOTYPE AND SIZE SUPPLIER
pBluescript™ Ampr, 2.96kb Stratagene Ltd., Cambridge,
U.K.
pMEX8 Ampr, 3.63kb United States Biochemical, 
Cleveland, OH, U.S.A.
pRIT5 Ampr, 6.9kb Pharmacia, St. Albans, U.K.
pMAL-c2 Ampr, 6.7kb New England Biolabs, Hitchin, 
U.K.
2.1.3 Enzymes
Restriction endonucleases and DNA modifying enzymes with associated buffers were 
purchased from New England Biolabs, Hitchin, U.K. or from the Promega Corporation, 
Southampton, U.K. with the exception of T4 DNA Ligase which was purchased from 
Gibco BRL, Paisley, U.K. and Expand™ Long Template PCR System, Expand™ High 
Fidelity PCR System and RNAse A which were from Boehringer Mannheim, Lewes, U.K. 





Antibodies directed against a synthetic 3D peptide were courtesy of Miss E. Nutter. The 
synthetic peptide amino acid sequence is:-
M I E Y R L K S Y D W W R M  F Y D Q C  
This corresponds to the C-terminus of the predicted sequence of HAV 3D (nucleotides 
7339 through to 7398 (Appendix 2 (7.2.3). By coupling this to thyroglobulin and forming 
an emulsion with the TiterMax™ Research Adjuvant (Sigma-Aldrich Chemical Company 
Ltd., Poole, U.K.) the serum collected from animals injected contained antibodies against 
the 3Dpo'. The titre of this antibody was found by Miss E. Nutter to be >1004.
Human convalescent serum was kindly supplied by the PHLS Laboratories, Royal United 
Hospital, Bath, U.K.
Anti-MBP antiserum was from New England Biolabs for use in pMAL expression 
analysis.
2.1.5 General laboratory reagents
Molecular biology grade chemicals were obtained from Fisons, Loughborough, U.K. 
Bacteriological culture media and Tris-saturated phenol:chloroform:isoamyl alcohol were 
obtained from the Sigma-Aldrich Chemical Company Ltd., Poole, U.K. Water-saturated 
phenol was from Rathbum, Walkerburn, U.K. Absolute ethanol was obtained from 
Hayman Ltd., Witham, U.K. Ultrapure Sequagel™ Sequencing Systems and Protogel™ 
acrylamide solutions were obtained from National Diagnostics, Hull, U.K. Falcon 
plasticware was supplied by Becton Dickinson and Company, Plymouth, U.K. and Nunc 
plasticware by Life Technologies, Glasgow, U.K. Whatman 3MM Chromatography 
Paper was from Whatman International Ltd., Maidstone, U.K. Trans-Blot® Transfer 
Medium (Pure Nitrocellulose Membrane) was from Bio-Rad Ltd., Hemel Hempstead, 
U.K.
Ultrapure dNTP sets were obtained from Pharmacia Biotech, St. Albans, U.K. Wizard™ 
Minipreps DNA Purification System kits were purchased from Promega and 
Sequenase™ Version 2.0 DNA Sequencing kits (United States Biochemical) from 
Amersham International Pic., Little Chalfont, U.K. The ECL kits and all radiochemicals 
were also purchased from Amersham International Pic. GENECLEAN //® kits (Bio101 
Inc.) were from Anachem, Luton, U.K. and QIAquick PCR Purification kits and QIAfilter
93
Chapter 2
Midi kits from QIAGEN Ltd., Dorking, U.K. Blue sensitive X-ray film was obtained from 
Genetic Research Instrumentation, Dunmow, U.K.
Oligonucleotides were synthesised either by R&D Systems Europe Ltd., Abingdon, U.K. 
or by Perkin Elmer - Applied Biosystems, Warrington, U.K.
2.1.6 Media and solutions
The composition of media and solutions used in the Methods section are given below. 
Solutions were sterilised either by autoclaving at 120°C, 1.41 KPa for 20 minutes, or by 
filtering using Millipore 0.22pM syringe filters. All solutions were stored at room 
temperature in colourless glass or plastic bottles, unless otherwise stated.
2.1.6.1 Enzyme buffers
2. 1.6. 1. 1 Polymerases and modifying
ENZYME REACTION BUFFER (1x)
Taq DNA polymerase 50mM KCI
10mM Tris-HCI (pH9.0) 
0.1% (v/v) Triton X-100
Vent® DNA Polymerase 10mM KCI
20mM Tris-HCI (pH8.8 @24°C) 
10mM (NH4)2S 04 
2mM MgS04 
0.1% (v/v) Triton X-100
Expand Polymerase Enzyme Mix 50 mM Tris-HCI (pH 9.2) 
16mM (NH4)2S04 
2.25 mM MgCI2
Polynucleotide Kinase (PNK) 70mM Tris-HCI (pH7.6) 
10mM MgCI2 
5mM DTT











Enzymes and buffers were stored at -20°C or as per manufacturer's recommendations.
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1mM Bis Tris Propane-HCI 
1mM MgCI2
0.1 mM DTT (pH7.0 @25°C)
YES
NO






0.1 mM DTT (pH7.9 @ 25°C)
YES





0.1 mM DTT (pH7.9 @ 25°C)
YES






0.1 mM DTT (pH7.9 @ 25°C)
NO






0.1 mM DTT (pH7.9 @ 25°C)
YES
All enzymes and buffers stored at -20°C as per manufacturer's recommendations.




Luria-Bertani (LB) Broth 1 % (w/v) bacto-tryptone 
1% (w/v) NaCI 
0.5% (w/v) yeast extract
LB-Agar LB Broth 
1.5% (w/v) agar
DYT 1.6% (w/v) bacto-tryptone 
0.5% (w/v) NaCI 
1 % (w/v) yeast extract
LB-Glucose LB Broth
0.02% (w/v) glucose
(added post autoclaving as filter-sterilised stock solution)
LB-Expression LB Broth
1mM IPTG (added post autoclaving)
Rich Broth (pMAL) 1 % (w/v) bacto-tryptone 
0.5% (w/v) NaCI 






Chloroform 24:1 (v/v) Chloroform:isoamyl alcohol
Phenol Obtained distilled and stored at 4°C, equilibrated with 2 volumes 
50mM Tris-HCI (pH8.0)
(stored in the dark at -20°C)
Phenol/chloroform 50% (v/v) Phenol equilibrated with 10mM Tris-HCI, pH7.6 
49% (v/v) chloroform 
1 % (v/v) isoamyl alcohol 
(stored in the dark at 4°C)
Ethidium Bromide 10mg/ml stock, stored in the dark at 4°C
RNAse A 
(DNAse free)
10mg/ml stock in TE Buffer, incubated at 95°C for 30 minutes 
and stored at -20°C.




2.1.6.4 Buffers used in plasmid
analysis
BUFFER COMPOSITION
GTE Buffer 25mM Tris-HCI (pH8.0) 
10mM EDTA 
50mM glucose
Standard Lysis Buffer 0.2M NaOH
(made up just prior to use) 1% (w/v) SDS
Potassium Acetate Solution 3M potassium acetate
11.5% (v/v) glacial acetic acid, pH4.6
TE 10mM Tris-HCI 
1mM EDTA, pH7.6
10x TBE 0.89M Tris-HCI 
0.89M H3BO3 
20mM EDTA, pH8.0
6x Loading Buffer 0.25% (w/v) bromophenol blue 




2.1.6.5 Buffers used in protei
2.1.6.5.1 SDS-PAGE gel ele
BUFFERS COMPOSITION
30% (w/v) Acrylamide 
(stored at 4°C)
28.4% (w/v) acrylamide 
1.6% (w/v) bis-acrylamide
Deionised by stirring with dextran beads for 2 hours 
and filtered.
Solution A (Protogel) 
(stored in dark at 4°C)
29.2% (w/v) acrylamide
0.8% (w/v) N,N'-methylenebisacrylamide
Solution B/Resolving Gel Buffer 
(stored in dark at 4°C)
18.2% (w/v) Tris-HCI 
0.4% (w/v) SDS, pH8.8
Solution C/Stacking Gel Buffer 
(stored in dark at 4°C)
6.1% (w/v) Tris-HCI 
0.4% (w/v) SDS, pH6.8
Solution D/10% APS 
(made up just prior to use)
10% (w/v) ammonium persulphate





0.1% (w/v) bromophenol blue 
10% (v/v) glycerol
Tank Buffer 25mM Tris-HCI 
0.25M glycine 
0.1% (w/v) SDS, pH8.3
Fix 45% (v/v) methanol 
10% (v/v) acetic acid
Coomassie Blue Stain Fix
0.25% (w/v) Coomassie Brilliant Blue R-250
2.1.6.5.2 Western blotting and
BUFFER COMPOSITION
Transfer Buffer 39mM glycine 
48mM Tris base 
0.037% (w/v) SDS 
20% (v/v) methanol, pH8.3
10x Ponceau-S 2% (w/v) Ponceau-S 
30% (w/v) trichloroacetic acid 
30% (w/v) sulfosalicylic acid
Blocking Buffer 5% (w/v) Marvel™ non-fat dried milk 
0.02% (w/v) NaN3 in PBS
Phosphate-free, Azide-free 
Blocking Buffer
5% (w/v) Marvel™ non-fat dried milk 
0.15M NaCI 
50mM Tris-CI




2.1.6.6 Buffers used in protein techniques
2.1.6.6.1 Buffers used in protein isolation
BUFFER COMPOSITION
IC Resuspension Buffer 50mM Tris-HCI (pH8.1) 
0.15M NaCI 
0.25mM EDTA




(sucrose added post autoclaving as filter sterilised stock)
2.1.6.6.2 GTP-Agarose affinity chromatography buffers
BUFFERS COMPOSITION
Equilibration Buffer (stored at 4°C) 50mM KCI
10(iM NaF




Column Equilibration Buffer 10mM Tris-CI
25mM NaCI, pH8.0
Buffer A 20mM Tris-CI
25mM NaCI, pH8.0





2.2.1 Techniques used in DNA preparation and 
synthesis
2.2.1.1 Calcium chloride competent cells
Competent cells were made using the calcium chloride method (adapted from Mandel 
and Higa, 1970). A 5pl culture of the desired cell strain, generally E. coli TG1 cells, in 
LB was incubated with shaking at 37°C overnight. An aliquot (200|il) of overnight culture 
was added to 50ml DYT and incubated with shaking at 37°C until an A55o of 0.3 was 
reached. The cells were placed on ice for 5 minutes, centrifuged at 1,090g, 4°C for 5 
minutes and the pellet resuspended in 20ml 0.1M CaCI2. After a further 20 minutes on 
ice, the cells were centrifuged as above and the pellet resuspended in 2ml 0.1M CaCI2. 
Competent TG1s were used within 24 hours. Ultracompetent Epicurian® XL2s were 
used as directed by manufacturer.
2.2.1.2 Transformation and culture of clones
DNA (50-100ng) was added to 200(j.l competent cells and incubated on ice for 40 
minutes. The cells were heat shocked at 42°C for 90 seconds, 1ml DYT was added and 
the cells incubated at 37°C for 40 minutes before being plated onto LB agar plates 
containing ampicillin at 100pg/ml for transformant selection. Plates were then incubated 
at 37°C overnight. Individual colonies were lifted and transferred aseptically to 10ml of 
LB containing 100pg/ml ampicillin. The cultures were incubated overnight at 37°C with 
shaking.
2.2.1.3 a-Complementation
Transformed competent cells which utilised the replacement of the lacZ gene with 
foreign DNA were selected for on LB ampicillin plates supplemented with the 




2.2.1.4 Storage of bacterial cultures
Bacterial cultures were stored indefinitely at -20°C with the addition of 15% (v/v) sterile 
glycerol, as described in Sambrook etal., (1989).
2.2.1.5 Plasmid DNA preparations
2.2.1.5.1 ‘Mini’-scale
2.2.1.5.1.1 Standard alkaline lysis method
Small amounts (~10|ng) of plasmid DNA were isolated from cultures using a modified 
alkaline lysis method (Bimboim and Doly, 1979). 1.5ml of an overnight culture was 
centrifuged for 1 minute, and the supernatant removed. The pellet was resuspended, 
with mixing, in 100|xl of ice-cold GTE and then 200pl of freshly prepared Standard Lysis 
Buffer was mixed in by repeatedly inverting the tube. The tube was incubated on ice for 
5 minutes, before 150jil of chilled Potassium Acetate Solution was added and the tube 
vortexed. After a further 5 minutes on ice the tube was centrifuged at 12,000g for 5 
minutes at 4°C and the supernatant preserved. The DNA was then extracted once with 
phenol:chloroform and precipitated for 15 minutes at -20°C with 2 volumes of ethanol. 
After a 10 minute centrifugation the pellet was washed with 70% (v/v) ethanol and dried 
under vacuum. The pellet was then resuspended in TE containing lO^g/ml RNAse A.
2.2.1.5.1.2 Promega “Wizard”™miniprep method
3ml of an overnight culture were centrifuged in a benchtop microcentrifuge in two 
microcentrifuge tubes at 10,000g for 90 seconds. Each of the pellets was resuspended 
by vortexing in 100|liI of Cell Resuspension Solution (50mM Tris-HCI (pH7.5), 10mM 
EDTA, 100pg/ml RNAse A) and the two aliquots combined. 200pJ of Cell Lysis Solution 
(0.2M NaOH, 1% (w/v) SDS) were added and the tube’s contents mixed by inverting 
several times. After the addition of 200pl of Neutralisation Solution (1.32M potassium 
acetate) the tube was again inverted several times and spun at top speed (10,000g) in a 




A Wizard™ Minicolumn was prepared by attaching the barrel of a 3ml syringe to the 
Minicolumn and 1ml of resuspended Wizard™ Minipreps DNA Purification Resin was 
added to the Minicolumn/syringe assembly. The clear supernatant was transferred to 
the barrel of the Minicolumn/syringe assembly and the plunger pushed home gently, 
after which the syringe was removed from the column and the plunger withdrawn. The 
syringe barrel was then reattached and 2ml of Column Wash Solution (80mM potassium 
acetate, 8.3mM Tris-HCI (pH7.5), 40jxM EDTA and 55% (v/v) ethanol) was passed 
through the Minicolumn. The syringe was again removed and the Minicolumn 
transferred to a clean 1.5ml microcentrifuge tube. The Minicolumn was centrifuged at 
10,000g in a microcentrifuge for 2 minutes to dry the resin. Plasmid DNA was eluted by 
adding 50|xl of water, waiting 1 minute and then centrifuging at 10,000g for 30 seconds.
2.2.1.5.2 ‘Midi’-scale
2.2.1.5.2.1 Alkaline lysis method
50ml of DYT media containing ampicillin at 100pg/ml was inoculated with 200pl of 
glycerol stock and incubated with shaking at 37°C overnight. Cells were harvested by 
centrifugation in a Sorvall SS34 rotor at 3,000g for 5 minutes. The pellet was 
resuspended in 4ml of GTE and the cells lysed with 4ml of fresh Standard Lysis Buffer. 
The alkali was neutralised by the addition of 4ml of neutralising solution (3M sodium 
acetate, pH4.8) and the mixture centrifuged in a Sorvall SS34 rotor at 17,400g for 5 
minutes.
The supernatant was mixed with an equal volume of isopropanol and centrifuged at 
17400g for 5 minutes. The pellet was resuspended in 500pl of sterile water in a 
microcentrifuge tube and the alkaline lysis and neutralisation steps repeated using 250pl 
volumes in order to eliminate any remaining cellular DNA. The pellet obtained after a 
second isopropanol precipitation was resuspended in 500pl of sterile water and 
incubated for 5 minutes with an equal volume of 6M LiCI in order to precipitate RNA. 
After centrifuging at high speed for 2 minutes the DNA in the supernatant was ethanol 
precipitated (as described in 2.2.2.2) and the subsequent pellet resuspended in 400pl of 
TE (pH7.8). RNA was digested by the addition of DNAse-free RNAse to a concentration 
of 100pg/ml and incubation at 37°C for 30 minutes. The reaction was stopped by the 
addition of 20pl 10% (w/v) SDS and incubation at room temperature with 6M LiCI for 15 
minutes and pelleted by centrifugation at high speed. DNA in the supernatant was
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ethanol precipitated and the subsequent pellet resuspended in sterile water before 
extraction of protein once with phenol:chloroform:isoamyl alcohol (25:24:1) and twice 
with chloroform:isoamyl alcohol (24:1). After a final ethanol precipitation, the DNA pellet 
was resuspended in 100(il sterile water.
2.2.1.5.2.2 QIAGEN “QIAfilter”™Midi method
LB containing chloramphenicol (180mg/l) improves yield of low-copy-number plasmids 
containing the ColE1 origin of replication, such as pMAL-c2, and they can then be 
treated as high-copy-number plasmids and as such the following procedure was adhered 
to:
The bacterial pellet was resuspended in 4ml of Resuspension Buffer (50mM Tris-HCI 
(pH8.0), 10mM EDTA, lOO^ig/ml RNAse A). 4ml of Lysis Buffer (0.2M NaOH, 1% SDS) 
was added, the solution was mixed gently and then 4ml of chilled Neutralisation Buffer 
(3M potassium acetate (pH5.5)) was added. Immediately the tube was mixed gently and 
the lysate transferred to the barrel of the QIAfilter Midi cartridge where it was incubated 
at room temperature for 10 minutes. Meanwhile, a QIAGEN-tip 100 was equilibrated by 
applying 4ml of Equilibration Buffer (0.75M NaCI, 50mM MOPS (pH7.0), 15% (v/v) 
ethanol, 0.15% (v/v) Triton X-100) and allowing the column to empty by gravity flow. The 
plunger was inserted into the QIAfilter Midi cartridge and the cell lysate filtered while 
holding it over the previously equilibrated QIAGEN-tip. The cleared lysate enters the 
resin by gravitational flow and the QIAGEN-tip washed twice with 10ml Wash Buffer (1M 
NaCI, 50mM MOPS (pH7.0), 15% (v/v) ethanol). The DNA was eluted with 5ml Elution 
Buffer (1.25M NaCI, 50mM Tris-HCI (pH8.5), 15% (v/v) ethanol), precipitated with 3.5ml 
room-temperature isopropanol and centrifuged at 15,000g for 30 minutes at 4°C. The 
supernatant was carefully removed and the DNA was washed with 2ml of 70% (v/v) 
ethanol, centrifuged at 15,000g for 10 minutes and the supernatant again carefully 
removed. The pellet was air-dried for approximately 5 minutes and then dissolved in a 
suitable volume of sterile distilled water or TE Buffer.
2.2.1.5.3 ‘Maxi’-scale
2.2.1.5.3.1 Alkaline lysis method using CsCI and EtBr
This method is a modification of the method of Birnboim and Doly (1979) and is
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designed to be used in conjunction with a subsequent purification step such as 
equilibrium centrifugation in CsCI>ethidium bromide gradients.
From the cells stored at 4°C, 500pl was used to inoculate 500ml LB broth with ampicillin 
(100^g/ml). The cells were grown overnight, then pelleted by centrifugation at 3,000g for 
20 minutes at 4°C. The pellet was resuspended in 8ml of GTE. The cells were lysed by 
adding 16ml Standard Lysis Buffer and then incubated on ice for 10 minutes. The cell 
debris was precipitated with 5ml Potassium Acetate Solution and then pelleted by 
centrifuging at 10,000g for 30 minutes at 4°C. The supernatant was decanted and kept. 
Nucleic acids were precipitated from the supernatant with 0.6 volumes of propan-2-ol at 
room temperature for 10 minutes, then pelleted by centrifugation at 10,000g for 10 
minutes at room temperature. The vacuum dried pellet was resuspended in 10ml of 
sterile distilled water and the volume accurately noted. Exactly 1g of CsCI for every 1ml 
(or part thereof) of DNA solution was added, with 300pl of 10mg/ml Ethidium Bromide 
(EtBr) and this solution transferred to Beckman heat-sealable tubes. The tubes were 
balanced to within 10mg, sealed and centrifuged at 340,000g for 18 hours.
The lower, supercoiled plasmid band was taken and solvent extracted with amyl-alcohol 
to remove the EtBr. The aqueous phase was diluted with 1ml sterile distilled water and 
then the DNA precipitated with 3 volumes ice cold absolute ethanol. The vacuum dried 
pellet was resuspended in 1ml sterile distilled water, then precipitated with 2ml absolute 
ethanol plus 100|il 3M sodium acetate (pH5.2). The vacuum dried pellet was 
resuspended in 1ml sterile distilled water and precipitated as before. This pellet was 
resuspended in 200pl sterile distilled water.
2.2.1.5.3.2 Alkaline lysis method using LiCI
From the cells at 4°C, 100ml LB broth was inoculated, cells pelleted and resuspended in 
4ml GTE as before. The cells were lysed with 8ml Standard Lysis Buffer and incubated 
on ice for 10 minutes. Cell debris from the lysate was precipitated with 15ml ice-cold 
Potassium Acetate Solution and the suspension incubated on ice for 15-30 minutes. 
The suspension was centrifuged at 1,000g for 15 minutes at room temperature. The 
supernatant was filtered through muslin into another tube. Nucleic acids were 
precipitated by adding 18ml propan-2-ol and incubating on ice for 30 minutes. The 
nucleic acids were pelleted by centrifugation for 30 minutes as before and the air dried
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pellet resuspended in 1ml TE Buffer. The suspension was split between two tubes, 
500pl 6M LiCI added to each tube and incubated on ice for 15 minutes. The 
RNA/protein/salt complex was pelleted at 20,000g for 10 minutes at room temperature. 
The supernatants were split between two tubes and 1ml of -20°C absolute ethanol 
added to each tube and incubated at -20°C for 30 minutes. The nucleic acids were 
pelleted by centrifuging for 10 minutes at 20,000g at room temperature. The pellets 
were then washed in 500|al 70% (v/v) ethanol and repelleted by centrifugation as before. 
The pellets were vacuum dried and combined by resuspension in 400pl TE Buffer. RNA 
was removed by the addition of 4jil (10mg/ml) RNAse A and incubation at 37°C for 30 
minutes. The sample was further incubated with 20pl 10% (w/v) SDS at 75°C for 10 
minutes. 420^1 6M LiCI was added and incubated for 15 minutes at room temperature 
before centrifugation as before. The supernatant was split between two tubes, 1ml 
absolute ethanol was added to each tube and the tubes incubated on ice for 30 minutes. 
The DNA was pelleted by centrifugation at 20,000g for 30 minutes at room temperature. 
The pellets were washed in 500^1 70% (v/v) ethanol, then repelleted by centrifugation for 
10 minutes at 20,000g at room temperature. The pellets were resuspended in 400pl 
sterile distilled water, then solvent extracted with an equal volume of phenol/chloroform 
(1:1). This was followed by 2 further equal volume chloroform extractions, then an 
absolute ethanol precipitation. The pelleted DNA was resuspended in 100jxl sterile 
distilled water and could be used in further procedures.
2.2.2 Techniques used in the purification of DNA
2.2.2.1 Extraction of DNA with phenol:ch loroform
Purification of DNA by phenolxhloroform extraction was routinely performed as 
described in Sambrooketal. (1989).
2. 2. 2.2 Concentration of DNA by ethanol precipitation
DNA was concentrated by precipitation with 0.1 volumes 3M sodium acetate (pH5.2) and 
2.5 volumes absolute ethanol at -70°C for 20 minutes or -20°C overnight, centrifuged at 




2.2.2.3 Purification of DNA from agarose gels
Bands of DNA were excised from agarose gels and purified using a GENECLEAN IIs Kit 
(Bio101, Inc.) or a Sephaglas BandPrep™ Kit (Pharmacia) as described below.
With Sephaglas, the band of interest was cut out with a clean razor blade and any 
excess agarose trimmed away. The gel slice was weighed and 250|il (or 1 jxl for each 
mg of agarose, whichever is the greater) of gel solubiliser (buffered Nal) added. The 
agarose was dissolved by incubating the tube at 60°C for 10 minutes. 5pl of Sephaglas 
BP (20% (w/v) Sephaglas in aqueous solution) was added (or 5 1^ per estimated pg of 
DNA present) the contents of the tube mixed by vortexing and incubation continued on 
the bench for a further 5 minutes with additional periodic vortexing. The Sephaglas was 
spun down at top speed in a microcentrifuge for 1 minute and the supernatant aspirated. 
40pl (or 8x the volume of Sephaglas used) of wash buffer (60% (v/v) ethanol, 20mM 
Tris-HCI (pH 8.0), 1mM EDTA, 0.1 mM NaCI) was added and the pellet resuspended by 
vortexing. The Sephaglas was again spun down and the supernatant aspirated. This 
step was repeated twice and the pellet was air dried for 10 minutes.
DNA was eluted by adding a suitable volume of elution buffer (10mM Tris-HCI, 1mM 
EDTA), not less than half the volume of Sephaglas used, vortexing briefly to resuspend 
the pellet and incubating at room temperature for 5 minutes. The Sephaglas was spun 
down again for 1 minute at top speed and the supernatant carefully removed and 
retained.
With the GENECLEAN //® Kit, 0.5 volume of TBE Modifier™ and 4.5 volumes of Nal 
stock solution were added to a given volume of agarose, excised from a gel, and the 
tube incubated at 45-55°C until the agarose completely dissolved. To solutions 
containing 5 i^g or less of DNA, 5pl of GLASSMILK® suspension were added with an 
additional 1^ 1 GLASSMILK® being added for each 0.5pg of DNA above 5pg. After 
addition of the GLASSMILK® suspension to the solution, the tube was mixed and placed 
on ice for 5 minutes to allow binding of the DNA to the silica matrix, mixing every 1-2 
minutes to ensure that the GLASSMILK® stayed suspended. The silica matrix with the 
bound DNA was next pelleted by centrifugation. The Nal supernatant was removed and 
discarded and the white pellet washed 3 times with NEW WASH by adding 
approximately 10-50 volumes of ice-cold NEW WASH to the pellet. Elution of the DNA 
was achieved by resuspending the washed, white pellet in water and heating to 45-55°C 
for 2 or 3 minutes. The tube was next centrifuged for about 30 seconds and the
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supernatant containing the DNA removed and placed in a new tube.
2.2.2.4 Removal of short fragments of DNA
Fragments of DNA less than 100bp in size, contaminating fragments, glycerol, salts, or 
enzymes were removed after enzymatic reactions, if necessary, using the QIAGEN 
QIAquick PCR Purification Kit. 5 volumes of buffer PB were added to the DNA solution 
and the mixture loaded onto a QIAquick spin column. The column was centrifuged for 2 
minutes at 10,000g and the eluate discarded. 750pl of buffer PE was loaded onto the 
column which was centrifuged as before and the eluate again discarded. The last traces 
of wash buffer were removed by a final spin for 1 minute at 10,000g. The purified DNA 
was eluted from the column by the addition of 30|xl of water and incubation for 2 minutes 
prior to a final spin at 10,000g for 2 minutes.
2.2.3 Techniques used in the analysis of DNA
2.2.3.1 Estimation of concentration of DNA
The concentration of nucleic acid was calculated from readings of the absorbance at 
260nm on a Perkin Elmer UVA/IS Lambda 11 Spectrometer. For double-stranded DNA, 
at 260nm, 10D  = 50pg/ml and for single stranded oligonucleotides, at 260nm, 10D = 
20pg/ml (Sambrook et al., 1989). Contamination with protein was calculated using the 
ratio: absorbance at 260nm / absorbance at 280nm. A ratio of > 1.8 was taken to 
indicate purity.
2.2.3.2 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis was performed as described in Sambrook et al. (1989). 
DNA samples for agarose contained 0.16 volumes of 6x loading buffer. These were 
loaded onto 1x TBE gels of varying percentage agarose, containing 50ng/ml ethidium 
bromide. Gels were typically run at 6Vcm'1 for an hour prior to visualisation under UV 
illumination. Phage X DNA cut with the restriction enzyme Pst I was used as a size 
marker. Gels were photographed under UV light using a Polaroid camera with yellow 
filter and Polaroid 667 black and white ISO 3000/36° film.
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2.2.3.3 Sequencing of cloned PCR products
DNA was sequenced using the dideoxynucleotide chain termination method of Sanger et 
al. (1977), using T7 DNA polymerase in a Sequenase™ Version 2.0 DNA Sequencing Kit 
(United States Biochemical/Amersham). Samples were electrophoresed on a 6% (w/v) 
acrylamide sequencing gel, for 2-4h at 30mA, 40W. Gels were fixed in 10% (v/v) 
methanol, 10% (v/v) acetic acid, dried, and exposed to Kodak X-Omat LS™ film at room 
temperature overnight. A number of clones were sequenced directly on an automated 
Perkin Elmer ABI PRISM™ 377 DNA Sequencer.
2.2.3.3.1 Preparation of polyacrylamide gels fo r  sequencing
The gels were cast in rigs supplied by Flowgen. Both glass plates were washed in water 
and polished with 95% (v/v) ethanol. The back plate was laid flat and coated in a 
mixture of 200pl silane, 25ml absolute ethanol and 1.2ml 10% (v/v) acetic acid. After 5 
minutes the plate was rinsed first with water then with ethanol and polished. The front 
plate was similarly coated in 1% (v/v) dichlorodimethylsilane in 1,1,1, trichloroethane, left 
for 5 minutes, washed with water and polished with 95% (v/v) ethanol. The gel rig was 
assembled with 0.2mm spacers and a gel mixture of the required acrylamide 
concentration was made up, adding 300(xl of fresh 16% (w/v) ammonium persulphate 
(APS) and 30jllI of TEMED just before pouring. The gel was poured in a horizontal 
position and the reverse (flat) face of a 0.2mm thick shark’s tooth sequencing comb 
inserted into the upper edge of the gel. The acrylamide was allowed to set for an hour 
before the comb was removed and reversed so that the teeth impinged about 1.5mm 
into the surface of the gel.
The gel rig was mounted vertically in the equipment supplied and the reservoirs filled 
with 1xTBE. The wells were washed clear of urea and any loose polyacrylamide 
fragments with a pasteur pipette to prevent interference with the DNA samples. 3^ 1 of 
each sample was loaded onto the gel which was run at a limiting 45W. The run was 
terminated after approximately 45 minutes when the first blue dye had reached the 
bottom of the gel. After the run, the two plates were separated and the back plate with 
attached gel was fixed with 10% (v/v) methanol, 10% (v/v) acetic acid for 10 minutes 
then rinsed under a gentle flow of water for a further 10 minutes. After drying in an oven 
at 90°C the gel was autoradiographed.
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2.2.3.3.2 Searching of sequence databases
The databases were searched using the specified sequence and GCG Tfasta program 
(Devereux et. al. 1984). The Tfasta method compares the specified amino acid 
sequence with the products of ail six reading frames of the query nucleic acid sequence, 
using the method of Pearson and Lipman (1988).
2.2.4 Techniques used in the manipulation of DNA
2.2.4.1 Restriction digests ofpiasmidDNA
The restriction digest was performed generally in a total volume of not greater than 50pl. 
Plasmid DNA (up to 1pg) in sterile water, 0.1 volumes of the appropriate 10x reaction 
buffer and 1Unit/(pg DNA) of the relevant restriction enzyme were mixed gently and 
incubated under optimal conditions of time and temperature (generally 37°C overnight). 
If necessary, 0.01 volumes of 100x BSA (10mg/ml) were also added to the digest. The 
digest was stopped by the addition of EDTA to 5mM and/or heat inactivation of the 
restriction enzyme (generally 75°C for 20 minutes). When using thermostable enzymes 
an additional QIAquick purification step was used instead.
DNA needing double digestion under incompatible conditions was digested with one 
restriction enzyme, the restriction enzyme inactivated, the DNA ethanol precipitated and 
then re-digested with the second restriction enzyme. In some cases, usually where an 
enzyme was thermostable, a QIAquick purification step was used after the first digest 
and the purified DNA digested with the second restriction enzyme.
2.2.4.2 Ligations
Ligations were performed with varying vectoninsert ratios (generally a 3-fold molar 
excess of vector, a 3-fold molar excess of insert and equal amounts of vector and insert). 
Two vector only controls were included, one without ligase. An optimal amount of vector 
(250ng), the corresponding amount of insert, 0.2 volumes 5x T4 DNA Ligase buffer and 
5Units T4 DNA Ligase were mixed in a minimal volume, generally 20pl.
Blunt end ligations were incubated at room temperature overnight whereas sticky end 
ligations were incubated at 16°C overnight. Ligations were diluted 5-fold in sterile water
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before adding to competent cells.
2.2.4.3 The polymerase chain reaction (PCR)
PCR amplification of DNA fragments was performed using oligonucleotide primers 
designed to specific sequences within the desired regions. Four different PCR methods 
were employed: Promega Taq polymerase, Vent DNA Polymerase and Expand Long 
Template and Expand High Fidelity as detailed below.
PCR was performed in a 100^1 total volume, containing 0.1 volumes 10x Taq DNA 
Polymerase buffer, 1.5-4mM MgCI2, 0.2mM dNTPs, 1pM each primer and approximately 
100ng DNA template. If necessary, magnesium titrations were performed, in which the 
concentration of Mg2+ was varied from 1 to 4mM, in order to achieve the optimal amount 
of specific product. The reaction mix was overlaid with sterile mineral oil in a 0.5ml 
microcentrifuge tube.
Using a PTC-100™ from MJ Research, Inc., the template was fully denatured at 95-96°C 
for 5 minutes (a hotstart reaction). 2.5Units Taq DNA Polymerase (Promega) was added 
and generally 30-40 cycles of denaturation at 95°C for 1 minute, annealing at 37-65°C 
for 1 minute, and extension at 72°C for 1 minute commenced. The cycles were followed 
by a final extension of 72°C for 5 minutes. Exact conditions were dependent on the 
annealing temperature and GC content of the primer pairs (see calculation of annealing 
temperature in Appendix 2, part d) and the length of the template, and are given in figure 
legends.
In some cases, the proof reading enzyme, VentR® DNA Polymerase (New England 
Biolabs) was used. Conditions were similar but used a different 10x reaction buffer. 
Again exact conditions are listed in figure legends.
PCR amplifications using Expand™ Long Template and Expand™ High Fidelity PCR kits 
(Boehringer Mannheim) were also undertaken.
Template DNA (250ng), 0.1 volumes of 10x reaction buffer (0.5M Tris-HCI (pH9.2 @ 
25°C), 0.16M (NH4)2S04, 17.5mM MgCI2), 0.35mM dNTPs, 0.3pM sense primer and 
0.3pM antisense primer and 2.5Units Expand™ Long Template were incubated at 94°C
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for 2 minutes and then subjected to 30 cycles of 94°C for 30 seconds, 50-65°C for 30 
seconds and 68°C for 2 minutes. Any PCR products were subjected to an extension of 
68°C for 5 minutes.
In preliminary experiments with the Expand High Fidelity PCR kit, reactions involved 
mixing 0.1 volumes of 10x buffer (0.5M Tris-HCI (pH9.2 @ 25°C), 0.16M (NH4)2S04, 
15mM MgCI2), 0.2mM dNTPs, 0.3pM sense primer, 0.3pM antisense primer, 2.6Units 
Expand High Fidelity PCR System enzyme mix, and template DNA (100ng) in a thin- 
walled tube and subjecting it to the following cycles: denaturation at 94°C for 2 minutes, 
10 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and 
elongation at 72°C for 2 minutes, followed by 20 cycles of the same conditions but with 
an extra 20 seconds for each elongation step of each cycle. Any PCR products were 
subjected to a final extension of 72°C for 5 minutes. Exact optimal conditions, however, 
for each primer pair are listed in figure legends.
2.2.4.4 Subcloning PCR products
PCR products were analysed on 1-3% agarose gels and bands of the predicted size 
were excised and purified with Sephaglas or GENECLEAN. Primers incorporating 
unique restriction sites resulted in PCR products that were digested with the appropriate 
restriction enzyme, re-purified and ligated into a suitable digested vector, either pMAL- 
c2, pBluescript™ or pMEX8.
PCR primers that did not incorporate restriction sites resulted in PCR products that were 
phosphorylated and ligated into a blunt ended, dephosphorylated vector as products 
generated using Taq DNA polymerase have a 5’ A overhang due to the terminal 
transferase activity of this enzyme. The purified, amplified DNA was simultaneously 
blunt-ended and phosphorylated with the addition of 0.1 volumes of Pharmacia's 10x 
One-Phor-AII buffer PLUS (0.1M Tris-acetate (pH7.5), 0.1M magnesium acetate, 0.5M 
potassium acetate), DNA Polymerase I (5Units), T4 Polynucleotide Kinase (10Units) and 
0.5mM ATP and incubated for 3 minutes at room temperature before 0.2mM dNTPs 
were introduced. The reaction mixture was incubated at 37°C for 30 minutes, after 
which time the reaction was terminated by the addition of EDTA to a final concentration 
of 50mM. The DNA was extracted once with an equal volume of 
pheno!:chloroform:isoamyl alcohol (25:24:1) and once with an equal volume of
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chloroform:isoamyl alcohol (24:1). The DNA was ethanol precipitated and resuspended 
in sterile water.
1-5pg vector (pBluescript) was digested with EcoRV at 37°C for 2 hours. Following heat 
inactivation of the enzyme at 75°C for 20 minutes, the linearised vector was 
dephosphorylated with 6pl CIAP (10Unit/|il) in CIAP buffer with incubation at 37°C for 1 
hour. The enzyme was inactivated with EDTA to 5mM and heat to 75°C for 10 minutes. 
The DNA was extracted once with an equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) and once with an equal volume of chloroform:isoamyl alcohol (24:1), ethanol 
precipitated and resuspended in sterile water.
Both insert and vector were run out on a 1% agarose gel, and the quantity of each 
estimated before ligation. Vector and insert were mixed in varying ratios as described 
under Ligations (2.2.4.2).
2.2.5 Techniques used in protein analysis
2.2.5.1 Estimation of protein concentration
Protein concentration was estimated by the method of Bradford (1976) using a kit from 
Bio-Rad and a standard curve prepared from dilutions of bovine serum albumin.
Alternatively 0.2ml of dye reagent (a solution of 0.06% (w/v) Coomassie Brilliant Blue 
G250 in 0.3M perchloric acid, filtered through Whatman No1) was added to 0.8ml of 
samples containing 1-20pg protein. Samples were left to stand for 5-30 minutes then 
absorbance at 595nm was measured against a blank prepared from 0.8ml of sample 
buffer and 0.2ml dye reagent.
2.2.5.2 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis
2.2.5.2.1 Preparation of samples
Protein samples were mixed with Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) Sample Buffer, boiled for 5 minutes and allowed to cool 
before analysis by SDS-PAGE and Western blotting.
111
Chapter 2
The concentrated GTP-affinity column eluate and crude sample were diluted 1:1 in SDS- 
PAGE Sample Buffer.
2.2.5.2.2 Preparation and running of polyacrylamide gels
This method of analysis was performed initially using the discontinuous buffer system of 
Laemmli (1970):
Samples were electrophoresed through a large polyacrylamide gel consisting of a 12% 
(w/v) resolving gel and a 6% (w/v) stacking gel comprised of the components listed in 
Table 5, using Tank Buffer, at a current of 40-65mA/gel using a Protean II (Bio-Rad) gel- 
rig. In both cases polymerisation was achieved by the use of ammonium persulphate 
(APS) and N,N,N',N-tetramethylethylenediamene (TEMED).
Table 5: Composition of 12% SDS-PAGE gels
RESOLVING GEL (ml) STACKING GEL (ml)
30% (w/v) Acrylamide 20 1.8
Resolving Gel Buffer 12 -
Stacking Gel Buffer - 7.2
ddH20 16 7.2
10% (w/v) APS 0.2 0.1
TEMED 0.05 0.01
(volumes shown are sufficient for one large gel)
Molecular weight markers, sometimes pre-stained (Bio-Rad) were used according to the 
manufacturer’s instructions.
Small 1mm thick 12% SDS-PAGE mini-gels (Gradipore) were used for the non- 
discontinuous, rapid analysis of partially-purified protein eluted from the GTP-agarose 
affinity column. 2 0 jli.I of sample prepared using the method described were loaded onto 
the mini-gel and electrophoresed at 20-40mA for approximately VA hours. The 
production of these gels was later discontinued.
Later SDS-PAGE analysis employed the Atto™ Mini gel system and a series of buffers 
A-D. The gels in this system proved more manageable than the larger gels.
Similarly, resolving gels for this mini system were made by mixing the components listed
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in Table 6 and they were poured into an "Atto™" minigel rig. Gels were overlaid with 
water-saturated butan-1-ol and allowed to set for 20 minutes. The butan-1-ol layer was 
discarded and the comb inserted between the gel plates. 5% stacking gels were made 
by combining the necessary components, again listed in Table 6. This was poured onto 
the resolving gel and allowed to set for a further 40 minutes. 10pl of sample was loaded 
into each well and gels were run in tank buffer at 175V for 90 minutes.
Table 6: Composition of 10% SDS-PAGE gel
RESOLVING GEL (ml) STACKING GEL (ml)
Solution A 6 0.9
Solution B 4.5 -
Solution C - 1.5
Solution D 0.08 0.01
TEMED 0.01 0.01
Water 7.5 3.6
(volumes shown are sufficient for two mini-gels)
2.2.5.3 Coomassie stain of polyacrylamide gels
Following electrophoresis the gel was stained for 1 hour at room temperature in 
Coomassie Blue Stain and then destained in several changes of fix until the background 
colour was removed.
2.2.S.4 Western transfer to nitrocellulose membranes
The method used for Western blotting has been adapted from the method used by 
Towbin etal. (1979). Protein samples were subjected to SDS-PAGE as described, using 
pre-stained molecular weight markers.
The graphite plates of a Pharmacia LKB NovaBlot Multiphor II electroblotter were rinsed 
in water. Six gel-sized pieces of Whatmann 3MM filter paper were soaked in Transfer 
Buffer and individually stacked onto the bottom plate, carefully eliminating any air 
bubbles formed, using a glass rod. Nitrocellulose paper presoaked in transfer buffer was 
placed on top of this and then the SDS gel was added to the stack. The sandwich was 
completed with a further six pieces of pre-soaked filter paper and the electroblotter was 
then run with the cathode at the base at 0.8mA.cm‘1 for 1% hours. Transfer efficiency 
was assessed by staining the gel with Coomassie Blue Stain at room temperature 
overnight followed by 8 hours in destain solution.
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2.2.5.5 Immunodetection of bound HAV proteins
Protein bands on the nitrocellulose were visualised by staining with Ponceau-S, marked 
with pencil or waterproof ink, and destained by washing with distilled water prior to 
probing with antibodies.
Detection was performed using the horseradish peroxidase chemiluminescent detection 
method which exploits indirect immunodetection with a peroxidase conjugated 
secondary serum. Detection relies on the oxidative action of peroxide on luminol, a 
cyclic diacylhydrazide, the activated oxidised form of luminol decays back to its ground 
state with the concomitant emission of light. The ECL kit was used which also contains 
enhancers such as phenols, in the presence of which, both the intensity and duration of 
the chemiluminescent reaction are enhanced.
Western blots were incubated in Blocking Buffer at room temperature on a shaking table 
for 1-2 hours, frequently overnight. The blots were incubated with shaking for 2 hours at 
4°C in primary antiserum diluted 1:1000 in Blocking Buffer. All subsequent steps were 
carried out at room temperature on a shaking table unless stated otherwise. The 
membranes were washed three times in 100ml PBS for 10 minutes each and then 
transferred to a tray containing Washing Buffer and incubated for 10 minutes. The 
membranes were incubated for 1 hour with the enzyme-coupled secondary reagent 
diluted 1:2000 in Phosphate-Free, Azide-Free Blocking Buffer. Unbound secondary 
serum was removed by washing 3 times with 10 minute washes in Washing Buffer as 
before.
3ml of each of the detection reagents were combined and poured onto the drained 
membranes. The luminescence reaction was allowed to proceed for 1 minute, before 
draining off excess solution, wrapping the filter in Saranwrap™ and autoradiography. A 
series of exposures were taken, starting with 1 minute and increasing or decreasing this 
time as required.
2.2.6 Techniques used in protein expression
2.2.6.1 Expression of 3D polypeptide in JRR constructs
10 1^ aliquots of glycerol stock cultures were used to inoculate 10ml LB containing the 
appropriate antibiotics. The overnight cultures were incubated with shaking at 
approximately 32°C. 1ml of overnight culture was used to inoculate 10ml LB-Glucose
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and incubated overnight at 32°C. 1ml of overnight LB-Glucose culture was used to 
inoculate 50ml LB-Glucose and incubation was continued for a further 4 hours. Aliquots 
for analysis were removed at this stage. Cells were pelleted and washed twice with 
50ml of 50mM NaCI solution before being resuspended in LB-Expression. The cultures 
were incubated at 32°C overnight for 15 hours. Aliquots were removed 2 hours after 
induction and after overnight induction for analysis.
2.2.6.2 Intracellular extraction of the 3D polypeptide
1ml aliquots removed from the expression medium were pelleted in a microcentrifuge. 
The supernatant was removed by aspiration and the cells resuspended in IC 
Resuspension Buffer. These samples were lysed by sonication (4x 30 seconds) and 
were observed to clarify. The lysate was spun in a microcentrifuge to sediment insoluble 
material and the supernatants predicted to contain the RNA-dependent RNA polymerase 
were removed for analysis.
2.2.6.3 Periplasmic space extraction of the 3D protein
10ml samples were removed from the overnight cultures and the cells pelleted by 
centrifugation in a Sorvall SS-34 rotor at 2,500g at 4°C for 10 minutes. The pellet was 
resuspended in 2.5ml of PS Resuspension Buffer, allowed to stand at room temperature 
for 10 minutes and re-pelleted. Periplasmic extracts were prepared by osmotic shock in 
2.5ml of ice-cold 0.5mM MgCI2) allowing to stand on ice for a further 10 minutes. Finally 
the extract was centrifuged at 12,000g for 10 minutes and the supernatants removed for 
analysis.
2.2.6.4 Expression of HAVproteins from pMAL 
constructs
Pilot experiments to identify the optimal conditions for expression of each protein were 
undertaken by inoculating 80ml of Rich Broth (containing 100^g/ml ampicillin) with 0.8ml 
of an overnight culture of XL2s transformed with pMAL/3AB, pMAL/3C, pMAL/3CD, 
pMAL/3D or pMAL/P3. The culture was incubated at between 30 and 37°C, depending 
on the construct, with shaking to an A 60o of -0 .5  (approximately 334 hours). 1ml of 
culture was taken and centrifuged at maximum speed in a microcentrifuge tube for 2
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minutes. The supernatant was discarded and the pellet resuspended in 100|il of SDS- 
PAGE sample buffer prior to storage at -20°C.
IPTG was added to the remainder of the culture to a final concentration of 0.3mM and 
the culture incubated for between 2 and 15 hours depending on the individual construct. 
A 0.5ml sample of induced culture was taken at various time points and processed as 
above.
Large-scale expression experiments were set up by inoculating 1L cultures of Rich 
Medium, containing ampicillin at 100jug/ml, with 10ml of overnight culture of the required 
plasmid construct.
2.2.7 Techniques used in protein purification
2.2.7.1 GTP-Agarose affinity chromatography
The following procedure was carried out at 4°C using a method based on that of 
Richards etal. (1992) in the purification of poliovirus RNA polymerase.
A 1ml GTP-agarose column was packed and washed thoroughly in equilibration buffer to 
remove all traces of glycerol. A 10ml sample of periplasmic space extract was dialysed 
overnight against equilibration buffer and filtered prior to loading the column. 5ml of the 
solution was loaded onto the column at a rate of 0.1-0.2ml/min and the column was 
washed with 2ml equilibration buffer. Bound protein was eluted with 2ml elution buffer 
and fractions of 0.5ml were collected. The column was re-equilibrated with 2ml 
equilibration buffer.
The procedure was scaled-up by packing a 5ml GTP-agarose column and purifying the 
protein from approximately 25ml of dialysed, filtered periplasmic space extract.
Protein-containing fractions eluted from the affinity column were concentrated 




2.2.7.2 Amylose affinity chromatography
1L of culture, containing the desired construct, induced for the appropriate time was 
harvested by centrifugation at 4,000g for 20 minutes and the supernatant discarded. 
The pellet of cells was resuspended in 50ml column buffer. This suspension was frozen 
overnight at -20°C and then thawed in cold water. The sample was placed in an ice- 
water bath and sonicated in short pulses of 15 seconds or less. The release of protein 
was monitored using the Bradford assay, by adding 10jul of the sonicate to 1.5ml 
Bradford reagent and mixing. Absorbance at 595nm was measured. Sonication was 
continued until the released protein reached a maximum (usually about 2 minutes 
sonication time). The suspension was then centrifuged at 9,000g for 30 minutes. The 
supernatant (crude extract) was saved and diluted if necessary to 2.5mg/ml with column 
buffer. 15ml of amylose resin (New England Biolabs) was poured in a 2.5x10cm column. 
The column was washed with 8 column volumes of Column Buffer. The diluted crude 
extract was loaded at a flow rate of [10x (diameter of column in cm)2]ml/h. This is about 
1ml/min for a 2.5cm column. The column was washed with 10-12 column volumes of 
Column Buffer. The fusion protein bound to the amylose was eluted with Column Buffer 
+10mM maltose. 10-20 fractions of 0.2 column volumes were collected. The protein- 
containing fractions were identified by Bradford assay and pooled and, if necessary, 
concentrated to about 1 mg/ml in a Centriprep™ concentrator (Amicon).
2.2.7.3 Cleavage of fusion proteins with Factor Xa
Factor Xa cleavage was carried out at a w/w ratio of 1 % the amount of fusion protein 
(e.g., 1mg factor Xa for a reaction containing 100mg fusion protein). A factor Xa 
cleavage pilot experiment was set up by mixing 20pl fusion protein (1 mg/ml) with 0.2|ig 
factor Xa and incubated at room temperature. 5\i\ samples taken at 2, 4, 8, and 24 hour 
intervals were mixed with 5(xl 2x SDS-PAGE sample buffer and stored at 4°C. A mock 
fusion control and an uncut fusion control were included. The samples were boiled for 5 
minutes and run on an SDS-PAGE gel. The pilot experiment was scaled up for the 
portion of fusion protein to be cleaved. Complete cleavage was ascertained by SDS- 
PAGE analysis.
2.2.7.4 Q-sepharose ion-exchange chromatography
Ion exchange chromatography was performed on a fast protein liquid chromatography
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(F.P.L.C.) system (Pharmacia LKB, Sweden).
A 1ml Mono-Q (anionic exchange) column was equilibrated with Column Equilibration 
Buffer and left running until a level baseline was obtained. The fusion protein cleavage 
mixture, dialysed against Buffer A overnight, was loaded onto the equilibrated column at 
a flow rate of 0.5ml/min. After unbound material had washed through the column (4-10 
volumes of Buffer A), bound material was eluted with a linear NaCI gradient, 20mM-0.5M 
(Buffer A-Buffer B) over 40ml, at a flow rate of 0.5ml/min. Fractions of 1ml were 
collected. Any A 28o peaks were concentrated using Centricon concentrators, checked by 
SDS-PAGE analysis, and the desired protein frozen by beading in liquid nitrogen and 
stored subsequently at -70°C.
2.2.8 Assay forpoly(A):poly(U)-dependent poly(U) 
polymerase activity
The assay was carried out essentially as described by Flanegan & Baltimore (1977) 
except for the removal of phosphoeno/pyruvic acid and pyruvate kinase from the reaction 
mixture and replacement of actinomycin D with rifampicin to inhibit E. coli RNA 
polymerase.
50|ul (the amount assayed depended on the concentration of protein in the preparation, 
generally between 5 and 50[xl) of cell lysate supernatant, MBP-fusion protein, fusion 
protein cleavage mixture or purified protein were assayed in a total volume of 125pl 
containing 50mM Hepes buffer (N-2-hydroxyethylpiperazine-N'-ethanesulphonic acid) 
(ph7.4), 8mM Mg(CH3COO)2, 1.7^M [5,6-3H] UTP (10pCi per reaction), 20pg/ml 
poly(A):poly(U) template, 74Units RNA-guard, 4mM DTT, 20pg/ml rifampicin and 
RNAse-free ddH20.
Assays were carried out at 31°C. 20pl aliquots were removed from the reaction mixture 
at various time intervals and precipitated for 10 minutes in 60pl ice-cold 8% (w/v)TCA to 
which had been added 400jig yeast carrier tRNA. The acid-insoluble material was 
collected on GF/C filters (Whatman) by filtration and the radioactivity solubilised in 5ml 




Aliquots were precipitated at 0, 14, 2, 5, 10 and 15 minute intervals and incorporated 
radioactivity assessed as above.
2.2.9 Oligonucleotides
2.2.9.1 In house synthesis and deprotection of 
oligonucleotides
Oligonucleotides were synthesised in house, using the phosphoramidite method, on an 
Applied Biosystems 381A DNA Synthesiser using chemicals supplied by Cruachem, 
Glasgow, UK. Oligonucleotides were deprotected with ammonia solution of Analar 
grade at 55°C for 6 hours. The ammonia was neutralised with glacial acetic acid and the 
oligonucleotide precipitated with absolute ethanol. The precipitated oligonucleotide was 
spun, washed, dried and resuspended in 1ml sterile water. The absorbance at 260nm 
was taken and the oligonucleotide diluted to a working stock solution of 20pM.
Other oligonucleotides, purchased from Perkin-Elmer, were used with the Expand™ kits 
at the required concentration.
2.2.9.2 Radiolabelling of oligonucleotides
Oligonucleotides at 2pM were radiolabelled with 5|xCi [y-32P]ATP (specific activity 
3000Ci/mmol; 10mCi/ml) and 10Units T4 Polynucleotide Kinase in 0.1 volumes of 10x 
buffer at 37°C for 30 minutes. The enzyme was inactivated with EDTA (pH8.0) to 5mM 
and 1 volume of sequencing stop dye (95% (v/v) formamide, 20mM EDTA, 0.05% (w/v) 
xylene cyanol FF) was added. The radiolabelled oligonucleotide was heated at 80°C for 
3 minutes and electrophoresed on a 12% (w/v) acrylamide sequencing gel for 1 hour at 
30mA, 40W. The gel was immediately exposed to Kodak X-Omat LS™ film at room 
temperature for 15-30 minutes.
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3. Detection and 
purification of HAV 3Dp0‘ 






The first report of an HAV specific polymerase activity was by Wolstenholme et al. 
(1993) where the HAV 30^ ' was expressed in an E. coli vector carrying the protein A 
gene fused to most of the P3 region of the genome. The purpose of the Staphylococcal 
protein A was to maintain soluble viral proteins which would be correctly post- 
translationally cleaved and hence, conserve enzyme activity. E. coli transformed with 
this plasmid exhibited poly (U) polymerase activity in the periplasmic space. This was 
found to be similar to that of other picornaviruses in that it was primer-dependent, with a 
requirement for magnesium, inhibition with manganese and an optimum temperature of 
30°C. However, the activity measured was much lower than reported for other 
picomavirus enzymes and attempts by other workers to express this enzyme in bacteria, 
or anywhere else for that matter, have been unsuccessful (Gauss-Muller et al., 1991; Jia 
et al., 1991a; Updike et al., 1991; Harmon et al., 1992; Tesar et al., 1994). Prior 
attempts at expressing this enzyme in the baculovirus expression system in this 
laboratory proved unsuccessful (Nutter, 1992).
With the ultimate aim of this project being the biochemical characterisation of the HAV 
polymerase, a necessary first step was the production of highly purified protein. This 
would also allow the identification of the protein species that is responsible for the 
poly(U) polymerase activity detected previously in the periplasmic space of bacteria 
transformed with pRITPOL and Protein A/HAV P3/pMEX8. A number of strategies have 
been described for the purification of picomaviral polymerases, but the most rapid 
approach is based on affinity chromatography using GTP-agarose, poly(A)-Sepharose or 
a similar matrix. By applying a suitable ammonium sulphate cut to such a matrix and 
eluting with increasing concentrations of ATP the eluted fractions can be monitored for 
poly(U) polymerase activity. Previously, preliminary experiments (Palmer, 1994) 
indicated that HAV-specific polypeptides from the periplasmic space of E. coli 
transformed with pRITPOL or Protein A/HAV P3/pMEX8 will bind to GTP-agarose and 
can be eluted with ATP, but at the commencement of this project it was uncertain 
whether these polypeptides were responsible for the poly(U)-polymerase activity 
detected.
3.1.1 Protein purification
Before embarking on the purification of a protein, however, a few key questions must
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first be addressed. Thus: what is the protein required for? Which would be the most 
suitable source? What is known about the protein? How should the protein be 
assayed? By answering these questions the aims of the purification and criteria for 
success were defined, and the background knowledge required to plan a suitable 
strategy was acquired.
3.1.1.1 What is the protein required for?
The purification of a protein is frequently not the end point itself, but is the means to 
obtain a pure protein for further studies. These studies may be on the activity of the 
protein, on its structure, or on its structure-function relationships. The requirements of 
these studies will define how much of the purified protein is required, whether loss of 
activity can be tolerated, how pure it should be, and the time and cost of purifying it. 
Thus, for studies on enzyme activity relatively small amounts of active protein will be 
required. High purity will probably not be essential provided any interfering activities are 
removed. Cost will probably not be very important, but speed will be important to 
minimize activity losses. In contrast, structural studies require larger amounts of highly 
pure protein. Cost and time will be of secondary importance, except for structure- 
function studies where activity is required and therefore speed will probably be 
important. Here, the protein was required eventually for activity assays and as such only 
small amounts of relatively pure protein were required.
3.1.1.2 What source should be used?
With the advent of gene cloning techniques proteins can now be expressed in high 
amounts in cells which can be grown in culture. In addition to the above-mentioned 
advantages the percentage of the protein of interest is usually higher than in its native 
source, thus making purification easier. The host cell should be chosen with care since 
each has its advantages and disadvantages. E. coli is the most commonly used host 
due to ease of handling, however, proteins are often not secreted, and in addition are 
often produced in an insoluble form (known as inclusion bodies). Secreted proteins are 
usually easier to purify since there are fewer contaminating proteins present. Inclusion 
bodies can be relatively easily purified and consist mainly of expressed protein, however 
the protein must be denatured and refolded to obtain a soluble, active form. With this 
information in mind, the constructs directing expressed proteins to the periplasmic space 




Cloned proteins can also be modified to ease purification. Thus, a basic tail may be 
added to aid purification by ion-exchange chromatography, or part of another protein 
may be added and exploited for affinity purification. After purification, the foreign part of 
the protein is removed by chemical or enzymatic cleavage. The pMAL protein 
purification system, discussed fully in Chapter 4, is an example of this, where fusion 
proteins bound to maltose-binding protein (MBP) are produced.
3.1.1.3 What do we know about the protein?
The RNA polymerase activity encoded by the hepatitis A virus is crucial for replication 
but so far, it has not been identified in vitro for HAV due to the inefficiency of this 
process. Previously the 3D region from several picomaviruses have been expressed in 
E. coli and the RNA-dependent RNA polymerase activity has been shown to be 
contained within the 3D protein sequence (Flanegan & Baltimore, 1977; Lowe & Brown, 
1981; Morrow et al., 1987; Plotch et al., 1989; Sankar & Porter, 1991; Newman et al., 
1994). Of some concern was whether enzyme produced by expression of cDNAs in 
bacterial cells would be structurally and functionally identical to enzyme synthesized in 
the natural mammalian host cell. Neufeld et al. (1991) have shown that PV enzyme 
preparations from bacteria, insect, or mammalian cells are indistinguishable by all 
measured criteria, and this research validates the use of these proteins for additional 
mechanism and structure studies. It was therefore reasonable to assume that the same 
would be true of the HAV enzyme.
3.1.1.4 How can the protein be assayed?
Assays devised for the investigation of polymerase activity in other picomaviruses 
(Flanegan & Baltimore, 1977; Sankar & Porter, 1991) were used as the basis for an 
assay developed by Palmer (1994) which was used in this research and is discussed 




3.2.1 Expression of P3 prote
Proteins expressed by the following constructs were extracted from the cytosol or 
periplasmic space as described in Chapter 2. Presence of protein was assessed using 
method 2.2.5.1 in order to ensure the extraction process was correct and/or complete, 
prior to SDS-PAGE. Controls, JRR-600, pMEX8 and pRIT5 were run at the same time. 
Generally two gels were run simultaneously. One was stained with Coomassie Blue, the 
other Western blotted, probed with an anti-3D peptide antibody and visualised using an 
ECL kit. Once transferred the nitrocellulose was stained with Ponceau-S and the location 
of lanes and any visible bands was marked before destaining and probing with antibody.
Table 7: Expression plasmids
PLASMID CONSTRUCT PROTEINS EXPRESSED WHERE?
Protein A/HAV P3/pMEX8 in JRR-600 Periplasmic expression
HAV P3/pMEX8 in JRR-600 Intracellular expression
PMEX8 in JRR-600 (control) Intracellular expression
pRITPOL in JRR-600 Periplasmic expression
pRIT5 in JRR-600 (control) Periplasmic expression
Induction of E. coli cultures transformed with the recombinant plasmids produced a 
number of novel, HAV-specific proteins which were visualised by Western blotting using 
the polyclonal rabbit a-3D peptide antibody. These proteins had apparent molecular 
weights of 36kDa, 53kDa, 77kDa, and 117kDa. The Western blot is shown in Figure 27, 
however the corresponding Coomassie-stained gel is not shown. Predicted sizes for the 
P3 proteins are 36kDa (Protein A-3A), 2.5kDa (3B), 24kDa (3C) and 53kDa (3D), as 
shown in Table 8, along with simplified tabulated results of initial expression studies.
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A clear band of approximately 117kDa, likely to correspond to Protein A-3ABCD can be 
seen in the lane containing Protein A/HAV P3/pMEX8 induced overnight, as would be 
expected, however, no such band is observed with pRITPOL, lanes 5 and 6, as we 
would expect. Surprisingly lane 2, containing HAV P3/pMEX8, displays a band of 
~117kDa however, with the absence of Protein A sequences in this construct, this band 
cannot correspond to Protein A-3ABCD, in this case anyway.
The next band of interest is ~77kDa, thought to correspond to 3CD, and appears in the 
lanes containing HAV P3/pMEX8 and Protein A/ HAV P3/pMEX8. No distinct band can 
be seen at this molecular weight in the lanes containing pRITPOL but a darker smear 
possibly indicates its presence.
Bands of 53kDa can be observed in lanes containing each of the three constructs with 
Protein A/HAV P3/pMEX8 and HAV P3/pMEX8 appearing as the more successful 
constructs. Lanes containing pRITPOL show the presence of a 53kDa protein but the 
banding is not so well defined. Finally, a 36kDa protein, thought to be Protein A-3A, can 
be seen in lanes 3 and 6, as would be expected of the constructs pRITPOL and Protein 
A/HAV P3/pMEX8 containing protein A sequences. This polypeptide is not observed in 
the lane containing HAV P3/pMEX8 nor in the pMEX8 control lane.
Interestingly, a large amount of protein expresses at about 32kDa in lanes containing 
induced Protein A/HAV P3/pMEX8 and pRITPOL and could correspond to protein ABC, 
a remarkably stable processing intermediate whose specific role is unknown (SchultheilJ 
etal., 1994), however such a cleavage, between Protein A sequences and 3A is unlikely 
in these constructs nor is it likely that an antibody raised against the C-terminus of 3D 
would react with this polypeptide. It is possible that the protein A sequences or some
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part thereof, in these constructs, could be responsible for this observation.
As well as the proteins of interest a great number of other bands can be seen in Figure 
27, demonstrating the need for further purification.






Figure 27: Initial expression studies of P3 proteins in E. coli
This figure shows a Western blot of a 12% SDS-PAGE gel (Coomassie-stained - not
shown) probed with polyclonal rabbit peptide anti-HAV 3Dpo1 antibody and visualised
using a light reaction - exposed for 15 seconds.
Lane 1: pMEX8 induced for 2h (control)
Lane 2: HAV P3/pMEX8 incduced overnight
Lane 3: Protein A/HAV P3/pMEX8 induced 2h
Lane 4: Protein A/HAV P3/pMEX8 induced overnight
Lane 5: pRITPOL expressed 2h
Lane 6: pRITPOL expressed overnight
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3.2.2 Initial GTP-agarose a
Attempts were subsequently made to purify 3D RNA polymerase from E. coli 
transformed with the plasmid constructs detailed in Table 7, using its nucleotide binding 
properties with the help of GTP-agarose. Pilot experiments were first carried out, which 
coincidentally allowed better visualisation of the proteins present in whole cell extracts 
and allowed further investigation into the suitability of GTP-agarose affinity 
chromatography as a method for purification of the 3Dpo1 (Palmer, 1994). Initial gels of 
whole-cell lysate samples appeared smeared and, hence, a series of gels were 
subsequently run with whole cell, crude extract, and insoluble extract samples, as well 
as crude extract and insoluble extract bound batch-wise to GTP-agarose samples, in an 
attempt to clarify the protein bands present from induction of the available constructs, 
prior to GTP-agarose affinity column chromatography. Western blots probed with anti 
3D-peptide antibody, yielded clearer results than their corresponding Coomassie-stained 
gels and hence more attention is paid to these results.
Table 9: Summary of proteins induced by pMEX8 constructs
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3 A BCD
117 X ? X ? ? X X X X
3CD 77 > / s ? X X
3D 53 S I X
Protein A- 
3A
36 X ? s ? X X
With Protein A/HAV P3/pMEX8, a number of novel bands were observed by Coomassie- 
staining of the SDS-PAGE gel (Figure 30), including bands of 53kDa and 77kDa, and 
possibly one of 36kDa and one of 117kDa. Furthermore, clear immunoreactive bands 
were observed at 36kDa, 45kDa, 53kDa, 77kDa and 117kDa (Figure 31), as well as 
numerous bands between 28kDa and 62kDa. The major band of approximately 32kDa
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could correspond to 3ABC, a stable intermediate whose specific role is unknown 
(Schultheifc et al., 1994), although, again one would not expect cleavage between 
Protein A and the truncated 3A to occur nor would one expect binding to the anti-3D 
antibody. As before, the 36kDa protein could be Protein A-3A, that of 53kDa could be 
3D, the 77kDa protein could represent the 3CD protein, and the 117kDA protein could be 
Protein A-3ABCD.
Soluble proteins binding to the GTP-agarose have molecular weights of, 32kDa 
(3ABC?), 77kDa (3CD?) and 53kDa (3D?). Proteins of between 32 and 36kDa are also 
observed to bind to GTP-agarose possibly representing Protein A-3A or parts thereof. 
Furthermore, faint bands of between 42 and 48kDa are observed which could represent 
bacterial proteins. No protein of 24kDa, corresponding to 3C, was observed which is as 
expected as anti-3D would not react with this protein.
The lane showing insoluble extract was essentially disregarded as the process of 
spinning the insoluble matter down with GTP-agarose, served only to concentrate it and 
not to 'select' those proteins specifically binding to the GTP.
Expression of the P3 proteins in HAV P3/pMEX8 and analysis by SDS-PAGE (Figure 28) 
revealed numerous novel proteins - 36kDa, 53kDa, 77kDa and again possibly 117kDa. 
As previously mentioned the latter band cannot represent Protein A-3ABCD as this 
construct is deficient in Protein A sequences.
Bands of ~28kDa, ~32kDa, 47kDa, ~53kDa, and 77kDa appear on the Western blot 
(Figure 29) and of these it appears that three are soluble and bind to GTP-agarose 
which are the 53kDa, 77kDa and 32kDa proteins. It is not known what the proteins of 
~28, ~32 and 47kDa correspond to and perhaps are evidence of bacterial contamination.
Little can be deduced from the control gel (Figure 32) showing proteins expressed upon 
induction of the pMEX8 vector alone, however immunoreactive proteins of ~79kDa and a 
faint band of ~53kDa can be seen on the Western blot (Figure 33), the latter of which 
interestingly does not bind to GTP-agarose. In addition to these, numerous bands of 




Samples of pRIT5 and pRITPOL used in pilot experiments were grown in LB-glucose 
throughout induction as pRIT5 is constitutive. In initial assessment of these constructs 
however, IPTG was added to all cultures as it may cause changes in bacterial protein 
expression even if it is not inducing gene expression from a plasmid.
Three dominant bands with an apparent molecular weight of, 53kDa, 77kDa, and 
117kDa, are visible on the Coomassie-stained gel (Figure 34) of pRITPOL. More can be 
gleaned from the Western blot (Figure 35) which shows that proteins of between -26 
and 31kDa, ~32kDa (3ABC7), 36kDa (Protein A-3A?), 45kDa, 50kDa, 53kDa (3D?) and 
77kDa (3CD?) are present and react with the anti-3D antibody. Of these proteins, it 
appears that a protein of ~31kDa, as well as those of ~32kDa, 36kDa, 53kDa, and 
77kDa are soluble and bind to the GTP-agarose.
In the pRIT5 control experiment various bands were observed (Figure 36 and Figure 37), 
although bands of the sizes predicted to correspond to FIAV P3 proteins were not 
apparent. As well as bands of ~85kDa, 65kDa, and ~33kDa, faint immunoreactive 
bands of between 32 and 65kDa were also observed in whole cell lysate samples. The 
proteins present which bound GTP-agarose included the 33kDa protein, possibly 
corresponding to a Protein A polypeptide, and two others of approximately 65 and 85kDa 
in weight of unknown identity.
A summary of these results can be found in Table 10.
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Figure 28: Expression of P3 proteins in E. coli transformed with HAV P3/pMEX8 
(Coomassie-stained 10% SDS-PAGE gel)
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Figure 29: Expression of P3 proteins in E. coli transformed with HAV P3/pMEX8 
(Western blot of SDS-PAGE gel shown above)
This figure shows a Western blot probed with polyclonal rabbit peptide anti-HAV 3Dpd 
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Figure 30: Expression of P3 proteins in E. coli transformed with Protein A/HAV 
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Figure 31: Expression of P3 proteins in E. coli transformed with Protein A/HAV 
P3/pMEX8 (Western blot of SDS-PAGE gel shown above)
This figure shows a Western blot probed with polyclonal rabbit peptide anti-HAV 3Dp0‘ 



















Figure 32: Expression of proteins in E. coli transformed with pMEX8 - control 
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Figure 33: Expression of proteins in E. coli transformed with pMEX8 - control 
(Western blot of SDS-PAGE gel above)
This figure shows a Western blot probed with polyclonal rabbit peptide anti-HAV 3Dp0‘ 
antibody and visualised using a light reaction - exposed 15s. Lane order as above.
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Figure 34: Expression of P3 proteins in E. coli transformed with pRITPOL 
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Figure 35: Expression of P3 proteins in E. coli transformed with pRITPOL (Western 
blot of SDS-PAGE gel above)
This figure shows a Western blot probed with polyclonal rabbit peptide anti-HAV 3Dp0‘ 














Figure 36: Expression of proteins in E. coli transformed with pRIT5 - control 
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Figure 37: Expression of proteins in E. coli transformed with pRIT5 - control 
(Western blot of SDS-PAGE gel above)
This figure shows a Western blot probed with polyclonal rabbit peptide anti-HAV 3Dp0‘ 




Batch-wise GTP-agarose affinity appeared successful at purifying the cell lysates to a 
certain degree, however it was assumed proper column chromatography was required 
for improved purification as no 'elution' step was employed during this assessment.
3.2.3 GTP-agarose affinity chromatography
On the basis of both previous studies in this laboratory and the pilot results, an attempt 
was made to purify 3D RNA polymerase from the periplasmic space of E. coli in order to 
obtain a pure sample of enzyme, free from contamination with bacterial proteins, for use 
in assay and possibly sequencing procedures.
Promising initial results were obtained from a 1ml affinity column (results not shown) but 
an increase in the amount of eluted protein was required to improve visibility of protein 
bands on SDS-PAGE gels and Western blots. The purification process was scaled up to 
a 5ml column, allowing a reduction in pressure in the column and an increase in flow 
rate. A number of bands were seen on the gel stained with Coomassie Blue, 
demonstrating that many different proteins in the periplasmic space have an affinity for 
GTP (not shown).
Results of Western blotting using the polyclonal rabbit peptide antibody showed a couple 
of HAV-specific bands which had been purified from the periplasmic space. These 
bands had apparent molecular weights of 36kDa and 53kDa; the protein of 36 kDa 
probably corresponds to Protein A-3A and the other is thought to be the 3Dpo1 enzyme 
(Figure 38). Other proteins visualised in pilot gels and by Western blotting which did not 
bind to the GTP-agarose affinity column had molecular weights of 32kDa (3ABC?), 
77kDa (3CD) and 117kDa (Protein A-3ABCD). Western blots probed with human 
convalescent serum (Public Health Laboratories Service Laboratories, Royal United 
Hospital, Bath, U.K.) were unsuccessful in visualising these proteins, probably due to the 
inability of the antibodies to bind to denatured proteins. In addition, it is uncertain 
whether the convalescent serum contains antibodies raised against non-structural HAV 
proteins, although anti-3D reactivity in sera from acute and convalescent HAV patients 
has previously been demonstrated by Jia et al. (1992), however, reactivity was 
demonstrable only with antigen that had not been denatured with SDS, suggesting that 
the antibodies were primarily directed against conformation-specific epitopes. In some 
cases a gel of JRR-600 extract was run and blotted. This blot was exposed to the 
antibody in the hope that the non-specific binding observed previously would be
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minimised. The pre-adsorbed diluted antibody was then added directly to blots where a 
degree of improvement in clarity of results was observed but did not warrant the extra 
labour involved.
It should be noted that the eluted fractions were concentrated approximately 20-fold 
before analysis by SDS-PAGE. A gel with E. coli transformed with the plasmid controls, 
pRIT5 and pMEX8, was run and yielded a blot (Figure 39) with no obvious 
immunoreactive bands when probed with antibody and subjected to ECL analysis.
Shortly thereafter, however, this result was not reproducible and other methods were 
investigated as described in 3.3.
To summarise, however, this result indicates that it is possible to isolate an HAV-specific 
53kDa protein from the periplasmic space of E. coli transformed with Protein A/HAV 
P3/pMEX8 and to a lesser extent pRITPOL, supporting the decision made to persevere 
with bacterial expression systems. Unfortunately, the samples used here were 
concentrated to minute amounts for SDS-PAGE analysis and as difficulties were 
encountered in reproducing this result, samples were not available for activity assay 
analysis nor protein sequencing.
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Figure 38: Proteins eluted from the GTP-agarose affinity column
This figure shows a Western blot probed with polyclonal anti-HAV 3Dp0‘ antibody and 
visualised using a light reaction - exposed 15 seconds.
pRITPOL eluted from column
Lane 1: crude sample of pRITPOL
Lane 2: fraction 1
Lane 3: fraction 2
Lane 4: fraction 3
Lane 5: fraction 4
Lane 6: fraction 5 „
Lane 7: crude sample of Protein A/HAV P3/pMEX8
Lane 8: fraction 1
Lane 9: fraction 2
Lane 10: fraction 3
Lane 11: fraction 4
Lane 12: fraction 5
Protein A/HAV P3/pMEX8 eluted from column
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Figure 39: Proteins eluted from the GTP-agarose affinity column (control)
This figure shows a Western blot probed with polyclonal anti-HAV 3Dp0‘ antibody and 
visualised using a light reaction. Exposed 15 seconds.
Lane 1: crude sample of pRIT5
Lane 2: fraction 1 '
Lane 3: fraction 2
Lane 4: fraction 3 ► pRIT5 eluted from column
Lane 5: fraction 4
Lane 6: fraction 5 >
Lane 7: crude sample of pMEX8
Lane 8: fraction 1 "
Lane 9: fraction 2
Lane 10: fraction 3 ► pMEX8 eluted from column
Lane 11: fraction 4




As a first step in the characterisation of the polymerase enzyme, I required a purified 
preparation of HAV 3Dpo1. Initially, expression was achieved by using the available 
plasmid constructs, pRITPOL, Protein A/HAVP3/pMEX 8 and HAVP3/pMEX8 which 
contained the P3 region from a truncated 3A to 3D. This allowed expression of all of the 
P3 products and therefore allowed normal post-translational processing of the 
polyprotein to yield mature 3Dpo1. This was initially important since no information on the 
actual site of cleavage in this region was available at that time, and the exact N-terminus 
of the 3D protein could not be definitely ascertained.
Proper post-translational processing appears to have been both possible and present 
with bands corresponding to both processing intermediates and mature products being 
observed - the 33kDa protein, possibly of 3ABC (more likely to be Protein A), the 53kDa 
protein of 3D, and the 77kDa protein of 3CD, as well as a band of 117kDa proposed to 
correspond to protein A-3ABCD - in various permutations in E. coli carrying the different 
constructs.
The pilot experiment gels gave a clearer indication of the immunoreactive species 
present upon induction of the constructs and revealed some interesting results with 
regard to GTP-agarose-binding of some of these species. The 53kDa protein was 
observed to bind consistently to the GTP-agarose, as was the 36kDa protein proposed 
to be Protein A-3A which is as expected. The 77kDa protein, although observed to bind 
to GTP-agarose in pilot experiments, was later absent from GTP-agarose column 
fractions eluted, which is probably due to the batch-wise pilot method being unsuitable 
for this purification purpose with the column chromatography method yielding much 
clearer results as discussed below. So, all in all, the 3CD is either more sporadic in its 
binding to GTP-agarose or else the pilot binding is an artefact. Evidence supports the 
latter hypothesis, that 3CD fails to bind to GTP, confirming the observation that the 
precursor of 3Dpo1, 3CDpro, displays no RNA polymerase activity (Harris etal., 1992).
A 33kDa protein, the size predicted for 3ABC, was observed to bind GTP in pRITPOL 
and Protein A/HAV P3/pMEX8. Previously during this study this band was assumed to 
have something to do with the 36kDa protein corresponding to Protein A-3A or perhaps 
could be Protein A alone although cleavage between Protien A and 3A was deemed 
unlikely. Interestingly though, RNA binding of the stable precursor polypeptide 3ABC has 
recently been shown to be 50 times stronger than that of 3AB and 3C, implicating a
139
Chapter 3
specific role of this stable processing intermediate in viral genome replication which 
would possibly account for its presence here (Kusov et al., 1997). As we would neither 
expect this protein to cleave itself from Protein A nor expect it to react with the anti-3D 
antibody however, a Protein A component, probably the IgG domain accounts for the 
presence of the large immunoreactive band observed at ~33kDa present in recombinant 
samples, the soluble protein of which binds GTP in Protein A/HAV P3/pMEX8 and 
pRITPOL, but, as expected, not in HAV P3/pMEX8 which lacks the Protein A sequences.
The presence of a major immunoreactive species of ~53kDa in samples eluted from a 
GTP-agarose affinity column was a real boost, however all of the concentrated fraction 
was loaded for analysis and as such, activity assays could not be undertaken. After 
these initially encouraging results, however, the reproducibility of the detection of the 
polymerase remained disappointingly uncertain and yields were frequently low, with 
fractions from the GTP-agarose affinity column often containing more than one protein. 
Here, inconsistent results for expression of 3D from both periplasmic and cytosolic 
preparations prompted the use of a different approach as these problems were expected 
to cause problems in further purification steps and it was anticipated that by making a 
fusion plasmid using pMAL™-c2, one could, with the resulting MBP-fusion protein, 
achieve better yields and purification. The cloning of genes into this plasmid, initial 
expression assessment of the fusion plasmids, large-scale expression and attempts at 
purification of the 3Dpo1 and other P3 nonstructural proteins will be covered in Chapter 4. 
Chapter 5 is devoted to 3Dpo1 enzyme activity and the effects, on this activity, of addition 
of the P3 nonstructural proteins I was able to 'purify'.
In conclusion though, this affinity chromatography protocol has been successful in 
initiating the purification of a protein from the periplasmic space of E. coli transformed 
with either Protein A/HAV P3/pMEX8 and pRITPOL, moreover the immunoreactive and 
GTP-binding 53kDa protein observed is the predicted size of the polymerase 3Dpo1; 
however its activity as a polymerase enzyme was not confirmed by enzyme assays. The 
aim of obtaining a sample of enzyme free from contamination with bacterial proteins was 
not realised, even though the Western blots appeared very encouraging. It is likely that 
a number of the proteins observed on Coomassie-stained gels would not react with the 
HAV-specific antibody, yet would bind and elute with the desired protein, therefore this 
affinity chromatography method can really only be regarded as a semi-purification step 
and further purification steps would be required. The results herein also indicate that 
Protein A is perhaps not the fusion partner of choice for subsequent attempts.
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4. Amplification of P3, 3AB, 
3C, 3CD and 3D from HAV 
P3/pMEX8 and their 
expression and purification 




Although the 3Dpo1 has been successfully expressed in the periplasmic space of E. coli using 
the available constructs, the amount of protein produced is low, making some of the 
experiments described above difficult and time-consuming. Tesar et al. (1994), who enjoyed 
good expression levels in a bacterial system and were surprised by the lack of measurable 
RNA polymerase activity, later observed that the HAV 3D proteins sedimented after low- 
speed centrifugation, suggesting that the protein was insoluble or somehow associated with 
large subcellular components, this is in contrast with observations made for PV.
A number of proteins have been expressed in E. coli in the Department of Biochemistry at 
Bath University using vectors based on the strong, inducible tac promoter, and gene fusions. 
Although not essential for the assay experiments described, high-level expression of the 3Dp0‘ 
would make it easier to detect low-activity enzyme, and may permit the purification of 
sufficient protein to allow biophysical characterisation. In this case it was decided to, as well 
as continuing attempts with the available constructs, create a fusion protein which, once 
purified, is separated into fusion partner and target protein, by chemical or enzymatic 
cleavage. By cloning the gene of interest into the pMAL vector, a gene fusion was created 
with the MBP-encoding malE gene, which, it was hoped, would ease purification of the 
desired protein and that the MBP-fusion partner would help keep the protein soluble. 
Transformed E. coli are grown and the culture induced to produce MBP-fusion protein 
constituting up to 30% of the cellular protein. Fusion protein expressed form pMAL™-c2 
constitutes 20-40% of the total cellular protein, while fusion protein expressed from pMAL™- 
p2, directing fusion protein to the periplasmic space constitutes 5-10% of the total cellular 
protein. So, whilst enjoying limited success with periplasmically expressed protein, the 
greater yields of fusion protein likely with pMAL™-c2 swung the balance in its favour.
4.1.1 The pMAL ™-c2 expression system
The E. coli plasmid expression vector pMAL-c2 is a fusion protein vector (Figure 40); the 
peptide encoded by the cloned sequence is expressed as a fusion protein linked by its N- 
terminus to a 40.6kDa MBP. Expression of the fusion protein is under the control of the high 
activity inducible Ptac promoter. Under normal growth conditions the promoter is silent due to 
binding of the Ptac inhibitor, encoded by the Laclq gene. Addition of IPTG disrupts this 
interaction resulting in high-level transcription of the Ptac gene product. The malE gene 
encoding the MBP (Duplay et al., 1984) lies downstream of this promoter, followed by a
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sequence which codes for a factor Xa cleavage site. The multiple cloning site is located 
immediately 3' to this recognition sequence permitting the insertion of a chosen coding 
sequence in the correct reading frame and subsequent recovery of the protein of study by 
factor Xa cleavage. Growth of transformed cells in the presence of IPTG induces high-level 
expression of the MBP fusion product. pMAL-c2 also includes the LacZ gene to allow 
blue/white selection of plasmids containing inserts, and the p-lactamase gene (Ap) which 















Figure 40: Map of the prokaryotic expression vector pMAL™-c2
Although it was possible that the lack of detectable HAV RNA polymerase activity, 
encountered by Tesar and colleagues (1994), was due to the absence of soluble protein in 
their preparations, an alternative explanation is that the poly(U) polymerase assay or the 
assay conditions are inappropriate for the HAV enzyme. The assay was optimised for the 
poliovirus 3D protein (Flanegan & Baltimore, 1977) and works well for the EMCV enzyme as 
well (Sankar & Porter, 1991). With HAV, only very low levels of activity have been unreliably 
detected which could imply that the RNA polymerase may require certain factors for activity 
not present in the reaction mixture used previously (Palmer, 1994).
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Knowledge of the amino-acid sequence of the N-terminus of the 3D protein allowed attempts 
to express this molecule in bacterial cells, without the rest of the P3 region of the HAV 
genome. Furthermore, it has been established that levels of polymerase activity observed for 
PV are greatly enhanced by addition of purified 3AB which may be a co-factor for 3Dpt)l in viral 
transcription (Lama et al., 1994). This led us to surmise that pertiaps the same could be true 
of HAV and addition of purified 3AB to the reaction mixture could be the missing piece to the 
puzzle.
Undoubtedly 3CD plays an important role and, with its interaction With both 3AB and the 5'- 
terminal cloverleaf, is essential for RNA replication (Xiang et al., 1995b). Harris et al. (1992) 
have suggested that PV 3CDpro has no polymerase activity. The same could be true of HAV, 
however one cannot eliminate the possibility that the HAV 3CD may be a component of the 
RNA polymerase. It was therefore decided to clone certain individual genes into the pMAL™- 
c2 expression vector and the polyproteins expressed would be used in assays for polymerase 
activity as well as providing information on the effect, on this activity, of the individual 
polyproteins. Interestingly, expression of protein 3A in E. coli with an N-terminal deletion 
rendered this protein toxic to bacteria (Beneduce et al., 1995). Moreover, the toxic potential 
to bacteria of protein 3AB of a cytopathic strain of HAV has been demonstrated, and found to 
be similar to that observed in PV (Pisani et al., 1995; Beneduce et al., 1997). The P3 region 
amplified here, and the constituent 3AB, were lacking the first 14 amino acids, and 
expression of the truncated 3AB region in this system could result in bacterial cell lysis if 
recombinant 3AB is active, thereby performing as a 'positive control'. With HAV 3C known to 
be expressable as a soluble and active enzyme in bacterial expression systems (Gauss- 
Muller et al., 1991; Malcolm et al., 1992), it became feasible to use this protein as a 'positive 
control' for the expression system used here as well.
Amplification of the required regions, however, was first of all necessary. As detailed in 
Chapter 1, the HAV P3/pMEX8 construct contains the HAV gene sequence stretching from a 
truncated 3A to 3D. In utilising this HAV sequence in HAV P3/pMEX8, endeavors to amplify 



































































Figure 41: Diagram of the desired amplification products
The five regions pictured above were successfully amplified and cloned into pMAL-c2™, and 
have undergone sequence analysis. Preliminary expression studies using these constructs, 
proved successful for some of the aforementioned regions, and the purified polyproteins 
produced from overexpression of some of these fusion proteins have been used in enzyme 
assays in an attempt to determine the activity, and requirements for such activity, of the HAV 
RNA polymerase. This approach to amplification and cloning of the desired genes/regions 
and the subsequent expression and purification of the related gene products and their results 
are discussed below, with the enzyme activity information covered in Chapter 6.
The objective of the work included in this chapter, therefore, was three-fold:
1. Development of a more efficient expression system
2. Purification of the polymerase enzyme






DNA extracted, using a standard mini-prep (2.2.1), from harvested cultures grown from 
glycerol stocks (courtesy of Dr. J. Rider) was checked for the presence of the HAV P3 insert 
by digesting a small volume with suitable restriction enzymes and analysing the results on a 
1% (w/v) agarose gel.
The sizes of the bands appearing on the gel corresponded with the expected fragment sizes 
as detailed below:
Table 11: Restriction products of HAV P3/pMEX8








4.2.2 Amplification by the P
Following the protocol outlined in 2.2.4.3, a number of PCRs, using primers HAV4 and HAV7- 
9 (Appendix 1), were carried out. Samples were then analysed on 1% (w/v) agarose gels as 
in 2.2.3.2, visualised under UV light and on completion of a successful PCR, purification of 
the amplified DNA was achieved using the Sephaglas BandPrep Kit from Pharmacia, as 
detailed in 2.2.5.
Attempts at amplifying the 3AB, 3C, 3CD, 3D and P3 regions from HAV P3/pMEX8 proved 
difficult. The PCR products were run on a 1% (w/v) agarose gel, but no bands corresponding 
to the 3AB at 0.24kb, 3C at 0.6kb, 3CD at 2.1 kb, 3D at 1.4kb or P3 at 2.4Kb were seen. 
Whenever PCR products were viewed in an agarose gel under UV light, there were always 
products of a very low molecular weight, which, it was concluded, were possibly the primers 
annealing together to form ‘primer-dimers’.
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4.2.2.1 Radiolabelling of HAV primers
End-labelling of the HAV primers and running with a primer of known size on a 
polyacrylamide gel (result not shown) revealed that they were all of approximately the correct 
size and no real degradation was seen. Continued attempts at amplification of these 
products, however, remained unsuccessful.
4.2.2.2 Sequencing of HAV P3/pMEX8
The plasmid construct HAV P3/pMEX8 was subsequently manually sequenced in order to 
identify the reason behind this continuing problem with amplifcation. Sequencing of the 
construct HAV P3/pMEX8 showed that the 5'-terminal nucleotides of the 3A region were 
missing thought to have been 'nibbled away', revealing that the primers constructed for 
amplification of 3AB and P3 had nothing to bind to apart from each other (Figure 42) and that 
the problem lay with the template and not the primers.
The sequence of HAV P3/pMEX8 should read:
pMEX8 HAV P3
& c a t g g g t a c X g t c t t t t c c a t c t g g t g a a c c a t c g a a t t c c a a a t t a t c t g g c t t t t t c c a a t c t  .T T
Manual sequencing however yielded the following results and from the bottom of the gel the 
sequence actually read:
pMEX8 HAV P3
C C A T G G G T A C T T T T T C C A A T C T . . .
This revealed that much of the 3A region was missing and new primers were required which 
encompassed this missing region, or at least the most part of it.
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pBluescript SK pMEX8 3' pMEX8 5' HAV P3/pMEX8 3' HAV P3/pMEX8 5'
T G C A  T G C A  T G C A  T G C A  T G C A




A new oligonucleotide primer synthesised (HAV9) encompassed the missing region and 
further attempts at amplifying these regions yielded bands at 0.24kb and 2.4kb using forward 
primer HAV9 and reverse primers HAV8 and HAV4 respectively (Appendix). These bands 
correspond to the 3AB region and P3 region of HAV (Figure 43). Bands were excised from 




Figure 43: PCR amplification of 3AB and P3
Using Promega Taq polymerase and HAV primers. Conditions as described in Chapter 2.
4.2.2.3 Successful amplification
With lack of progress in amplifying the remaining regions, reactions employing the Expand 
PCR kits were undertaken, as per the manufacturer’s instructions, using the HAV family of 
primers (HAV4 and HAV8-12) and products obtained were treated as detailed above.
Immediate improvements were observed when the Expand kits were used, as indicated by 
the amplification again of P3 and 3AB with bands of 2.4kb and 0.24kb respectively, as well as 





Figure 44: Amplification of 3AB and P3
Using Expand High Fidelity PCR Kit and HAV primers.
1 x 94°C for 2 minutes 
f  94°C for 30 seconds 
30 x^ 65°C for 30 seconds 
I  72°C for 2 minutes 
1 x 72°C for 5 minutes
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Figure 45: Amplification of 3C, 3CD and 3D
Using Expand High Fidelity PCR Kit and HAV primers.
1 x 94°C for 2 minutes
f  94°C for 30 seconds
30 x i  50°C for 30 seconds
I  72°C for 2 minutes
1 x 72°C for 5 minutes
Unfortunately, shortly after this, PCR reactions became non-reproducible using the cycles 
and solutions previously successful and, after making checks, it appeared that the HAV 
primers used had degraded. New ready-pure primers, the LJ family (Figure 46 and 
Appendix), purchased from Perkin Elmer were used for all subsequent PCR reactions. 
These reactions also employed the Expand kits already mentioned.
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4.2.3 Amplification by the P
The LJ family of primers were used in all subsequent amplification reactions (Figure 46) and 
their sequences can be found in the Appendix. The position on the genome of the HAV 
primers used prior to this, and their sequences can also be found in Appendices 1 and 2.
pMEX8MEX8 3A 3B
Figure 46: Position on genome of LJ primers
See Appendix 2 for sequences
4.2.3. 1 Successful amplification
P3
Successful amplification of all the desired products: 3AB signified by a band at 0.24kb, 3C by 
a band at 0.66kb, 3CD by a band at 2.1 kb, 3D by a band at 1.5kb and P3 by a band at 2.4kb 
ensued (Figure 47) and these products were gel purified and attempts at cloning these 
products into the vector pMAL-c2™ were made.
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Figure 47: Amplification of 3AB, 3C, 3CD, 3D and P3
Using Expand High Fidelity PCR Kit and LJ primers. Cycles and temperatures as described 
in Chapter 2.
4.2.4 Cloning of HAV regions
3D into pMAL ™-c2
Subsequent DNA inserts, amplified using Expand PCR kits, were successfully purified 
straight from the reaction mixtures using the QIAgen PCR purification kit and ligated into 
pMAL™-c2, cut with Xmn\ and BamHI, and verification of the existence of these new 
constructs has been confirmed by restriction digest (Figure 48 to Figure 50), protein 
expression (Figure 51 to Figure 54) and sequence analysis (Figure 55 and Figure 56).
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4.2.5 Confirmation of successful
Screening for the presence of inserts was undertaken in the following ways:
4.2.5.1 Restriction digestion of p
Minipreps of the putative constructs 3AB/pMAL, 3C/pMAL, 3D/pMAL, 3CD/pMAL and 
P3/pMAL were produced and double-digested using the restriction enzymes Sacl, found just 
upstream from the Xmn\ site used for cloning and BamH\, one of the sites used for cloning, 
resulting in the removal of the insert from the vector, in positive clones, thus yielding two 
bands: one the size of the vector alone, approximately 6.6kb and one the size of the 
respective insert.
In the case of Figure 48 we can see the desired bands of both 2.1 kb (3CD) and 1.5kb (3D), 
visualised by UV light on the agarose gel. Similarly, in Figure 49, where one can clearly see 
the desired band of 0.66kb representing 3C and in Figure 50, we can see that clones AB2 
and AB4 are cloned successfully, as are P3-5 and P3-8 to the right of this figure.




Figure 49: Clone confirmation of 3C/pMAL by restriction digest





Figure 50: Clone confirmation of 3AB/pMAL and P3/pMAL by restriction digest
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4.2.5.2 Protein expression in pu
A culture of each of the new constructs, 3AB/pMAL, 3C/pMAL, 3CD/pMAL, 3D/pMAL and 
P3/pMAL was grown in LB, containing the appropriate antibiotics until an OD6oo of 0.5 was 
reached. A 1ml aliquot was removed and IPTG was added to the remainder of the culture to 
a concentration of 0.3mM. This was incubated at 37°C for 2 hours and then the uninduced 
and induced cultures were centrifuged at 15,000g, the pellets resuspended in reducing 
sample-buffer, boiled for 5 minutes and then subjected to SDS-PAGE on a 10% gel which 
was subsequently blotted to nitrocellulose. Blots probed with the available anti-3D peptide 
antibody yielded little in the way of conclusive evidence and hence are not shown.
With the exception of 3AB/pMAL, bands of the size estimated for the respective fusion 
proteins were observed (Figure 51 to Figure 54). These proteins were expected to have the 
molecular masses shown in Table 12.
Table 12: Predicted molecular weights of fusion proteins produced
HAV PROTEIN HAV PROTEIN (kDa) FUSION PROTEIN FUSION PROTEIN (kDa)
P3 89 MBP-P3 139.8
3CD 77 MBP-3CD 127.8
3D 53 MBP-3D 103.8
3C 24 MBP-3C 74.8
3AB -12 (truncated) MBP-3AB 62.8
4.2.5.2.1 Expression of 3D/pMALand 3CD/pMA L
As can be clearly seen dramatic differences can be seen in all four possible clones of 
3D/pMAL and 3CD/pMAL as compared with the control which shows a band of ~50kDa 
probably corresponding to the MBP-p-gal-a fusion which has a molecular weight of 50.8kDa 
(Figure 51 and Figure 52). Bands of ~125kDa and ~100kDa, thought to correspond to MBP- 
3CD and MBP-3D can be seen. Interestingly, a faint band at about 75kDa can also be seen 
and is thought represents MBP-3C, which could imply that the protease activity of 3CD is 




Attempts at expressing the MBP-3AB protein resulted in either clearing of the culture or 
production of what appeared to be MBP alone. Sequencing of clone 4 of 3AB/pMAL revealed 
93.8% identity with the complete RNA genome of HAV in a 243bp overlap (Figure 56), 
however attempts at culturing bacteria containing this construct proved difficult, with clearing 
of the cultures being observed shortly after induction. Further DNA analysis on this construct 
revealed that the insert had been expelled from the plasmid. Further attempts at subcloning 
proved unsuccessful. With hindsight this result should have been expected due to the toxicity 
to bacteria of expressed 3AB (Beneduce etal., 1995; Pisani etal., 1995).
4.2.5.2.3 Expression of P3/pMAL
A similar effect is seen in Figure 53 and Figure 54 where in clone 8 of MBP-P3, at ~139kDa, 
MBP-P3 can be seen to be cleaving itself into what appears to be perhaps the nonstructural 
proteins. If this is the case and it cleaves off 3D and 3C (or 3CD for that matter) from itself, 
what remains bound to MBP will be 3AB. In a sense this is a negative result as the whole P3 
region was not obtained, however, with problems encountered during 3AB/pMAL expression, 
this construct could still perhaps be of some use. Prolonged induction of P3/pMAL resulted in 
clearing of cultures similar to that seen in 3AB/pMAL implying that MBP-3AB was the 
resultant product of the autocatalysis being observed, however time did not permit proper 
assessment of growth kinetics. This is supported by the presence of a band of approximately 
63kDa which could correspond to MBP-3AB and appears on both the Coomassie-stained gel 
and on the Western blot. Interestingly a band of ~43kDa can be seen upon induction of clone 
5 of P3/pMAL indicating either an out of frame fusion or a severe protein degradation 
problem.
4.2.S.2.4 Expression of 3C/pMAL
Expression of MBP-3C was easily observed with a protein of about 75kDa being produced as 
can be seen in lanes 9 and 11 of Figure 53 and Figure 54. Using this construct as a positive 
control for bacterial expression it was apparent that this system was working successfully and 
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Figure 51: Coomassie-stained 10% SDS-PAGE gel of 3CD/pMAL and 3D/pMAL
Lane 1: markers
Lane 2: uninduced „ pMAL (control)
Lane 3: induced I
Lane 4: uninduced




Lane 9: induced  ^ 3D (clones 1 and 2)
Lane 10: uninduced
Lane 11: induced
kDa 1 2 3 4 5 6 7 8 9







Figure 52: Western blot of gel of 3CD/pMAL and 3D/pMAL













Figure 53: Coomassie-stained 10% SDS-PAGE gel of P3/pMAL and 3C/pMAL
Lane 1: markers
Lane 2: uninduced „ pMAL (control)
Lane 3: induced I
Lane 4: uninduced













Figure 54: Western blot of gel of P3/pMAL and 3C/pMAL
Lane order as above. Exposure of 5 seconds.
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4.2.5.3 Sequencing of putative
Samples containing approximately 300-500ng of miniprep DNA and 3.2pmol of malE primer 
were sequenced on an automated ABI 377 Prism Sequencer. Sequences were analysed 
using the GCG suite of programs and this confirmed that the genes had been successfully 
cloned. The results are shown summarised in Table 13. Typical results are shown in Figure 
55 and Figure 56 for P3/pMAL and 3AB/pMAL respectively.
Table 13: Summary of sequencing results for pMAL constructs
CONSTRUCT IDENTITY OVERLAP (bp)
Human HAV RNA, 
complete genome 
(hpacg)
3C/pMAL (clone 2) 60.8% 549
hpacg 3CD/pMAL (clone 3) 88.2% 825
hpacg 3D/pMAL (clone 2) 86.1% 648
hpacg P3/pMAL (clone 8) 96.6% 412
hpacg 3AB/pMAL (clone 4) 93.8% 243
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H u m a n  h e p a t i t i s  v i r u s  t y p e  A  R N A , c o m p l e t e  g e n o m e  
A C C E S S IO N  N U M B E R  M 2 0 2 7 3
9 6 .6 %  i d e n t i t y  i n  4 1 2  b p  o v e r l a p
6 0  7 0  8 0  9 0  1 0 0  1 1 0
p 3 8 . s e  A A C A A C A A C C T C G G G A T C G A G G G A A G G A G C T T T C C A T C T G G T G A A C C A T C N A A C T C T A A A
I I I I I I I I I I I I I I I I I I I I : I I II I I I  
h p a c g  G A T A G T G C A A T G G C A G A G T T T T T T C A G T C T T T T C C A T C T G G T G A A C C A T C G A A T T C C A A A  
5 0 2 0  5 0 3 0  5 0 4 0  5 0 5 0  5 0 6 0  5 0 7 0
1 2 0  1 3 0  1 4 0  1 5 0  1 6 0  1 7 0
p 3 8 . s e  T T A T C T G G C T T T T T C C A A T C T G T T A G T A A T C A C A A G T G G G T T G C T G T G G G A G C T G C A G T T  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
h p a c g  T T A T C T G G C T T T T T C C A A T C T G T T A C T A A T C A C A A G T G G G T T G C T G T G G G A G C T G C A G T T  
5 0 8 0  5 0 9 0  5 1 0 0  5 1 1 0  5 1 2 0  5 1 3 0
1 8 0  1 9 0  2 0 0  2 1 0  2 2 0  2 3 0
p 3 8 . s e  G G TG T T C T T G G A G T G C T C G T T G G G G G A T G G T T T G T G T A T T A G C A T T T C T C C C G A A A A G A G  
I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
h p a c g  G G T A T T C T T G G A G T G C T C G T T G G G G G A T G G T T T G T G T A T A A G C A T T T C T C C C G A A A A G A G  
5 1 4 0  5 1 5 0  5 1 6 0  5 1 7 0  5 1 8 0  5 1 9 0
2 4 0  2 5 0  2 6 0  2 7 0  2 8 0  2 9 0
p 3 8  . s e  G A A G A G C C A A T T C C A A C T G A A G G G G T A T A T C A T G G T G T A A C T A A N C C T A A G C A A G T G A T T
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I : I I I I I I I I I I I I I I I
h p a  e g  G A A G A G C C A A T T C C A G C T G A A G G G G T A T A T C A T G G T G T A A C T A A G C C T A A G C A A G T G A T T  
5 2 0 0  5 2 1 0  5 2 2 0  5 2 3 0  5 2 4 0  5 2 5 0
3 0 0  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
p 3 8  . s e  A A A T T A G A T G C A G A T C C A G T A G A A T C T C A G T C A A C T T T G G A A A T A G C A G G A C T G G T T A G G  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
h p  a  c  g  A A A T T A G A T  G CAG AT C C A G T A G A A T  CT CAG T C A A C T T T  G G A A A TA G C A G G A C T GG TTAG G  
5 2 6 0  5 2 7 0  5 2 8 0  5 2 9 0  5 3 0 0  5 3 1 0
3 6 0  3 7 0  3 8 0  3 9 0  4 0 0  4 1 0
p 3 8  . s e  A A G A A T T T G G T T C A G T T T G G A G T T G G A G A G A A G A A T G G A T G T G T G A G A T G G G T T A T G A A T  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
h p  a  c  g  A A G A A T T T  G G TT C A G T T T  G G AG TT G G AG AG A AG AA T G GAT GT GT G AG A T G G G TTA T  G AA T 
5 3 2 0  5 3 3 0  5 3 4 0  5 3 5 0  5 3 6 0  5 3 7 0
4 2 0  4 3 0  4 4 0  4 5 0  4 6 0  4 7 0
p 3 8 . s e  G C C T T A N G G G T N A A A G A T G A T T G G T T G C T T G T A C C T T C C C A T G C T T A C N N A T T T G A A G A A  
I I I II I : I I I I : I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I : : I I I I I I I I I 
h p a c g  G C C T T A G G G G T G A A A G A T G A T T G G T T G C T T G T A C C T T C C C A T G C T T A C A A A T T T G -A G A A  
5 3 8 0  5 3 9 0  5 4 0 0  5 4 1 0  5 4 2 0  5 4 3 0
4 8 0  4 9 0
p 3 8 . s e  A G A T T A T G A A N T G A T G G A G T T T
I I I I I I I I I I : I I I I I I I I I I I
h p a c g  A G A T T A T G A A A T G A T G G A G T T T T A T T T T A A T A G A G G T G G A A C T T A C T A T T C A A T T T C A G C  
5 4 4 0  5 4 5 0  5 4 6 0  5 4 7 0  5 4 8 0  5 4 9 0
Figure 55: Alignment of part of putative P3/pMAL with part of the sequence encoding 
the complete RNA genome of human HAV
This sequence represents the highest nucleotide identities obtained from searching the 
Genbank and EMBL databases using the GCG programme Fasta (Pearson & Lipman, 1988).
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H u m a n  h e p a t i t i s  v i r u s  t y p e  A  R N A , c o m p l e t e  g e n o m e  
A C C E S S IO N  N U M BE R  M 2 0 2 7 3
9 3 . 8 %  i d e n t i t y  i n  2 4 3  b p  o v e r l a p
6 0  7 0  8 0  9 0  1 0 0  1 1 0
a b 4  . s e  A A C A A C A A C C TC G G G A T C G A G G G A A G G A G C T T T C C A T C T G G T G A A C C A T C G A A C T C T A A A
I I I I I I I I I I I I I I I I I I I I I I I II I I I  
h p a c g  G A T A G T G C A A T G G C A G A G T T T T T T C A G T C T T T T C C A T C T G G T G A A C C A T C G A A T T C C A A A  
5 0 2 0  5 0 3 0  5 0 4 0  5 0 5 0  5 0 6 0  5 0 7 0
1 2 0  1 3 0  1 4 0  1 5 0  1 6 0  1 7 0
a b 4 . s e  T T A T C T G G C T T T T T C C A A T C T G T T A G T A A T C A C A A G T G G G T T G C T G T G G G A G C T G C A G T T  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
h p a c g  T T A T C T G G C T T T T T C C A A T C T G T T A C T A A T C A C A A G T G G G T T G C T G T G G G A G C T G C A G T T  
5 0 8 0  5 0 9 0  5 1 0 0  5 1 1 0  5 1 2 0  5 1 3 0
1 8 0  1 9 0  2 0 0  2 1 0  2 2 0  2 3 0
a b 4 . s e  G G T G T T C T T G G A G T G C T C G T T G G G G G A T G G T T T G T G T A T T A N C A T T T C T C C C N A A A A G A G
I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I : I I I I I I I I I I : I I I I I I I
h p a c g  G G TA TT C TT G G A G T G C T C G T T G G G G G A T G G T T T G T G T A T A A G C A T T T C T C C C G A A A A G A G  
5 1 4 0  5 1 5 0  5 1 6 0  5 1 7 0  5 1 8 0  5 1 9 0
2 4 0  2 5 0  2 6 0  2 7 0  2 8 0  2 9 0
a b 4  . s e  G A A N A G C C A A T T  C C A A C T GAAN G G G TA TA T  C A T  GGT G T A A C T A A N  C C T A A G C A A G T  G A T T
I I I : I I I I I I I I I I I I I I I I : I I I I I I I I I I I I I I I I I I I I I I : I I I I I I I I I I I I I I I
h p a  e g  G A A G A G C C A A TT  CCAG C T G AA G G G G TA TA T  C A T  GGT G T A A C T A A G C C T A A G C A A G T G A T T  
5 2 0 0  5 2 1 0  5 2 2 0  5 2 3 0  5 2 4 0  5 2 5 0
3 0 0  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
a b 4  . s e  A A N T T A G A T N C A G A T C C A G T A C A A T C T C A G T N A T A A G G A T C C T C T A N A G T C N A C C T G C A G
I I : I I I I I I : I I I I I I I I I I I 111111111:1
h p a  e g  A A A T T A G A T  G CAG AT C C A G T A G A A T  C T C AG T C A A C T T T  G G A A A TA G C A G G A C T G G TTAG G  
5 2 6 0  5 2 7 0  5 2 8 0  5 2 9 0  5 3 0 0  5 3 1 0
3 6 0  3 7 0  3 8 0  3 9 0  4 0 0  4 1 0
a b 4  . s e  G C A A N N TT G G C A C T G G C C G TC G T TT TA C A A C TT C G TN A C TG G G A A A A A C C C T G G C N TT C C
h p a c g  A A G A A T T T G G T T C A G T T T G G A G T T G G A G A G A A G A A T G G A T G T G T G A G A T G G G T T A T G A A T  
5 3 2 0  5 3 3 0  5 3 4 0  5 3 5 0  5 3 6 0  5 3 7 0
Figure 56: Alignment of part of putative 3AB/pMAL with part of the sequence encoding 
the complete RNA genome of human HAV
This sequence represents the highest nucleotide identities obtained from searching the 
Genbank and EMBL databases using the GCG programme Fasta (Pearson & Lipman, 1988).
4.2.6 Pilot experiments showing expression and 
amylose binding capabilities
Initially, pilot experiments were undertaken for each of the successful constructs, in order to 
find out the conditions for protein expression ideally suited to each construct. The samples
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run on the SDS-PAGE gels were initially uninduced, induced for 1 hour, induced for 2 hours, 
induced for 3 hours, crude cell extract, insoluble matter and protein bound to amylose. 
Coomassie-stained gels and anti-MBP probed Western blots are shown below for each HAV 
construct except 3AB/pMAL.
4.2.6.1 Pilot expression of3C/pMAL
When expression of MBP-3C was satisfactory a distinct band of ~75kDa was observed, 
(lanes 5 to 10 of Figure 57) which reacted with anti-MBP antibody and yielded a major band 
of ~75kDa (Figure 58). Crude extract lanes showed that the band of interest was relatively 
soluble and it appeared also to be the dominant band bound to amylose in lane 10 of these 
two figures. The lane containing undiluted protein bound to amylose resin in Figure 58 
revealed, however a few other proteins which bound to amylose resin. It was clear however 
that the polypeptide predominantly binding to amylose was that corresponding to the MBP-3C 
species. Some bands appeared smaller than they actually were on the gel and blot due to 
slight 'smiling' caused by temperature fluctuations.
4.2.6.2 Pilot expression of3CD/pMAL
In the case of the pilot experiment with 3CD/pMAL, polypeptides (~125kDa) of about the size 
expected for MBP-3CD (127.8kDa) were observed. In addition very faint bands of ~90kDa, 
75kDa, 66kDa, and 44kDa were observed on the Coomassie-stained gel (Figure 59) of 
3CD/pMAL. Only the 75kDa, 66kDa and 44kDa bands were observed to be soluble and 
either only weakly reacted with the anti-MBP antibody (Figure 60) or were present in very 
small amounts. Some of these bands present can be accounted for however, with the band 
of 75kDa possibly corresponding to MBP-3C, if the 3CD has undergone autocatalysis at its 
natural cleavage site. It is expected that the 43kDa protein would possibly correspond to 
MBP2* indicating either an out of frame fusion or a severe protein degradation problem. No 
proteins were observed to bind to amylose resin. Again 'smiling' of the bands has occurred.
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Figure 57: Pilot expression of 3C/pMAL - Coomassie-stained gel
Lane 1: markers
Lane 2: uninduced \  pMAL (control)
Lane 3: induced J
Lane 4: uninduced
Lane 5: induced 1 hour
Lane 6: induced 2 hours
Lane 7: induced 3 hours
Lane 8: crude extract
Lane 9: insoluble extract
Lane 10: protein bound to amylose resin









Figure 58: Pilot expression of 3C/pMAL - Western blot
Exposure of 1 minute. Lane order as above with samples diluted 1:10 with the addition of:- 
Lane 11: crude extract (neat)
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Figure 59: Pilot expression of 3CD/pMAL - Coomassie-stained gel
Lane 1: markers
Lane 2: uninduced 1 pMAL (control)
Lane 3: induced J
Lane 4: uninduced
Lane 5: induced 1 hour
Lane 6: induced 2 hours
Lane 7: induced 3 hours
Lane 8: crude extract
Lane 9: insoluble extract
Lane 10: protein bound to amylose resin











Figure 60: Pilot expression of 3CD/pMAL - Western blot
Exposure of 5 minutes. Lane order as above with samples diluted 1:10 with the addition of:- 
Lane 11: crude extract (neat)
Lane 12: protein bound to amylose resin (neat)
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4.2.6.3 Pilot expression of 3D/pMAL
Upon induction with IPTG, 3D/pMAL expressed high levels of a dominant protein of ~100kDa 
proteins, expected to represent MBP-3D (Figure 61). Expression of this protein increased 
proportionally with induction time. The MBP-3D appeared to be soluble to an extent, however 
the bulk of it was insoluble and temperature of induction was subsequently altered (reduced 
to 23°C) in the hope of remedying this. A very faint band was observed by SDS-PAGE to 
bind to amylose resin, however this was easier to see on the Western blot (Figure 62). A 
smaller band of ~75kDa appears to bind amylose resin as well, if not better, than the putative 
MBP-3D protein, however its identity is unknown.
4.2.6.4 Pilot expression of P3/pMAL
The results of the pilot experiment with P3/pMAL were confusing. A novel band of ~139kDa 
can be seen in lanes 5, 6 and 7 (Figure 63). The lane showing crude extract revealed that 
the actual MBP-P3 present was insoluble and only proteins of 95kDa, ~83kDa, ~75kDa, 
63kDa, and ~43kDa were present in the soluble crude extract. For the mostpart, these 
proteins, however were also present in varying degrees in the control. The band of 63kDa 
could correspond to MBP-3AB and appeared to be present in P3/pMAL lanes only. A clear 
band of ~139kDa could be seen in the insoluble extract lane which shows promise, but 
autocatalysis, or at least proteolysis, is obviously occurring as the MBP fusion protein binding 
to amylose resin is only 43kDa long, which could correspond to degraded MBP alone. The 
83kDa protein could correspond to MBP-3ABC, however this remains unknown.
Similar results were seen in the Western blot of P3/pMAL (Figure 64) with a band of the 
predicted size being visible in lanes 5, 6 and 7, but the amylose affinity resin bound either to a 
much smaller protein or to no protein at all and MBP was present alone. Bands of ~75kDa 
and ~83kDa were also observed, the latter of which could as already mentioned correspond 
to MBP-3ABC, but this remains unknown. Analysis of neat crude extract revealed that a 
minute amount of P3/pMAL was soluble, along with a protein of ~83kDa and one of ~66kDa. 
Attempts continued at changing conditions to yield more favourable results.
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Figure 61: Pilot expression of 3D/pMAL - Coomassie-stained gel
Lane 1: markers
Lane 2: uninduced \  pMAL (control)
Lane 3: induced J
Lane 4: uninduced
Lane 5: induced 1 hour
Lane 6: induced 2 hours
Lane 7: induced 3 hours
Lane 8: crude extract
Lane 9: insoluble extract
Lane 10: protein bound to amylose resin
3D/pMAL






Figure 62: Pilot expression of 3D/pMAL - Western blot
Exposure of 2 minutes. Lane order as above with samples diluted 1:10 with the addition of> 
Lane 11: crude extract (neat)
Lane 12: protein bound to amylose resin (neat)
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Figure 63: Pilot expression of P3/pMAL - Coomassie-stained gel
Lane 1: markers
Lane 2: uninduced \  pMAL (control)
Lane 3: induced J
Lane 4: uninduced
Lane 5: induced 1 hour
Lane 6: induced 2 hours
Lane 7: induced 3 hours
Lane 8: crude extract
Lane 9: insoluble extract
Lane 10: protein bound to amylose resin












Figure 64: Pilot expression of P3/pMAL - Western blot
Exposure of 1 minute. Lane order as above with samples diluted 1:10 with the addition of: 
Lane 11: crude extract (neat)
Lane 12: protein bound to amylose resin (neat)
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Table 14: Expressed proteins demonstrating solubility and amylose binding 
capabilities
BAND (kDa) EXPRESSED SOLUBLE AMYLOSE BINDING
-139 (MBP-P3?) V X X
-125 (MBP-3CD?) V X X
-100 (MBP-3D?) S s ?
-75 (MBP-3C?) s V
-63 (MBP-3AB?) s ? ? ?
4.2.7 Large-scale purification
After optimisation of the expression conditions for each construct, large-scale production was 
launched. Generally 1L cultures of each construct were grown as detailed in 2.2.7.2, 
however due to poor yield at times, cultures of 4L were used in some cases, by inoculating 4L 
of Rich Media with 40ml of overnight culture and growing to an A6oo of -0.5 or cell density of 2 
x 108 cells/ml. Essentially, the same protocol was followed but scaled up to accommodate 
the larger volumes involved. By reducing the temperature of induction (Bishai et al., 1987) to 
23°C and inducing for longer (one has to increase the time of induction to compensate for the 
slower growth at reduced temperature - the rule of thumb used here was 2x for every 7°C 
below 37°C) solubility was marginally increased for MBP-3D, however degradation or 
cleavage of the putative processing intermediates, P3 and 3CD was still observed.
Protein-containing fractions eluted from amylose columns were identified by Bradford Assay, 
pooled and concentrated to approximately 1 mg/ml for subsequent factor Xa cleavage as 
described in 2.2.7.3. Pilot experiments to assess factor Xa cleavage yielded the following 
results. In each case a band of the size predicted for MBP was seen at -50kDa, and in some 
cases uncut fusion protein and the target protein alone at their respective masses were 
observed. As can be seen, the yields were variable and low.
4.2.7.1 Factor Xa cleavage o f MBP
Factor Xa cleavage of a sample hoped to contain MBP-P3 yielded unusual results as shown 
in Figure 65. The appearance of two bands upon factor Xa cleavage of 'MBP-P3' indicates 
that it is in fact a fusion protein and not just MBP alone. The obvious bands are ~55kDa,
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corresponding to uncut fusion protein and a band of ~50kDa, probably corresponding to 
MBP. The small second cleavage product is not observed on the gel as the markers indicate 
that a protein of approximately 21,5kDa is the smallest protein likely to be observed. Perhaps 
the protein released, and lost, could correspond to 3AB, or 3A. The approximate size of 
MBP-3AB is 63.8kDa. Perhaps the band of ~55kDa could correspond to MBP-3A, however 
this is unlikely unless further degradation has occurred or the 3A region is truncated more so 
than previously thought. It must be borne in mind that a truncated 3A region was used for 
cloning purposes. Interestingly, prolonged induction times of P3/pMAL also caused clearing 
of the culture and this could imply that autocatalytic cleavage is occurring releasing toxic 
MBP-3AB or MBP-3A, resulting in 'leaky' cells as was observed with expression of HAV 3A 
by both my 3AB/pMAL construct and by Beneduce etal. (1995).








Figure 65: Factor Xa cleavage of MBP-P3
Coomassie-stained 10% SDS-PAGE gel.
Lane 1: markers
Lane 2: uncut ^
Lane 3: 2 hour digestion
Lane 4: 4 hour digestion
Lane 5: 8 hour digestion





4.2.7.2 Factor Xa cleavage of MBP
In the case of 3C/pMAL the band of 75kDa corresponding to MBP-3C was clearly present in 
all 7 lanes (Figure 66). As expected, and hoped for, digestion with factor Xa produced a 
further two bands of ~50kDa (expected to be MBP) and one of 24kDa, the size of the target 
protein, 3C, alone.
4.2.7.3 Factor Xa cleavage of MBP
3D/pMAL eluted from column appeared to be a heterogeneous mixture even before cleavage 
commenced. The uncut sample originated from pooled concentrated samples eluted from a 
15ml amylose column, as was described in Chapter 2. The bands appearing at the very top 
of the gel of molecular mass ~100kDa may be MBP-3D. Other bands of ~75kDa and ~66kDa 
were also observed throughout the samples, as well as a band of ~50kDa (MBP) and the 
target protein appears as a very faint smear at 53kDa as expected. This result is not as 
'clean' as that of 3C/pMAL but suggested that it would be possible to purify 3Dp0‘ from this 
material. Since I was unable to purify sufficient quantities of MBP-3CD and MBP-P3 due to 
insolubility and self-cleavage, only MBP-3D and MBP-3C were pursued to this stage.
31 ►
Figure 66: Factor Xa cleavage of MBP-3C
Coomassie-stained 10% SDS-PAGE gel.
Lane 1: markers
Lane 2: uncut
Lane 3: 2 hour digestion
Lane 4: 4 hour digestion ► pilot-scale
Lane 5: 8 hour digestion
Lane 6: 24 hour digestion.
Lane 7: 24 hour digestion large-scale
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Figure 67: Factor Xa cleavage of MBP-3D
Coomassie-stained 10% SDS-PAGE gel.
Lane 1: markers
Lane 2: uncut
Lane 3: 2 hour digestion
Lane 4: 4 hour digestion ► pilot-scale
Lane 5: 8 hour digestion
Lane 6: 24 hour digestion.
Lane 7: 24 hour digestion large-scale
All three of the fusion proteins containing 3D sequences were analysed further for eventual 
use in activity assays. Although P3/pMAL offered little hope for eventual purification of the 
whole P3 region, the observed bacterial lysis was interesting and was worthy of further 
investigation, unfortunately time for extensive research was unavailable, however attempts at 
purifying the MBP-P3 protein continued.
4.2.8 FPLC purification of prot
cleavage mixture
As described in Chapter 2, FPLC using anion exchange chromatography with a Mono-Q 
column was the chosen method for purifying the target protein away from MBP and factor Xa 
as it provided an additional purification step for removing trace contaminants.
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4.2.8.1 FPLC analysis of MBP-3C
The elution profile for 3C is not shown here, however, SDS-PAGE analysis of the fractions 
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Figure 68: SDS-PAGE analysis of fractions of eluted from Mono-Q column loaded with 
MBP-3C cleavage mixture- gel 1
Coomassie-stained 10% SDS-PAGE gel
Lane 1: markers
Lane 2: aliquot of sample loaded onto column
Lane 3: aliquot of flow-through during equilibration of column
Lane 4: fraction 8
Lane 5: fraction 9
Lane 6: fraction 10
Lane 7: fraction 11
Lane 8: fraction 12
Lane 9: fraction 13
Lane 10: fraction 14
Lane 11: fraction 15
Lane 12: fraction 16
Protein of ~50kDa, corresponding to MBP was observed along with protein of ~75kDa (uncut 
MBP-3C?), however no protein bands of 24kDa, corresponding to the target 3C protein were 
observed. Close inspection of the equilibration flow-through of the Mono-Q column revealed 
that the 3C target protein had in fact passed straight through the column and predominantly 
uncleaved or MBP alone was bound to the column. The gels showing this are not shown as 
the bands were very faint and only visible with the help of a light box. The fractions of flow­
through were subsequently concentrated to ~1 mg/ml and the resultant solution containing 3C 
was beaded into liquid nitrogen for storage. It was thought that protease activity assays could 
be set up if time permitted.
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Figure 69: SDS-PAGE analysis of fractions eluted from Mono-Q column loaded with 
MBP-3C cleavage mixture - gel 2
Coomassie-stained 10% SDS-PAGE gel
Lane 1: markers
Lane 2: fraction 17
Lane 3: fraction 18
Lane 4: fraction 19
Lane 5: fraction 20
Lane 6: fraction 21
Lane 7: fraction 22
Lane 8: fraction 23
Lane 9: fraction 24
Lane 10: fraction 25
Lane 11: fraction 26
Lane 12: fraction 27
4.2.8.2 FPLC analysis of MBP-3D




Figure 70: Chart recording of FPLC of 3D-MBP cleavage mixture
6ml fusion protein cleavage mixture (~1 mg/ml) was loaded at a rate of 0.5ml/min. Chart 
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Figure 71: SDS-PAGE analysis of fractions eluted from Mono-Q column loaded with 
MBP-3D cleavage mixture - gel 1














aliquot of sample loaded onto column










SDS-PAGE analysis of the fractions eluted from a Mono-Q column loaded with cleaved MBP- 
3D revealed little, with MBP being the protein most easily observed followed by a protein, of 
~80kDa. Fractions thought to contain any protein of the desired size were concentrated and 
the results can be seen in Figure 73.
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Figure 72: SDS-PAGE analysis of fractions eluted from Mono-Q column loaded with 
MBP-3D cleavage mixture - gel 2
Coomassie-stained 10% SDS-PAGE gel
Lane 1: markers
Lane 2: fraction 27
Lane 3: fraction 28
Lane 4: fraction 29
Lane 5: fraction 30
Lane 6: fraction 31
Lane 7: fraction 32
Lane 8: fraction 33
Lane 9: fraction 34
Lane 10: fraction 35
Lane 11: fraction 36
Lane 12: fraction 37
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Figure 73: Concentration of proteins eluted from Mono-Q column loaded with MBP-3D 
cleavage mixture
Coomassie-stained 10% SDS-PAGE gel 
Lane 1: markers
Lane 2: original MBP-3D eluted from amylose column and concentrated
Lane 3: factor Xa cleavage products loaded onto Mono-Q
Lane 4: fraction 18 (MBP)
Lane 5: fraction 27 concentrated (~48kDa?)
Lane 6 fraction 31 and 32 pooled and concentrated (~52kDa?)
Once concentrated the volume of 'purified' protein obtained with 3D in particular, was minute, 
however the fractions thought to contain protein of, roughly, the desired mass were 
concentrated to ~0.5mg/ml, beaded into liquid nitrogen and stored for assay purposes. The 
results indicate that yields of the putative 3D polypeptide were very low (~5pg from 4 litres of 
culture) and it was not completely pure, however, yields were sufficient to permit assays for 





As a first step in the characterisation of the polymerase enzyme, a purified preparation of 
HAV 3Dpo1 was required and having enjoyed limited success with bacterial expression 
systems, it was thought best to continue down this path. Some problems were encountered 
with regard to template sequence, primer denaturation etc., however once solved, 
amplification of the desired regions was successful and allowed subsequent subcloning into 
pMAL™-c2. Restriction analysis indicated that fragments of the expected size have been 
cloned into this expression vector and sequencing results show that the inserts have been 
cloned into pMAL™-c2 in the correct orientation. Expression of the desired proteins was 
successful to an extent. Some insolubility was initially observed which in some cases was 
helped to a degree by inducing cultures at lower temperatures for a longer time period as 
recommended by the manufacturer. Harvesting of the cells had to be undertaken as quickly 
as possible keeping the cells chilled at all times, which reduced the loss of protein through 
degradation by proteases released from the bacterial cells during harvesting.
The inserts, P3, 3C, 3CD and 3D, ligated into pMAL-c2, have been over-expressed in E. coli, 
some of the fusion proteins have been affinity purified, cleaved from the MBP by Factor Xa 
and one, possibly two of these have been separated from the MBP. Overexpression of 
processing intermediates, such as P3 and 3CD yielded both encouraging and disappointing 
results: the proteins appeared to be active in their fusion protein form, as autocatalytic 
cleavage appears to have occurred in the correct positions, resulting in the constituent 
proteins being seen by SDS-PAGE analysis, however, this proteolysis could be due to 
indigenous bacterial proteinases recognising the respective cleavage junctures within the 
expressed proteins of 3CD and P3. Others have experienced such autocatalytic activity 
when expressing processing intermediates and have had to generate mutants with changes 
in the cleavage sites to allow purification of the precursor (Harris et al., 1994 and references 
therein; Kusov & Gauss-Muller, 1997 and references therein). Although active as fusion 
proteins which was encouraging, the protein linked to the MBP after autocatalysis, important 
for affinity chromatography, was thought to be 3C, in the case of 3CD, and 3AB, in the case 
of P3. As such, affinity purification of these intermediates was not ultimately possible.
Protein 3AB of other picomaviruses has been shown to be toxic and the data obtained here 
suggest that HAV 3AB, as a fusion with MBP, is also active in bacterial cells with the 
observation that clearing of the cultures upon induction occurred, probably correlating with 
lysis of cells as described by Beneduce et al. (1995) and Pisani et al. (1995). Furthermore, 
as previously mentioned, the truncated 3A region cloned in would result in a 3A protein
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lacking the N-terminal amino acids and the data presented in this Chapter supports the 
observation of Beneduce et al. (1995) that such an N-terminal deletion would render this 
protein toxic to bacteria. Shortly afterwards, results obtained during expression of this 
construct revealed that there was a problem. Subsequent DNA analysis of the 3AB/pMAL 
constructs revealed that the plasmid had lost its insert, the 3AB region. Further attempts at 
cloning this region proved unsuccessful. Similarly, if P3/pMAL was induced for extended 
periods of time (8 to 16 hours), clearing of the culture was observed which could be due to 
autocatalysis or degradation causing release of MBP-3AB or MBP-3A, and this product again 
causing cell lysis. This result could imply that the 3C protease was also active in the system 
used. While this was a disappointing result, with regard to eventual purification of 3AB, with 
hindsight, it was a predictable result and indicates that the system is working. So, with good 
circumstantial evidence that 3C and 3AB were active in this expression system, it was 
thought worthwhile to attempt purification and activity analysis of the 3D protein.
When concentrating on the polymerase and protease proteins, limited success was realised. 
Purification of 3C in acceptable amounts was relatively easy (It was at this stage of the 
project that Bergmann et al. (1997) published their results of the refined crystal structure of 
this protein), however the larger 3D polymerase proved harder to purify with yields being 
dismally low and solubility presenting a problem as others have found (Palmer, 1994; Tesar 
et al., 1994). Attempts at improving solubility by reducing induction temperatures (Bishai et 
al., 1987) proved marginally helpful, but the yield of 'pure protein1 obtained from 4 litres of 
culture remained poor (<5pg of 'pure' 3D compared with >500pg of 'pure' 3C). It could be 
that the fusion protein produced was just too large for the bacteria to cope with. Very large- 
scale expression of this construct would be necessary to actually isolate the target 3Dpo1 
protein, however, the facilities are not available here. Protease assays of the 3C protein 
purified would have been another aspect for investigation if time permitted.
Essentially though, a variety of products resulted from these expression experiments which 
could subsequently be used in activity assays. These included soluble cell extract, MBP- 
fusion proteins and MBP-fusion cleavage mixture. The 'purified' 3D obtained was thought 
insufficient for activity assay analysis. Assays were undertaken as described in Chapter 5 
using the whole cell extract, MBP-fusion protein and the MBP-fusion cleavage mixture 
samples described above with the hope of observing some incorporation of 3H-UTP signifying 
the presence of active polymerase enzyme.
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5. Assay for 
poly(A):oligo(U)- 
dependent poly(U) 
polymerase activity and 
the effect of other non- 





Previous attempts to express the HAV 3D region in E. coli have been unsuccessful, 
resulting in intracellular accumulation of an insoluble product which showed no activity 
(Updike et al., 1990) although the 3C proteinase has been successfully expressed in E. 
coli (Gauss-Muller, 1991). Efforts to detect and characterise a biochemical activity of the 
3D protein have so far been unsuccessful (Tesar et al., 1994) although a weak poly(U) 
polymerase activity was detected in the periplasmic space of E. coli carrying pRITPOL 
(Wolstenholme et al., 1993). The poly(U) polymerase described had many of the 
properties expected for a picomavirus 3Dpo', with a temperature optimum of about 30°C, 
a requirement for Mg2+ and not Mn2+, and a dependence on the presence of an 
oligonucleotide primer for activity.
Particular problems highlighted previously include the absence of apparent soluble 
protein in preparations used for activity assays and, perhaps, inappropriate conditions 
used for assays. In addition, repeated efforts to show RNA polymerase activity in 
extracts of HAV-infected BS-C-1 cells, either in a template-dependent form or as an 
enzyme-template complex, have also been negative (Tesar et al., 1994 and references 
therein). Preliminary data obtained in this laboratory by Palmer (1994) indicated that a 
poly(A):oligo(U)-dependent poly(U) polymerase activity, representative of RNA 
polymerase activity, was present in the cytoplasm of E. coli transformed with HAV 
P3/pMEX8 and in the periplasmic space of E. coli transformed with Protein A/HAV 
P3/pMEX8 as well as pRITPOL. For Palmer (1994) reproducibility of initially
encouraging results using this assay, however, presented a problem, and a number of 
strategies were employed by Palmer (1994) in order to improve the protocol:
1. E. coli strain change to JM-105
Eliminated the possibility that the reason for poor enzymic activity was due to 
construct instability in JRR-600. In the current project, the strain used for assay 
analysis of pMAL constructs was XL-2 and miniprep analysis revealed that the 
constructs had been faithfully retained in each case.
2. Reduced induction period
Long induction period of 15 hours leading to degradation of the RNA-dependent RNA 
polymerase? 5 hour induction was believed to be sufficient for good expression of 




3. Addition of RNAse inhibitors
Eliminated the possibility that low activity encountered previously was the result of 
nuclease-destruction of the radiolabelled RNA due either to reagent contamination or 
endogenous nucleases in the extracts. Then, as in this study, RNA-guard and 
dithiothreitol (DTT) were added to the reaction.
4. Poly(A):poiy(U) template
To exclude the possibility that a lack of observed 3Dpo1 activity was due to a defective 
oligo(U) primer a new template and primer were investigated by Palmer (1994). 
Poly(A):poly(U) replaced poly(A) as the template and oligo(U) as the primer. This 
method assumes that there are imperfections in the template in the form of missing 
uracil and adenine residues. Any breaks along the poly(U) strand would therefore be 
filled in by the enzyme, utilising the tritiated UTP. The poly(A):poly(U) template was 
used in the activity assays reported here.
Here, the poly(A):oligo(U)-dependent poly(U) polymerase assay, originally developed for 
the PV RNA-dependent RNA polymerase, modified by Palmer (1994) as described in 
Chapter 2 and explained above, was applied in the detection of HAV RNA-dependent 
RNA polymerase activity in the available purification products from the pMAL protein 
purification system. It was hoped that improvements to the results already obtained in 
this laboratory would be made by use of a more 'pure' enzyme preparation in the form of 
MBP-fusion protein, MBP-3D. In addition, it was expected that the MBP fusion partner 
would aid the solubility of the 3D protein. Investigation into the effects of other 
nonstructural proteins on any enzyme activity observed could also be undertaken using 
similar preparations of fusion proteins representing the 3CD and P3 regions. At 
commencement, it was hoped that a 'purified' sample of 3AB or its fusion protein would 
be available at this stage to determine whether this protein exerts the same stimulation 
on HAV polymerase activity as its PV counterpart does on PV polymerase activity, 
however, as previously discussed this was not possible.
Using the HAV 'optimised' protocol, the poly(U) polymerase activity of whole cell lysate 
(induced for 5 and 15 hours), as well as purified MBP-fusion protein and factor Xa 
cleaved fusion protein was assessed. Unfortunately, the yield of 'purified' proteins 3D 
obtained was insufficient for assay analysis. Data gleaned from whole cell lysate 
experiments appeared confusing and predictions as to what was occurring could not be 
made, however results obtained from assays undertaken using MBP-fusion proteins 
proved more promising possibly due to the absence of bacterial contamination.
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Furthermore, the results obtained appeared to be reproducible.
This Chapter could be regarded as an investigation into the suitability of the 
'optimised/modified' poly(U) polymerase assay as well as an assessment of the 
effectiveness of using purified fusion proteins or their cleavage products in such assays.
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5 . 2  Results
5.2.1 Assays of crude cell
constructs
Poly(U) polymerase assays of soluble cell lysates of pMAL and 3D/pMALt and the effect 
of 3CD/pMAL and P3/pMAL lysates induced also for 5 and 15 hours were undertaken as 
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Figure 74: Incorporated 3H-UTP for assays of cell lysates induced fo r 5 hours
Standard reaction mixture of 125pl containing 50pg protein (25pg single sample assays), 
50mM Hepes, 8mM Mg(CH3COO)2, 1.7pM [5,6-3H] UTP, 20pg/ml poly(A):poly(U) 
template, 74Units RNA-guard, 4mM DTT, 20pg/ml rifampicin was incubated at 31 °C and 
samples taken at the time points indicated above. All measurements are the average of 
triplicate samples.
Data from assays undertaken using cell lysates of induced pMAL constructs (5 hour 
induction) appeared similar to data obtained by Palmer (1994) for the HAV P3/pMEX8, 
Protein A/HAV P3/pMEX8 and pRITPOL constructs, with high incorporation at time 'O'
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which decreased to virtually background levels by the next time point. Reaction mixtures 
were set up simultaneously and incubated on ice until one minute prior to addition of 
enzyme extract at time 'O'. Initial readings were high for all 'enzyme mixtures' tested, but 
the amount of radiolabelled precipitate measured at 'O' minutes decreased as the pre­
assay incubation time increased. This suggested that a precipitate incorporating 
radiolabelled UTP was forming rapidly as the reaction mixture was set up and appeared 
to partially redissolve before addition of enzyme extract. The precipitate may affect 
polymerase activity by depriving the enzyme of assay constituents and/or forming an 
inactive complex with the enzyme. The decrease in detected labelled RNA observed 
could however be due to the presence of nucleases in the reaction mixture. The 
conditions described may not therefore be appropriate for assay of the putative HAV 
RNA polymerase. The 3D/pMAL soluble lysate exhibited the greatest incorporation of 
3H-UTP, which was a promising result, however, pMAL alone gave a reading well above 
background levels. Levels of incorporation for a combination of 3D/pMAL and 
3CD/pMAL appear to be above background levels, however, the standard error apparent 
could indicate no real incorporation. The concentration of protein present could cause 
interference, with single lysate assays exhibiting greater incorporation throughout the 15 
minutes. Strangely, doubling the concentration of 3D/pMAL appeared to reduce 
incorporation which is not as we would expect if incorporation was really reflecting 
enzyme activity.
It was hoped that by incorporating more time points poly(U) polymerase activity could be 
better assessed and as such the assay was repeated with soluble lysates induced for 5 
hours and 15 hours (Figure 75 and Figure 76) with sampling taking place at t=0, 34. 2, 5, 
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Figure 75: Incorporated 3H-UTP for assays of soluble lysates induced for 5 hours
Standard reaction mixture as before. All measurements are the average of triplicate 
samples.
Results for 5 hour induced lysates incorporating more time points revealed little more 
than those using only three time points. A measure of activity, which decayed over time, 
was observed with 3D/pMAL. When assayed in combination with soluble lysates 
of3CD/pMALs incorporation of 3H-UTP was also apparent but at a lower level and at a 
rate which decayed more rapidly than 3D/pMAL alone. This was an encouraging result 
in that, at least some 'activity' was seen and found to be reproducible (Typical data 
shown). Lysates of 3D/pMAL mixed with lysates of P3/pMAL and 3D/pMAL were 
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Figure 76: Incorporated 3H-UTP for assays of cell lysates induced for 15 hours
Standard reaction as before. All measurements are the average of triplicate samples.
The incorporation of 3H-UTP observed for 15 hour induced whole cell lysates was 
dramatically lower than the corresponding figures for 5 hour induced lysates with the 
highest reading being less than 14nmoles/mg protein compared with more than 
30nmoles/mg protein observed for samples induced for 5 hours. Furthermore, data 
obtained for the lysates of pMAL fusions expressed for 15 hours were confusing to say 
the least with pMAL alone giving one of the highest readings. If this was really indicative 
of true enzyme activity, one would expect an increase in activity with an increase in 
protein concentration, however this was not observed here and the samples containing 
pMAL or 3D/pMAL alone gave higher readings than those samples containing mixtures 
of lysates. It could be, yet again, that the sheer amount of protein present in samples 
induced for such a length of time is causing problems or interfering in some way. 
Doubling the amount of 3D/pMAL would be expected to give a higher level of 
incorporation of 3H-UTP as there is more putative enzyme present, however the activity 
observed for this combination was little more than background suggesting that the 
precipitation of UTP observed was not due to a true enzyme activity.
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The curve representing the 3D/pMAL and 3CD/pMAL lysate mixture displayed an 
increase in 'activity' which peaked at about 10 minutes then decayed rapidly, however no 
real conclusions could be drawn from these results. This could be due to RNAse in the 
lysate being active in spite of the inclusion of inhibitors in the assay buffer. It was hoped 
that by assaying the purified MBP-fusion proteins, lacking contamination from bacterial 
proteins, a better picture of the activities of the expressed fusion proteins could be 
obtained. Furthermore, all subsequent experiments were set up just prior to assaying in 
order to reduce pre-assay incubation time in the hope of minimising the possible 
precipitation of assay certain constituents. Moreover, all assays were started with the 
addition of enzyme as is normal, however radiolabelled UTP became the penultimate 
solution added to the reaction in the hope of remedying the precipitation problem.
5.2.2 Assays of MBP-fusion proteins
Fusion proteins, eluted from amylose columns, were concentrated to ~1 mg/ml and 
assayed for poly(U) polymerase activity using the 'optimised' protocol employed 
previously. The fusion proteins assessed, included MBP-3D, MBP-3CD and MBP-P3 
and combinations thereof. The results of four separate assays are shown below in 
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Figure 77: Incorporated 3H-UTP for assay of purified MBP-fusion proteins
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Figure 78: Incorporated 3H-UTP for assay of purified MBP-fusion proteins




Assays of purified MBP-fusion proteins again yielded very confusing results with assays 
conducted on subsequent days yielding slightly differing results. Four typical results are 
shown in Figure 77 and Figure 78. Although differences were apparent, a consistent 
encouraging observation was that a certain degree of incorporation was seen for the 
MBP-3D protein. Unfortunately, again the sample containing double quantities of MBP- 
3D revealed very low activity in all assays. In some assays MBP-3D mixed with MBP-P3 
showed an increase in the amount of radiolabelled UTP incorporated at about 10 
minutes which, although very slight, could be due to the processing of the P3 releasing 
polypeptides useful or essential for polymerase activity. One would expect in this 
situation to see a 'lag' phase. This slight 'activity', however decayed toward 15 minutes 
and in all cases displayed incorporation not much higher than that observed for MBP 
alone.
5.2.3 Assays of fusion protein ciea vage products
Digestion of the MBP-fusion proteins used previously with factor Xa for 24 hours, as 
described in Chapter 2, yielded cleavage products which although not purified from the 
MBP, were employed in another set of activity assays. Again, four sets of typical results 
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Figure 79: Incorporated 3H-UTP for assays of MBP-fusion cleavage products
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Figure 80: Incorporated H-UTP for assays of MBP-fusion protein cleavage 
products




In the case of the cleaved fusion proteins, poly(U) activity was apparent for the cleavage 
products of MBP-3D alone. The activity observed decayed after 2 minutes, almost down 
to background levels and well below initial levels, indicating degradation of RNA. 
Interestingly the incorporation of radiolabelled UTP in the case of cleaved MBP-3D 
occurs rapidly and decay is evident after, at most 5 minutes. This is, in contrast to the 
incorporation observed for analysis of fusion proteins, where the MBP-3D apparently 
incorporates 3H-UTP only after at least 5 minutes. Perhaps this is indicative of a 'lag' 
phase? In some cases, the cleavage products of MBP-3CD mixed with MBP-3D gave a 
higher than 'background' reading initially which then decayed to background levels. 
Again, the increased protein present appeared to reduce activity, however cleaved MBP- 
3CD and cleaved MBP-P3 yielded low results which would not be expected if only 
protein saturation hampered the enzyme activity. Unfortunately, as before doubling the 
concentration of cleaved MBP-3D drastically impaired the incorporation of 3H-UTP 
apparent.
Interestingly, when plotted together (Figure 81), the results for the MBP-fusion proteins 
and their cleaved products revealed that only the cleaved MBP-3D displayed dramatic 
poly(U) polymerase activity. When assayed in conjunction with MBP-3CD and MBP-P3, 
cleaved or uncleaved, all exhibited similar activity profiles, not discemable from the 
control levels observed for MBP alone. Others have used fusion proteins for successful 
characterisation of viral polypeptides, however, it was observed here that the 3D protein 
required cleavage from, but not necessarily separation from, the MBP for activity. The 
reason for this is not known. In conclusion, however, this was a very encouraging result 
and implied that the assay, as modified by Palmer (1994), could be suitable for the 
investigation and characterisation of the HAV 3Dpo1. The reason why increasing the 
concentration of MBP-3D cleaved or otherwise reduces the activity observed for MBP- 
3D alone, remains unknown. It appears though, that the semi-purified 3D protein 
obtained using the pMAL purification system was both soluble and active and as such, 
fulfilled some of the aims of this project. Time unfortunately did not permit further 












~o(D -»—> TOi__0 



















0 2 4 6 8 10 12 14 16
Time (minutes)
Figure 81: Incorporated 3H-UTP for assays of both MBP-fusions and their cleavage 
products
Plot of a typical MBP-fusion protein assay result superimposed on a plot of cleaved 





In principle, one of the more easily assayed functions of the polypeptides encoded by the 
nonstructural regions of picomaviruses is the RNA-and poly(U) polymerising activity of 
the picomavirus 3Dpo1. The 3Dpo1 of other picomaviruses have been successfully 
expressed in bacterial cells and have been shown to have properties similar to the 
activities detected in infected cells. Generally, bacterially expressed picomavirus RNA 
polymerases are primer-dependent, usually assayed using a poly(A):oligo(U) template, 
show a requirement for magnesium ions and are inhibited by manganese, with a 
temperature optimum of about 30°C (Morrow et al., 1987; Richards et al., 1987; Plotch et 
al., 1989; Neufeld et al., 1991; Sankar & Porter, 1991). Wolstenholme et al., 1993 
detected a novel poly(U) polymerase activity in the periplasmic space of E. coli cells 
transformed with pRITPOL and this activity showed many of the expected properties of a 
picomavirus 3Dpo‘.
Preliminary assay data of pMAL constructs (5 hour induced cell lysates) appeared 
similar to data obtained by Palmer (1994) for the Protein A/HAV P3/pMEX8, HAV 
P3/pMEX8 and pRITPOL constructs used previously, with initial high counts at time 'O' 
which decreased to background levels by the next time point. These results support the 
observation that a precipitate incorporating radiolabelled UTP was forming rapidly as the 
reaction mixture was set up, indicating that perhaps the assay conditions of the putative 
HAV RNA polymerase may not be appropriate. It is conceivable that the RNA 
polymerase is being subjected to degradation or precipitation in the assay or the enzyme 
extract due to an inherent insolubility as observed previously (Tesar et al., 1994). It 
should be noted that the 'zero' time-points were taken after addition of enzyme and a 2 
second vortex, and as such are not true zeros. This could imply that a rapid 
incorporation is observed in the 2 seconds it takes to vortex the tube.
Palmer (1994) observed that the 'incorporation' did not decay as rapidly for Protein 
A/HAV P3/pMEX8 or pRITPOL as observed for the HAV P3/pMEX8 construct, possibly 
due to a lower concentration of endogenous nucleases located in the periplasmic space 
than in the intracellular extract. Here, only intracellular extracts were used and as such 
no comparison regarding decay could be made. Decay of the 'activity' was however 
observed, and in some cases was very rapid, often decaying to background levels after 
only 2 to 5 minutes.
Fears of degradation of the RNA-dependent RNA polymerase due to a long induction
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period of 15 hours appeared unfounded; however, the vast quantities of protein present 
in some samples appeared to interfere with the putative polymerase activity although the 
mechanisms of this interference are not known. It could be, however, that degradation is 
occurring, hence the low activity observed. If this was the case, however, it would be 
unlikely that the 3D/pMAL and pMAL lysates would show the degree of activity, albeit 
low, displayed. Furthermore, the 3' NTR may be required which is known in EMCV to be 
involved in binding of the polymerase prior to replication, poly(A) alone being unable to 
bind the enzyme (Cui et al., 1993), and it is conceivable that a lack of both poly(A) tail 
and the 3' NTR in this case prevents binding of HAV 3Dpo1 to the poly(A):poly(U) 
template.
Several explanations could be forwarded for the lack of activity observed in cell lysate 
experiments, including phosphatase contamination of the reaction mixture which may 
cause UTP degradation such that little UTP can participate in chain elongation. This 
could be remedied by addition of phosphatase inhibitors to the reaction mixture. The 
primer or template may be defective or inappropriate thereby inhibiting elongation of the 
poly(U) chain. It has been shown that when assaying purified picornaviral RNA 
polymerase, activity becomes absolutely dependent on addition of exogenous template 
and primer. 50% of normal enzyme activity, however, has been observed in 
experiments lacking oligo(U), possibly due to the presence of a host factor which 
normally acts as a primer in vivo (Wolstenholme et al., 1993). This could also be 
explained by the presence of RNase which is not inhibited by the inhibitors used; 
moreover, perhaps the 3D could have RNase activity itself. The latter could be 
especially true in the case of purified fusion proteins free from bacterial contamination, 
unless of course the enzyme has either co-purified with an RNase or perhaps been 
contaminated during column chromatography with an RNase.
The much sought-after observation of 'activity' of a bacterially-expressed 3Dp0‘ 
demonstrated that the assay described could be suitable for the investigation and 
perhaps eventual characterisation of the HAV 3Dp0‘. The effect of other nonstructural 
proteins on this 'activity' could not definitively be investigated, with little in the way of 
conclusive evidence from addition of MBP-3CD or MBP-P3 (possibly MBP-3AB, MBP- 
3A, or MBP?) in their variously 'purified' forms to polymerase assays. The observation 
that the addition of 3CD/pMAL to 3D/pMAL yielded 'activity' above background in some 
cases was interesting; however, upon addition of more purified forms of these proteins 
this augmentation was not apparent, implying an artefactual nature of this result. As
198
Chapter 5
described, purification of 3AB was not realised and as such, addition of this protein to 
standard polymerase assays was not effected which is unfortunate in light of the 
stimulation afforded by its PV counterpart of PV 3Dpo1 which amounts to nearly 100-fold 
(Lama etal., 1994).
Although not shown, 3C/pMAL, 3CD/pMAL and P3/pMAL, and their respective purified 
fusion proteins and cleavage products, assayed alone yielded no incorporation above 
background levels. The lack of activity observed in assays of the two processing 
intermediates could be due to incorrect cleavages due to processing interference caused 
by bacterial proteases, although this seems unlikely in view of the SDS-PAGE and 
Western analysis results demonstrating, what appears to be, correct cleavage, be it 
autocatalytically or by bacterial intervention. Even more unlikely is the presence of 
bacterial proteases in purified fusion protein samples implying that this lack of activity is 
due to another unknown effect. In the case of the putative MBP-P3 or P3/pMAL, lack of 
activity could purely be due to the fact that no real HAV-specific polypeptides were 
present and only MBP or a degradation product was present in the reaction. Obviously, 
the apparent insolubility of MBP-P3 and MBP-3CD would compound the matter, resulting 
in the absence of the desired protein in the reaction mixture, with only constituent 
proteins present.
Assuming that the incorporation observed when assaying MBP-3D (and its Factor Xa 
cleavage product) alone is not artefactual, it is apparent that addition of MBP-3C, MBP- 
3CD, MBP-3D, MBP-P3, or MBP (and their respective cleavage products) reduces the 
incorporation observed with MBP-3D (or its cleavage product) alone. This could be due 
to interference or competition from excess protein by an unknown mechanism. With 
regard to this phenomenon in the assays where doubling the amount of MBP-3D in the 
reaction also reduces the apparent incorporation, it is possible that by assaying a more 
dilute sample would dilute out an inhibitor present in the sample, thus allowing more 
incorporation to occur. After an initial increase in incorporation with time a reduction is 
observed in most of the graphs showing MBP-3D or MBP-3D cleavage products and it 
would be beneficial to investigate the cause of this, whether it be due to RNases or some 
other mechanism of degradation.
The weak poly(U) polymerase activity observed previously by Wolstenholme and 
colleagues (1993) could arise in one of three possible ways, listed overleaf:
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1. Protein 3CD is active as a polymerase
If this is the case, one would expect the activity to decline rapidly as cleavage would 
result in production of 3C and 3D, both lacking activity.
2. Polymerase becomes active when cleavage of 3CD releases 3D
If this is the case, one would expect to see a lag phase and sigmoid curve, as with 
time an increase in the enzyme concentration would be seen resulting in an increase 
in activity.
3. Both of the above occur
If both 1 and 2 are true, one would expect an intermediate result. It is unlikely that 
both would have the same activity, one would be more active than the other.
The basis for the slow growth properties of HAV likely resides in the activities and 
functions of its nonstructural proteins or RNA sequences. The absence of virus-induced 
interference with host cell macromolecular synthesis and the failure to accumulate 
nonstructural proteins during infection (Updike et al., 1991) have impeded the 
characterisation of viral proteins by standard analyses of infected cell cultures. Some 
progress has been made, however by expression of subgenomic HAV cDNAs in 
recombinant systems (Gauss-Muller et al., 1991; Jia e ta l,  1991a; Harmon et al., 1992). 
It has been suggested that the slow replication of HAV in cell culture may be due to 
inefficient replication of viral RNA (Anderson et al., 1988) although this also could be 
explained by an inefficient viral RNA polymerase however expression of the HAV 3D in 
E. coli remains elusive, with prior attempts resulting in intracellular accumulation of an 
insoluble product which showed no activity (Updike et al., 1990). Overall, therefore, the 
lack of activity observed is not a new phenomenon. A similar lack of polymerase activity 
has been routinely observed when attempting to assay HAV 3D protein from other 
expression systems. Repeated efforts to show RNA polymerase activity in extracts of 
HAV-infected BS-C-1 cells, either in a template-dependent form or as an enzyme- 
template complex, have also been negative (Tesar etal., 1994 and references therein).
+0
To conclude, however, two observations were made from the work undertaken here. 
Firstly, the addition of large quantities of protein appeared to inhibit activity. Secondly, 
the cleavage products of the purified MBP-fusion protein 3D did appear to have some 
poly(U) polymerase activity albeit at a low level. With hindsight, the use of, perhaps PV 






Hepatitis A virus has been classified as a separate genus in the picomavirus family on 
the basis of relatively low sequence relatedness between its RNA or protein sequences 
and those of members of the other picomavirus genera (Francki et al., 1991). Moreover, 
HAV undergoes a slow, relatively prolonged, nonlytic growth cycle resulting in persistent 
infection of cultured cells, in contrast to the rapid, lytic cycles of other picomaviruses in 
most host cells (Wheeler et al., 1986a; De Chastonay & Siegl, 1987; Harmon et al., 
1989; Cho & Ehrenfeld, 1991).
The main aim of this project was to characterise the non-structural P3 proteins of the 
HAV in order to elucidate the reason for its slow proliferation in cell culture which is 
causing practical and economic difficulties in vaccine production. Although not wholly 
successful in achieving the ultimate aim of characterisation of the 3 0 ^  enzyme of HAV, 
certain advances towards this aim were attained throughout this project. These include:
1. Successful expression of a polypeptide of the same size as the 3Dpo1 enzyme 
and its partial purification from the periplasm using a GTP-agarose affinity 
protocol.
The GTP-agarose purification protocol was successful in partially purifying the 
putative 53kDa RNA polymerase from the periplasmic space extract, however a 
second protein of 36kDa, presumed to be Protein A-3A, was copurified. The fact that 
the Protein A sequence encodes an IgG binding domain indicates its inadequacies as 
a fusion partner especially in this case. If this result were reproducible a further 
purification step, ammonium sulphate fractionation or ion-exchange chromatography, 
would be necessary before the 53kDa protein is sufficiently pure for use in an assay 
system free from bacterial proteins. It is interesting to note that the failure of 3CD to 
bind to GTP supports the observation that the precursor of PV 3Dpo1, 3CDpro, has no 
RNA polymerase activity (Harris et al., 1992). However, it remains possible that the 
HAV CD may be a component of the RNA polymerase.
2. Successful amplification and cloning of P3 regions, 3AB, 3C, 3CD, 3D and the 
whole of P3, into the pMAL™-c2 expression vector.
Amplification of the constituent regions was successful only after problems with 
template had been solved. Cloning of all of the aforementioned recombinant 
plasmids regions and transformation of bacteria with these recombinants proved 
successful with bands of the desired size being observed upon restriction digest. 
This success was further supported by the presence of bands, in all but one case, of 
the predicted sizes of the respective fusion proteins as well as sequencing evidence.
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3. Expression of apparently active polypeptides MBP-3C and MBP-3AB as well as 
expression of MBP-3CD, MBP-3D and MBP-P3.
Several points can be raised regarding the expression of the MBP-fusion proteins in 
terms of their activity, solubility and yield. Expression of MBP-3AB resulted in lysis of 
bacteria supporting the observations of Beneduce et al. (1995) and Pisani et al. 
(1995) that protein 3A or 3AB is toxic to bacteria. The 3AB region cloned into 
pMAL™-c2 actually codes for a protein lacking the first 14 amino acids, thereby 
lacking the N-terminal negatively charged amino acids thought to be essential for 
formation of an a-helix with amphipathic properties (Pisani et al., 1995). Furthermore, 
the data of Beneduce et al. (1997) indicate that both the formation of a putative 
amphipathic helix and the presence of negative charges at N-terminus are crucial for 
the cytotoxic feature of 3A. This is in contrast with the observations made here, 
where, upon induction, cell lysis occurred. Unable to purify this protein, the effect of 
this polypeptide on polymerase activity could not be investigated with regard to the 
100-fold stimulation of 3Dpt)l as observed in PV upon addition of purified PV 3AB 
(Lama et al., 1994). The plasmid lost the insert and further attempts at cloning were 
unsuccessful.
Expression of the P3 and 3CD intermediates revealed that autocatalysis was 
occurring indicating that either the 3C protease was active or that indigenous bacterial 
proteinases were effecting cleavage at the correct cleavage sites. Although, again 
this showed a degree of activity of the MBP-3C protease expressed in this system, it 
meant that purification of the intermediates was not possible and generation of inserts 
containing a mutation at the respective cleavage site would be necessary. Solubility 
of fusion proteins varied with 3C being very easily expressed and purified, 3D, 3CD 
and P3 were invariably insoluble but by inducing at reduced temperatures, often at 
21-23°C, for longer periods, solubility and thereby purification were somewhat 
improved.
Another interesting observation worthy of a mention is the probable cleavage of MBP- 
P3 to MBP-3A or MBP-3AB which was evident by virtue of the fact that prolonged 
induction of P3/pMAL resulted in lysis of bacteria similar to that seen for 3AB/pMAL. 
A band of the size predicted for MBP-P3 was observed in these cells but was found to 
be almost wholly insoluble. Cleavage with factor Xa revealed that only a very small 
protein could be fused to MBP, possibly 3A, but more likely to be a component of the 
induced MBP protein. This suggests that only very low concentrations of 3AB are
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required to lyse the bacterial cells.
Acceptable yields were obtained for few of the fusion proteins, with large cultures 
being required for each. Losses at each step of purification meant that the eventual 
yield of purified protein (3C and 3D only) was minimal. Even at this stage the purity of 
3D was questionable, with contaminating proteins of other molecular weights.
4. Assessment of the poly(U) polymerase activity of pMAL constructs by 
assaying soluble cell lysates, MBP-fusion proteins and their factor Xa cleavage 
products.
Two observations in particular can be highlighted from the series of activity assays 
undertaken. Firstly, the addition of more protein to the assay appeared to interfere 
with the incorporation of radiolabelled UTP. Moreover, on doubling the concentration 
of putative polymerase 'enzyme' a drastic diminution of incorporation was observed. 
This poses a problem when analysing enzyme activity as one would expect an 
augmentation of incorporation when increasing the concentration of enzyme. 
Secondly, reproducible incorporation of large amounts of 3H-UTP was observed 
consistently when assaying MBP-3D, and in particular its factor Xa cleavage 
products. Comparison of all the collected data revealed that only the cleaved MBP- 
3D incorporated radiolabelled UTP at levels above background, however the 'enzyme' 
did not exhibit classic 'enzyme activity' which was unfortunate. Apparent 
contamination of the protein with RNase would possibly account for the decay in 
incorporation observed with time, however, samples free from bacterial contamination 
also exhibited such decay, which could be due to copurification with an RNase, 
contamination of the fusion protein with an RNase possibly from the column, or 
perhaps the MBP-3D protein possesses some RNase activity itself. Increasing 
enzyme concentration would increase the RNase concentration which could 
contribute to the diminished incorporation observed when doubling the concentration 
of the putative polymerase enzyme.
If further investigation into the HAV RNA-dependent RNA polymerase is successful in 
the long-term, then it will go some way to explaining the slow and non-cytopathic growth 
of this virus in tissue culture, and eventually lead to the development of a more 






7. 1 Appendix 1
7. 1. 1 Primer location







Figure 82: Schematic of HAV P3/pMEX8 showing approximate location of HAV 
primers
Numbering consistent with text. Not to scale.
7.1.2 Calculation of annealin
primer
Predicted melting temperatures (Tm) of HAV primers estimated using the 
equation:




7.2.1 Primer sequences and location on genome
<3 A
4 9 8 1  T T G T G G T C T C A G G G A A T T T C A G A T G A T G A T A A T G A T A G T G C A A T G G C A G A G T T T T T T C A G  5 0 4 0  
L W S Q G I S D D D N D S A M A E F F Q
5 0 4 1  T C T T T T C C A T C T G G T G A A C C A T C G A A T T C C A A A T T A T C T G G C T T T T T C C A A T C T G T T A C T  5 1 0 0  
S F P S G E P S N S K L S G F F Q S V T
5 1 0 1  A A TC A C A A G TG G G TTG C TG TG G G A G C TG C A G TTG G TA TTC TTG G A G TG C TC G TTG G G G G A  5 1 6 0  
N H K W V A V G A A V G I L G V L V G G
3 A X 3 B
5 1 6 1  T G G T T T G TG T A T A A G C A TT TC T C C C G A A A A G A G G A A G A G C C A A TT C C A G C T G A A G G G G TA  5 2 2 0  
W F V Y K H F S R K E E E P I  P A E G V
5 2 2 1  T A T C A T G G T G T A A C T A A G C C T A A G C A A G T G A T T A A A T T A G A T G C A G A T C C A G T A G A A T C T  5 2 8 0  
Y H G V T K P K Q V I  K L D A D P V E S  
3 B X 3 C
5 2 8 1  C A G T C A A C TT TG G A A A T A G C A G G A C T G G T T A G G A A G A A T T T G G T T C A G T T T G G A G T T G G A  5 3 4 0  
Q S T L E I A G L V R K N L V Q F G V G
5 3 4 1  G A G A A G A A TG G A T G TG T G A G A T G G G T TA TG A A TG C C TT A G G G G TG A A A G A T G A T TG G T TG  5 4 0 0  
E K N G C V R W V M N A L G V K D D W L
5 4 0 1  C T T G T A C C T T C C C A T G C T T A C A A A T T T G A G A A A G A T T A T G A A A T G A T G G A G T T T T A T T T T  5 4 6 0  
L V P S H A Y K F E K D Y E M M E F Y F
5 4 6 1  A A T A G A G G T G G A A C T T A C T A T T C A A T T T C A G C T G G T A A T G T T G T C A T T C A A T C T T T G G A T  5 5 2 0  
N R G G T Y Y S I  S A G N V V I  Q S L D
5 5 2 1  G T G G G A T T T C A G G A T G T T G T T C T G A T G A A G G T T C C T A C A A T T C C T A A G T T T A G A G A T A T T  5 5 8 0  
V G F Q D V V L M K V P T I  P K F R D I
5 5 8 1  A C C C A A C A T T T T A T T A A G A A G G G A G A T G T G C C T A G A G C T T T G A A T C G T C T G G C A A C A T T A  5 6 4 0  
T Q H F  I  K K G D V P R A L N R L A T  L
5 6 4 1  G TG A C A A C TG T G A A T G G A A C T C C T A T G T T A A T T T C T G A G G G G C C A T T A A A G A T G G A A G A G  5 7 0 0  
V T T V N G T P M L I  S E G P L K M E E
5 7 0 1  A A A G C T A C T T A T G T T C A T A A G A A A A A T G A T G G T A C A A C A G T T G A T T T A A C T G T G G A C C A G  5 7 6 0  
K A T Y V H K K N D G T T V D L T V D Q
5 7 6 1  G C ATG G A G A G G A A A A G G C G A G G G TC TTC C TG G A A TG TG TG G TG G G G C C TTG G TTTC A TC A  5 8 2 0  
A W R G K G E G L P G M C G G A L V S S
5 8 2 1  A A T C A G T C T A T A C A G A A T G C A A T T T T G G G T A T T C A T G T T G C T G G A G G A A A T T C A A T T C T T  5 8 8 0  
N Q S I Q N A I L G I H V A G G N S I L
3C>
5 8 8 1  G T T G C A A A A T T G G T T A C T C A A G A A A T G T T C C A A A A T A T T G A T A A G A A A A T T G A A A G T C A G  5 9 4 0  
V A K L V T Q E M F Q N I D K K I E S Q  
<3D
5 9 4 1  A G A A T C A T G A A A G T G G A A T T T A C T C A G T G T T C A A T G A A T G T A G T C T C C A A A A C G C T T T T T  6 0 0 0  
R I M K V E F T Q C S M N V V S K T L F
6 0 0 1  A G A A A G A G T C C C A T T C A T C A T C A C A T T G A T A A A A C C A T G A T C A A T T T T C C T G C A G C T A T G  6 0 6 0  
R K S P I H H H I  D K T M I N F P A A M
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6 0 6 1  C C T T T T T C T A A A G C C G A A A T T G A T C C A A T G G C T A T G A T G T T A T C T A A G T A T T C A T T A C C C  6 1 2 0  
P F S  K A E I  D P M A M M L S K Y  S L P
6 1 2 1  A T  T  G TA G A A G A G  C C AG AG  G AT T A T A A A G A A G  C T  T  C A A T  T  T  T  T  T A T  C A A A A T A A A A T A G T A  6 1 8 0  
I V E E P E D Y K E A S I  F Y Q N K I V
6 1 8 1  G G C A A G A C T C A G C T A G T T G A T G A T T T T C T A G A T C T T G A T A T G G C C A T T A C A G G G G C C C C A  6 2 4 0  
G K T Q L V D D F L D L D M A I T G A P
6 2 4 1  G G A A T T G A T G C T A T T A A T A T G G A T T C A T C T C C T G G A T T T C C T T A T G T T C A A G A G A G G T T G  6 3 0 0  
G I D A I N M D S S P G F P Y V Q E R L
6 3 0 1  A C C A A A A G A G A T T T A A T T T G G T T G G A T G A G A A T G G T T T A T T G C T G G G A G T T C A T C C A A G A  6 3 6 0  
T K R D L I W L D E N G L L L G V H P R
6 3 6 1  T T G G C T C A G A G A A T T T T G T T C A A T A C T G T C A T G A T G G A A A A T T G T T C T G A T T T G G A T G T T  6 4 2 0  
L A Q R I  L F N T V M M E N C S D L D V
6 4 2 1  G T T T T T A C  T A C T  T  G C C C A A A A G A T  G A A T  T  GAGAC C A T  T  G G AGAAG GT GT T  G G A A T C A A A A  6 4 8 0  
V F T T C P K D E L R P L E K V L E S K
6 4 8 1  A C A A G A G C T A T T G A T G C T T G T C C T C T G G A T T A C A C A A T T T T G T G T C G A A T G T A C T G G G G T  6 5 4 0  
T R A I D A C P L D Y T I L C R M Y W G
6 5 4 1  C C A G C T A T T A G T T A T T T T C A T T T G A A T C C A G G G T T C C A T A C A G G T G T T G C T A T T G G C A T A  6 6 0 0  
P A  I  S Y F H L N P G F H T G V A I G I
6 6 0 1  G A T C C T G A C T G T C A G T G G G A T G A A T T A T T T A A A A C A A T G A T A A G A T T T G G A G A T G T C G G T  6 6 6 0  
D P D C Q W D E L F K T M I  R F G D V G
6 6 6 1  C T T G A T T T A G A T T T T T C T G C T T T T G A T G C T A G T C T T A G T C C A T T T A T G A T T A G G G A A G C A  6 7 2 0  
L D L D F S A F D A S L S P F M I R E A
6 7 2 1  G G T A G A A T T A T G A G T G A A T T G T C T G G A A C T C C A T C C C A T T T T G G A A C A G C T C T C A T G A A T  6 7 8  0 
G R I M S E L S G T P S H F G T A L M N
6 7 8 1  A C T A T C A T T T A T T C T A A G C A T T T G C T G T A C A A C T G T T G T T A T C A T G T T T G T G G T T C A A T G  6 8 4  0 
T I I Y S K H L L Y N C C Y H V C G S M
6 8 4 1  C C T T C T G G G T C T C C T T G C A C A G C T T T G C T G A A T T C A A T T A T C A A T A A T G T C A A T T T G T A T  6 9 0 0  
P S G S P C T A L L N S I I N N V N L Y
6 9 0 1  T A T G T G T T T T C C A A G A T A T T T G G A A A G T C T C C A G T T T T C T T T T G T C A G G C T T T G A A G A T T  6 9 6 0  
Y V F S K I  F G K S P V F F C Q A L K I
6 9 6 1  C T C T G T T A T G G A G A T G A T G T T C T T A T A G T T T T T T C C C G A G A T G T T C A G A T T G A T A A T C T T  7 0 2 0  
L C Y G D D V L I V F S R D V Q I D N L
7 0 2 1  G A T T T G A T T G G A C A A A A A A T T G T A G A T G A G T T T A A G A A A C T T G G C A T G A C A G C T A C T T C T  7 0 8  0 
D L I  G Q K I V D E F K K L G M T A T S
7 0 8 1  G C T G A C A A A A A T G T A C C T C A G C T G A A G C C A G T T T C A G A A T T G A C T T T T C T C A A G A G A T C T  7 1 4 0  
A D K N V P Q L K P V S E L T F L K R S
7 1 4 1  T T C A A T T T G G T A G A A G A T A G G A T C A G A C C T G C A A T T T C G G A A A A A A C C A T T T G G T C T T T G  7 2 0 0  
F N L V E D R I R P A I  S E K T I W S L
7 2 0 1  A T A G C A T G G C A G A G A A G T A A C G C T G A G T T T G A G C A G A A T T T G G A A A A T G C T C A G T G G T T T  7 2 6 0  
I A W Q R S N A E F E Q N L E N A Q W F
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7 2 6 1  G C T T T T A T G C A T G G C T A T G A G T T T T A T C A G A A A T T T T A T T A T T T C G T T C A G T C T T G T T T G  7 3 2 0  
A F M H G Y E F Y  Q K F Y Y F V Q S C L
7 3 2 1  G A G A A A G A G A TG A TA G A A TA C A G A C TA A A A TC A TA TG A TTG G TG G A G A A TG A G A TTC TA T  7 3 8 0  
E K E M I E Y R L K S Y D W W R M R F Y
3 D >
7 3 8 1  GACCAGTGCTTCATTTGTGACCTTTCATAA 7 4 1 1  






5'TCG GCAAGC TTT CCA TCT GGT GAA CCA TCA AAT TCT 







































Kpn I Nsi I
5'A GCC GGTACC ATGCAT TTA TCA CTG AGA TTC TAC





5'T CGG GGTACC ATG TCT TTT CCA TCT GGT GAA CAA 

















5'T CGG GAAGGATTTC ATG AAT TAT GAA AGT GGA GTT 
TAC TCA G3.
61.3°C
7.2.3 Sequence of pepti
production







Ara Mutation destroys ability to use arabinose
Carrf Chloramphenicol resistance
EndA1 DNA specific endonuclease 1, mutation improves quality and 
quantity of miniprep
F Contains the F plasmid
GyrA46 DNA gyrase subunit A
HsdR(rkmk+) Ablates type I restriction but not methylation of E. coli strain K
Lac Unable to utilise lactose
Laclq Overproduces the lac repressor protein
LacZ p-Galactosidase
LacZM15 Specific N-terminal deletion permitting a-complementation
ProAB Requires proline for growth
RecA1 Recombination deficient
RelA1 Permits RNA synthesis in absence of protein synthesis
RpsL 30S ribosomal subunit S12: mutation confers streptomycin 
resistance
SupE44 Suppressor of amber (UAG) mutations
Thi Requires thiamin (vitamin B1) for growth
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